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Part I
Gene therapy
1 Motivation
A broad group of acquired or inherited fatal diseases such as immunodeficiency syn-
dromes, cystic fibrosis or some types of cancer are ultimately caused by gene defects
and to date the vast majority of those can only be treated in a symptomatic manner.
The idea of “simply” replacing defective or adding missing genes has been around
for a couple of decades, but it finally found serious attention with the information
explosion in DNA technology as well as the ability to transfer and express genes in
mammalian cells [1]. Gene therapy, introducing nucleic acids into cells, is supposed
to provide serious benefit by directly influencing genetic material as compared to con-
ventional non-causal therapies. Genes that are missing owing to a genetic mutation
could be complemented to supply a vital protein. Unwanted genes could be blocked
by the introduction of a counteracting one. Distinct cells may be selectively des-
troyed via suicide strategies [2]. Furthermore, antisense routes offer the opportunity
to selectively down-regulate the expression of specific genes on the translational level
by sequence specific interaction with messenger RNA (mRNA). Especially in cancer
treatment novel therapeutic scopes, exhibiting high selectivity plus low toxicity, are
urgently needed to so replace/support classical chemo-therapeutics and radiation
therapy.
2 Carriers
Due to their inability to enter negatively charged cells and due to enzymatic de-
gradation, nucleic acids require formulations for a successful gene therapy approach.
Therefore, the idea of gene carriers is conceptually simple: So-called vectors are
responsible for packaging, protection and cell internalisation of genetic drugs.
Generally, two different carrier approaches have been utilised, namely viral and
non-viral ones. Viruses have evolved efficient mechanisms to enter cell and nuc-
leus and therefore impress by their cell specificity and their efficiency to internalise
genetic material into host cells. Researchers tried to “tame” viruses for exploiting
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their properties. However, in recent years, a rethinking occurred, mainly due to
severe safety concerns (such as high immunogenicity after repeated administration
or potential oncogenicity due to insertional mutagenesis). Non-viral vectors, using
cationic polymers and lipids, are generally regarded as superior in terms of safety
and furthermore offer virtually unlimited loading capacity [3]. Cationic polymers
such as polyethyleneimine (PEI) are the ideal candidates to serve as nucleic acid
carriers, due to their ability to condense nucleic acids to nano-scaled complexes.
Electrostatic interaction of polycationic carrier polymers and polyanionic nucleic
acids lead to the formation of complexes, often referred to as “polyplexes”. Those
protect the genetic cargo from nuclease-induced degradation and enable cell inter-
action (Figure I.1). Cationic polymers are comparatively easy to manufacture on an
industry level (and in good manufacturing practice) with tailored chemical function-
alities and versatile physicochemical properties. Nevertheless, limited transfection
efficiency commonly remains a major drawback of many non-viral approaches. An-
other important challenge will be to reduce the toxicity induced by cationic charges.
Although remarkable advances have been made in vitro, in vivo applications are still
scarce [1]. Nevertheless, polymeric delivery systems do have the potential to sur-
pass their viral counterparts, if those limitations could be overcome. Perhaps novel
chemical design strategies along with a better understanding in structure activity
relationships may help to overcome those issues.
Figure I.1: Vector mediated internalization of DNA [4]
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3 Permanent and transient gene therapy approaches
Originally gene therapy was designed to treat inherited diseases, such as the defi-
ciency of a specific gene. Therefore, it was the goal to deliver plasmid DNA (pDNA)
into the nucleus of a defective cell to express the resulting transgene. Depending
on the vector, DNA either integrates into the host genome or exists as an episomal
vector. Therefore, the resulting transfection can either be permanent or transient
[1]. Stable lifelong expression, on one hand, has the potential to ultimately “cure”
inherited diseases caused by a monogenic defect (e.g. in case of cystic fibrosis, hae-
mophilia or familial hypercholesterolemia [3]). On the other hand, altering the host
genome causes safety concerns: in case of intolerance or side effects there is no pos-
sibility of intervention and also re-administration is barely feasible. By contrast,
transient gene therapy lasts for a couple of days or weeks (depending on the rate of
cell division) and the dose can be adjusted more easily. Additionally, for acquired
diseases like infection or cancer, permanently altering the patient’s genome is often
not desirable and drugaction is therefore supposed to be a transient one. [5]
The discovery of RNA interference (RNAi) techniques enabled a new scope of
transient gene therapy at the post-transcriptional messenger RNA (mRNA) level.
This involves the delivery of short (21-25 base pairs) nucleic acid fragments, e.g.
small interfering RNA (siRNA) instead of high molecular weight DNA plasmids
(up to 100 000 base pairs). This new therapeutic pathway allows to temporarily
down-regulate the expression of virtually any gene of interest by administration
of tailor made synthetic oligonucleotides. Whereas pDNA needs to be introduced
into the nucleus, the site of action for siRNA is the cytosol. There, siRNA is
loaded into the so-called “RNA-induced silencing complex” (RISC) (Figure I.2).
After cleavage of one strand, the residual one guides the RISC to its complementary
sequence of mRNA and endonuclease enzymes of the RISC sequence-specifically
cleave a distinct mRNA region. The degraded mRNA is subsequently no longer
available for translation, leading to a transient down-regulation of the corresponding
protein (knock-down). [6]
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Figure I.2: Steps in the RNAi process: siRNA gets loaded onto the RISC, followed by
the formation of an activated RISC containing only one siRNA guide strand.
The activated RISC is subsequently guided to its complementary mRNA
sequence. After region specific mRNA cleavage, RISC gets recycled to carry
out additional silencing loops.
DNA and siRNA generally share many common properties: They are both double
stranded nucleic acids with a negatively charged phosphodiester backbone. As the
packaging of cationic non-viral delivery systems is based on electrostatic interaction,
delivery of DNA or siRNA is generally feasible using quite similar vectors. However,
there may be a need to adapt carrier properties to fulfil the needs of the respective
payload. As compared to DNA, siRNA shows a longer persistence length, making
it a stiffer molecule. Hence, despite the lower molecular weight, siRNA is generally
harder to condense by cationic agents [6]. This may lead to undesirable large and
unstable complexes and makes colloidal stability of carriers even more important.
Furthermore, the ribose functionalities make RNA more susceptible to hydrolysis
and degradation by serum nucleases than DNA (containing desoxyribose residues)
[6]. This further exacerbates the need of an intelligently designed protective carrier
for delivery of siRNA.
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4 Hurdles for in vivo usage
Despite the tremendous promises of gene therapy, there are (especially in vivo)
numerous obstacles to overcome for a successful therapeutic application.
4.1 Systemic hurdles
4.1.1 Administration
The first question that has to be addressed when dealing with nucleic acid drugs is
a suitable way of administration. On one hand, this can be done by loco-regional
administration, such as direct tissue injection or by inhalation for treating airway
diseases. For the latter the respiratory mucus layer represents an additional barrier
[4]. In case of direct injection into a tumour, the low extent of diffusion throughout
the tissue limits the applicability. On the other hand, systemic delivery by intra-
venous injection represents a more desireable approach, in turn presenting further
issues.
4.1.2 Targeting
Once systemically administered, therapeutics undesirably tend to accumulate in
tissues and organs such as lung, liver, spleen or kidney. Therefore, to enable thera-
peutic levels of transgene expression and to avoid side effects, carriers have to be
taken up by the target tissue in a selective way. Ultimately, the ideal vector is
supposed to be cell type specific, which can be achieved, up to a certain degree, via
targeting ligands. Utilising receptor mediated uptake mechanisms has the potential
to dramatically decrease nonspecific interaction with healthy cells and body tissues
plus increasing drug concentrations at the target site. One promising example is the
folic acid receptor; whereas there are high expression levels in some types of cancer
cells, expression is comparatively low in normal tissue [7, 8]. Transferrin [9, 10] or
epidermal growth factor (EGF) [11] represent other potent ligands which have been
widely employed for tumour targeting.
4.1.3 Endothelium
But even in absence of homing ligands, there is a chance for nano-scaled delivery sys-
tems to passively accumulate in solid tumours. Whereas the endothelial membrane
is quite tight in most regions of the human body (except some organs such as liver,
spleen or bone-marrow), cancer tissues often result in a leaky vasculate together
with an impaired lymphatic drainage (Figure I.3) [3]. This may lead to a capture
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of long-circulating carriers in the tumour interstitium, which is often referred to
as the so-called enhanced permeation and retention (EPR) effect [12, 13, 14]. On
one hand using this technique represents a way to pass the endothelial barrier. On
the other hand, irregular distribution of carriers throughout the cancer tissue along
with a diminished concentration towards the mass of the tumour [3] remains a major
problem. Therefore, using actively targeted vector systems with additional benefit
from the EPR effect appears to be a promising strategy [13].
normal tissue
circulation
tumour cell
drug encapsulated NP
    drug release in
tumour tissue
Figure I.3: Schematic illustration of the EPR effect
4.1.4 Immune response and “stealth” properties
The host immune response represents yet another hurdle in gene therapy. Even
though non-viral delivery systems do not stimulate any antigen-dependent immunity
as compared to viral approaches, unspecific activation of the host immune system be-
comes an issue for in vivo administration. Once systemically administered via intra-
venous injection, the mammalian immune system has developed effective strategies
to eliminate non-innate invaders. This clearance process is mediated by interaction
of carriers with components in the blood serum. Opsonin molecules (e.g. immun-
oglobulins or the C-reactive protein) are adsorbed onto the carrier’s surface, which
renders them recognisable to the complement system. Tagged materials are sub-
sequently cleared from the circulation e.g. via phagocytosis by macrophages (e.g.
Kupffer cells in the liver) [15].
Modification of the carrier surface to hinder the adsorption of opsonins is a feas-
ible method to diminish unspecific immune response. In this context surface chem-
istry, charge, structure and hydrophobicity are known to play an important role [15].
Hydrophobic surfaces are generally thought to be more prone to the opsonisation
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process and a rapid removal of hydrophobic particles from the bloodstream as com-
pared to their hydrophilic counterparts was previously demonstrated by Illum et
al. [16]. Apart from that an unexpected increase of proinflammatory signalling was
reported [17, 4]. Polyethylene glycol (PEG), covalently attached or adsorbed onto
the carrier surface, is commonly employed for hydrophilic modification of carrier
systems. PEGylated surfaces generally show reduced toxicity as well as prolonged
circulation times in vivo [18, 19]. PEG’s so-called “stealth” effect is owed to unique
solution properties and molecular conformation in aqueous medium [15]. Hydrogen
bonds between ether oxygens and water hydrogens lead to a hydrophilic water-like
structure with highly mobile and flexible PEG polymer chains. Resulting surfaces
are believed to repel approaching proteins due to a reduced interface. Covalent at-
tachment of PEG, which typically involves the formation of block copolymers, was
proven to be more effective in shielding the PEI charges than absorption of PEG onto
the carrier surface [20]. Length and density of attached PEG chains were shown to
have an effect on “stealth” properties [21, 22], whereas minimal chain-length between
1500-3000 Da is generally accepted as a prerequisite for the formation of a protective
hydrogenated shell [15].
4.2 Cellular hurdles
Carriers that have survived degradation and clearance in the blood stream and have
passed the endothelial of a target tissue, finally reach the cell membrane. But this
is only half the way to successful gene therapy, as additional hurdles on the cellular
level are to be overcome.
4.2.1 Cell membrane
Complexes with suitable surface properties were shown to be capable of traversing
the cell membrane [3]. A size of approximately 150 nm [6] and a positive surface
charge are generally accepted as prerequisites for cell interaction. Untargeted carri-
ers bind electrostatically to the cell membrane and are typically internalised via pass-
ive (adsorptive) endocytosis. Alternatively, as mentioned above, ligand-decorated
carriers are capable of active receptor mediated endocytosis; ligands specifically
bind to receptors on the surface of distinct cells, which triggers an internalisation
signal. Receptor and ligand are then clustered into coated pits and enter the cell
very effectively [23].
15
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4.2.2 Endosome
Independent from the mechanism of endocytosis, carriers are subsequently located in
vesicular structures, so-called endosomes. Those invariably follow the same pathway
leading from the early to the late endosome, ultimately ending up in the lysosomal
compartment. In the course of this cellular trafficking an influx of protons leads
to a decrease in pH from 7 to approximately 5. The resulting ion gradient in turn
leads to an influx of chloride ions, thereby increasing the osmolality inside the en-
dosome/lysosome. A subsequent influx of water finally results in overpressure and
rupture of the lysosomal membrane [24]. However, prior to this, due to prevailing
aggressive nucleases and decreasing pH values, nucleic acids inside the endosome
are typically digested and therefore need to be protected and previously released
into the cytosol in order to be effective [3]. The prime importance of endosomal
protection for gene delivery efficiency was demonstrated by addition of chloroquine,
which represses endosomal degradation and therefore leads to increased transfection
efficiency [24].
Viruses have developed effective ways to escape from the endosome. For non-viral
approaches one potential way of escape, which has been hypothesised for polyamine
carriers with different degrees of protonation (such as PEI or some dendrimers), is
commonly referred to as the “proton sponge” effect (Figure I.4). Carrier’s amine
functionalities accept inflowing protons due to a buffering capacity in the respective
pH-range. This leads to stable pH values and hinders nucleic acid degradation. An
influx of chloride ions and water into the buffered endosome finally facilitates nucleic
acid release through overpressure induced rupture of the vesicular membrane [24, 25].
However, apart from the proton sponge hypothesis, alternative ways of endosomal
escape via electrostatic induced membrane fusion [26, 27] or disruption [28, 6] have
been discussed in literature.
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Figure I.4: Schematic illustration of the proton sponge mechanism: functionalities on
the carrier accept protons streaming into the endosomal vesicle. An influx of
chloride counter ions and water cause swelling and ultimately rupture of the
endosomal membrane.
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4.2.3 Cytosol
After release from the endosome, nucleic acids are located in the cytosol. In some
cases nucleic acid and gene carrier are already disassembled at the time of endosomal
release, for others the carrier complex is still intact [6]. In any case the cytosol is
an destructive place for nucleic acids; the mobility of large molecules is extremely
low and prevailing cytoplasmic nucleases favour digestion. For siRNA the cytosol is
already the site of action. DNA, however, has to be transported into the nucleus to
facilitate transgene expression. As transport into the nucleus typically occurs upon
cell division, DNA has to be stable until the next disassembly during the next cell
cycle. For RNA and DNA approaches, the carrier has to be tailor made in a way that
provides sufficient protection via tight complexation. By contrast, the electrostatic
interaction between nucleic acid and polycation must not be too strong, as this may
lead to insufficient unpacking at the appropriate stage. Therefore, in order to be
effective, a balance of complexation strength has to be adjusted to enable protection
and release of genetic material at the right time [3, 6].
4.3 Issues arising from cationic surface charge
Whereas for the majority of non-viral delivery systems positive charges are abso-
lutely necessary for complexation and delivery, they do have a downside regarding
non-specific interaction and toxicity.
4.3.1 Carrier loading via electrostatic interaction
As stated previously, aside from encapsulation approaches, loading of most non-
viral delivery systems is generally an electrostatically driven process and the cationic
charge is therefore a prerequisite for interaction with nucleic acids. With surprising
accuracy the complexation process of non-viral carrier and nucleic acid can be de-
scribed by the classical DLVO (Derjaguin, Landau, Verwey, Overbeek) theory, with
according implications on colloidal stability [29]. Upon carrier loading, the ratio of
positively charged nitrogens (e.g. from PEI amine-functionalities) and negatively
charged phosphates (from the backbone of nucleic acids), which is commonly re-
ferred to as the N/P ratio, is one of the most crucial factors for carrier stability,
performance and toxicity. Figure I.5 exemplarily shows the charge of a PEI-based
delivery system (manufactured in the course of this thesis) as a function of N/P.
Despite various conditions upon complex preparation, complex formation is mainly
driven by electrostatic interaction.
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Figure I.5: Charge (⇣-potential determined via LDA) of cationic carrier (PEG500-
PCL10k-PEI2500) upon complexation with siRNA (100 µm solution) as a
function of N/P. Despite changing polymer concentrations used for complexa-
tion, resulting carriers are mainly controlled by their electrostatic interaction.
(Data collected from various experiments in the course of this thesis)
4.3.2 Colloidal stability
By design unloaded carriers bear a positive surface charge (with a ⇣-potential of
up to 50 mV), which (according to the DLVO theory) contributes to overall col-
loidal stability. Upon addition of negatively charged nucleic acids, there is a decline
in surface charge (Figure I.5), which generally favours aggregation. This is one
of the reasons why the N/P is typically chosen in a way that results in an excess
positive surface charge (in most cases N/P-ratios of approximately 5 are employed
[30]). However, carriers not only need to be stable in a sample vial, but also inside
a medium of high ionic strength (such as blood serum). In such an environment
salt ions and anionic proteins tend to shield the stabilising cationic functionalities
of like-charged carriers. Therefore, exclusively charge-stabilised unmodified carri-
ers exhibit tremendous problems, rendering them unlikely for in vivo application.
First of all interaction with negatively charged serum components (e.g. albumin or
fibronectin), erythrocytes or tissue membranes may occur. This was demonstrated
recently for carrier-interaction with albumin, leading to the formation of large ag-
gregates with inverted surface charge [3]. Those are known to be excluded from
cellular internalisation altogether [6]. Additionally, unspecific interaction dramatic-
ally decreases circulation time [15] and ultimately leads to blockage of blood vessels
accompanied by embolism (first of all in the lung). Actually, a direct correlation
between the number of accessible surface charges and the amount of complement
activation has been claimed [31]. Alternatively, apart from Coulomb repulsion, there
is the opportunity of steric shielding via surface modification (e.g. by attachment of
PEG moieties) to increase physical stability. This is believed to be the favourable
18
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technique under physiological salt and polyelectrolyte concentrations. However, this
may in turn have an adverse effect on cell uptake [32].
4.3.3 Cell uptake and cytotoxicity
Cationic surface charge increases the interaction with negatively charged cell mem-
branes. Hence, one way to improve cell uptake may be to increase the carrier
surface charge (as already mentioned above, another way may be utilising targeting
ligands). At the same time, however, this will inevitably increase unwanted interac-
tions with blood components and tissue membranes in an unspecific manner. As a
result membrane damage and cell necrosis lead to increased toxicity both on cellular
and systemic level [33].
4.3.4 Balance of positive charges
Consequently, colloidal stability and cell uptake ability on the one hand and toxicity
and lack of specificity on the other hand have to be balanced. Targeting ligands and
“stealth” properties through shielding moieties may help to conquer this dilemma. A
thoroughly adjusted N/P ratio may further contribute to tailor the surface charge:
lower N/P ratios generally lead to a decrease in toxicity due to decreased surface
charges (similarly this may lead to a reduced efficiency as well). Furthermore, at
lower N/P ratios less potentially toxic polymer is required to administer the same
therapeutic amount of nucleic acid, which is also reducing overall toxicity. In the
end a compromise between stability, efficiency and toxicity has to be found, typically
ending up with a slightly positive surface charge in the order of a few mV.
5 Evolution of non-viral delivery systems
Amajor benefit of using unit-by-unit constructed cationic polymers as non-viral gene
delivery vehicles is the possibility of straightforward modification using the tools of
organic chemistry. Hence, from the beginning of non-viral gene delivery in the 1990s,
constant evolution resulted in increasingly sophisticated delivery systems to tackle
the above-described challanges in the course of the delivery process and meet the
special needs of various host systems. The overall goal must be to manufacture
delivery systems with “virus-like” high efficiency, specificity and low safety risks [3].
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5.1 Homopolymers
Early gene vehicles were basically assembled from positively charged homopoly-
mers. So far, various macromolecules such as PEI, poly(lysine), chitosan, poly((2-
dimethylamino)ethyl methacrylate) (pDMAEMA) or several polysaccharides have
been used for complexation of nucleic acids. Apart from that, amine bearing
dendrimers, such as poly(amidoamine) (PAMAM) have been reported (Figure I.6).
Positive charges typically arise from protonation of primary and secondary amines.
These amine functionalities trigger complexation with nucleic acids, are capable of
accepting protons for buffering the endosome, and additionally are strong nucle-
ophiles, which can also be further employed for coupling of targeting ligands or
functional groups. Tertiary amines (e.g. included in branched PEIs) are less nucle-
ophilic, but may be helpful for further buffering the endosomal compartment after
endocytosis [34].
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Figure I.6: Structures of commonly used homopolymer gene delivery vehicles
A: poly(ethyleneimine); B: poly(lysine); C: chitosan; D: poly((2-
dimethylamino)ethyl methacrylate); E: poly(amidoamine) (generation 3)
Among different types of macromolecules used for gene delivery, PEI surely is re-
garded to play the most important role. The polyamine has been introduced roughly
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two decades ago and even today PEI is one of the most frequently employed non-viral
gene delivery vehicles [30]. A high density of protonable amino groups results in a
remarkable charge density, leading to very effective condensation of nucleic acids.
Among non-viral carriers, PEI based systems are paramount effective, possibly due
to the formation of homogeneous, nano-scaled and spherical nucleic acid-complexes
bearing a high surface charge. Those are well-suited for cell internalisation and offer
effective protection of nucleic acids from degradation [3]. Amino groups in different
protonation states are furthermore believed to be particular effective regarding the
above mentioned endosomal buffering capacity [4].
PEI exists in a linear (lPEI) as well as in a (hyper)branched architecture (bPEI)
and both have been successfully employed as gene vectors. bPEI is generally reported
to exhibit stronger complexation affinity towards nucleic acids, leading to smaller
complexes. Furthermore, probably due to the additional ternary amines offering
buffering capacity over a wider pH range, a pronounced proton sponge capability
was hypothesised for the branched species [3, 4]. However, regarding the potency
of branched and linear forms, there is some controversy in literature; several studies
revealed that “polyplexes” formed from lPEI are more effective than their branched
counterparts [35, 36, 37, 38, 39]. According to that, the higher transfection efficiency
of lPEI was hypothesised to arise from differences in intracellular trafficking [35] or
altered stability under salt conditions [39]. Besides transfection efficiency, branched
and linear forms differ in terms of toxicity, typically increasing with increasing degree
of branching [6]. However, various PEI based systems reported in literature are
somewhat difficult to compare, as complex structure, testing conditions and most
importantly the MW of PEI have a tremendous impact on transfection efficiency
and toxicity as well.
PEI MWs between 5 and 25 kDa are generally believed to be suitable for gene
delivery [4]. At higher MW cell-surface aggregation of the polymer typically leads
to excessively increased cytotoxicity, which is also one of the major limiting factors
for in vivo usage. Low MW PEI in turn is less toxic but usually also less effective,
because at the same time the ability to condense nucleic acids is reduced. One
promising strategy to overcome this discrepancy is the linkage of shorter PEI chains
[40] or oligo-amines [41] via local environment specific bioreducible disulfide bonds.
This approach was reported to reduce the cytotoxicity and simultaneously enhance
the gene transfer activity.
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5.2 Hydrophilic modification
The most prominent modification of PEI homopolymers is clearly the attachment
of hydrophilic moieties, at the very most PEG, to reduce the cytotoxic effects of
cationic charges. Covalent attachment of PEG generally involves the formation of
PEG-PEI block copolymers, assembling to core-shell type structures upon complex-
ation; core-forming complexes are surrounded by shielding PEG shells [4, 21]. This
PEGylation commonly leads to the above described effects on toxicity, circulation
time, transfection efficiency and proinflammatory signalling (Section 4.1.4).
5.3 Hydrophobic modification leading to amphiphilic block
copolymers
PEG segments in PEG-PEI diblock copolymers facilitate the formation of hydro-
philic shells upon complexation with nucleic acids. Beyond that basic diblock struc-
ture, the incorporation of hydrophilic and hydrophobic blocks into the PEI struc-
ture results in amphiphilic block copolymers (ABCs). ABCs are extensively used in
pharmaceutical technology for controlled release of drugs and/or nucleic acids [42].
Several triblock copolymers comprising PEG, PEI plus an additional hydrophobic
block have been reported to spontaneously self-assemble to various multifunctional
carrier types in aqueous milieu, even in absence of complex-forming negative charges
(compare Table I.1). Therefore, delivery vehicles from ABCs can be manufactured
in a first step and are subsequently capable of loading with drugs and/or nucleic
acids. Consequently, optimising complex properties by applying various loading
techniques or stabilising and storing loaded and unloaded carriers for further use is
a reasonable and promising approach.
23
P
art
I
5
E
volution
ofnon-viraldelivery
system
s
Table I.1: Literature overview of amphiphilic block copolymers used in drug- and gene-delivery
hydrophilic
segment
hydrophobic segment cationic segment payload interaction mechanism reference
PEG PCL - - - [43, 44]
PEG PCL - Neurotrophic Agent
(FK505/L-685,818)
encapsulation [45]
PEG PCL - Nimodipine encapsulation [46]
PEG PCL - Indomethacin encapsulation [47, 48]
PEG PCL - Insulin encapsulation [49]
PEG PCL - Hydroxycamphothericin encapsulation [18]
PEG PCL - Phthalocyanine 4 encapsulation [50]
PEG PCL/PLA - Doxorubicin encapsulation [51]
PEG PCL/PLA - Sagopilone encapsulation [52, 53]
PEG PCL/PLA/TMC - - - [54]
PEG pVaLa - Camphothericin encapsulation [55]
PEG PLA - - - [56, 57, 58, 59, 60]
PEG PLA - Doxorubicin conjugation [61]
PEG PLA - Procain encapsulation [62]
PEG PLA -  -Lapachone encapsulation [63]
PEG PLGA - - - [20]
PEG PLA/PLGA - Antiestrogen RU58668 encapsulation [64]
PEG PPDO-PLAb - pDNA electrostatic [65]
apoly(valerolactone)
bpoly(p-Dioxanone-co-L-Lactide)
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hydrophilic
segment
hydrophobic segment cationic segment payload interaction mechanism reference
PEG PCL-TMCc - Amphothericin B encapsulation [66]
PEG - PMDSd pDNA electrostatic [67]
PEG - lPEI - - [68]
PEG - lPEI pDNA electrostatic [38]
- PCL PDMAEMA siRNA/Paclitaxel electrostatic,
encapsulation
[69]
- pBMAe PDMAEMA siRNA/Doxorubicin electrostatic,
encapsulation
[70]
- p(IPAAm-co-
DMAAm)f
PLA - - [71]
- PDMSg PDMAEMAh - - [72]
PEG PCL PPEEAi siRNA electrostatic [73, 74]
PEG PCL PPEEAi siRNA/Paclitaxel electrostatic,
encapsulation
[75]
PEG PCL bPEI - - [76]
PEG PCL bPEI pDNA electrostatic [77, 78, 79, 80]
PEG PCL bPEI siRNA electrostatic [19, 81]
PEG PCL bPEI pDNA/Doxorubicin electrostatic,
encapsulation
[82]
cPCL-co-poly(Triethylenecarbonate)
dpoly(N-methyldietheneamine sebacate)
epoly(butylmethacrylate)
fpoly(N-isopropylacrylamide-co-N,N-dimethylacrylamide)
gpoly(dimethylsiloxane)
hpoly(2-dimethylamino ethyl methacrylate)
ipoly(2-aminoethyl ethylene phosphate)
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hydrophilic
segment
hydrophobic segment cationic segment payload interaction mechanism reference
PEG PCL lPEI siRNA/Doxorubicin electrostatic,
encapsulation
[83]
PEG PCL P2VPj - - [84]
PEG PLys(Z)k bPEI - - [85]
PEG PS P2VP - - [86, 87]
PEG PBLGl bPEI pDNA electrostatic [88]
jpoly(2-vinylpyridine)
kpoly(✏-benzyloxy-carbonyl-L-Lysine)
lpoly( -benzyl-L-glutamate)
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5.3.1 Employed hydrophobic polymers
In contrast to the omnipresence of PEG as a hydrophilic block, diverse hydro-
phobic moieties have been employed for block copolymer manufacturing. Methac-
rylic polymers, poly(amino acids), poly(siloxanes), different types of poly(esters)
as well as their copolymers have been reported. Table I.1 gives an overview of
various compounds with different hydrophilic and hydrophobic segments in liter-
ature. Some of the most frequently used materials consist of polyesters, includ-
ing poly(glycolic acid), poly(lactic acid) (PLA), copolymers from lactide/glycolide
(PLGA) and poly(✏-caprolactone) (PCL) [42]. Those polymers have been employed
in biomaterials or drug delivery systems for a long time and they have a history of
safe application in humans. Moreover, polyesters are well known for their degradab-
ility via unspecific hydrolytic cleavage. In case of polyester containing copolymers,
cleavage of the ester bonds may lead to small enough (<30 kDa) non-degradable
fragments (such as PEG or PEI) that may be excreted via the kidneys [30]. This is
paramount important after (repeated) systemic application to prevent accumulation
in body tissues, that maybe lead to unknown long-term toxicity effects. Usually the
degradation half-live of PCL is greatly enlarged as compared to PLA or PLGA;
whereas PCL degrades typically over a period of several years [89], the degradation
behaviour of PLGA can easily be controlled from a few months up to several years
by altering the copolymer ratio [90]. However, the presence of hydrophilic and/or
amine moieties was reported to accelerate hydrolytic degradation [79, 76].
5.3.2 Self organisation
The unique chemical composition of covalently tethered hydrophilic and hydrophobic
segments makes ABCs capable of self-organisation, leading to the formation of nano-
scopic, typically core-shell-structured assemblies in aqueous milieu. Hydrophobic
core regions may increase stability and serve as reservoirs for hydrophobic drugs
or dyes, shell moieties protect from aggregation or phagocytosis. Co-loading of hy-
drophobic substances allows simultaneous delivery of nucleic acids and drugs (e.g.
chemotherapeutics) or dyes (e.g. for “theranostic” approaches). Depending on the
nature of the core-forming block, drugs may be incorporated by chemical, physical
or electrostatic means [91]. As a function of the MW-ratio of hydrophilic and hydro-
phobic blocks, different types of carriers, such as polymeric micelles, nanoparticles,
polymersomes and a couple of more complicated structures have been reported in
literature [92]. As each structure has distinct advantages regarding drug solubilisa-
tion, circulation time or the drug release profile it may be possible to tailor those
properties by controlling the structure of the assemblies. Despite the knowledge
27
Part I 5 Evolution of non-viral delivery systems
about the general relationships between polymer and carrier structure, details are
still unclear [3]. The overall goal must be to deduce a relationship between chem-
ical structure and important biological properties such as toxicity and transfection
efficiency in vitro and in vivo.
Polymeric micelles Predominantly hydrophilic block copolymers are known
to preferably form polymeric micelles [42] (Figure I.7). Driven by thermodynamic
force in order to achieve a state of minimum free energy (G°), self-assembly appears
above the critical micelle concentration (CMC) in a reversible process, as described
in equation I.1, with the gas constant R (8.31 J/mol/K) and the CMC in mol/L.
 G°=RT·ln(CMC) (I.1)
hydrophilic block
hydrophobic block
self-assembly
aqueous solution 
> CMC
Figure I.7: Micellisation model for an amphiphilic AB-diblock copolymer
Typical CMC values for polymeric micelles are in the range of 10 7-10 6 m, which is
generally much lower than in case of low molecular weight surfactants (10 4-10 3 m)
[42]. This involves a distinct advantage of polymeric micelles as consequently those
are more robust against disassembly upon rapid and extreme dilution, which is
a prerequisite for intravenous injection. In addition to thermodynamic stability,
polymeric micelles typically also exhibit increased physical stability due to the in-
teraction of hydrophobic chains leading to a more stable kinetically “frozen” core.
Typical sizes for polymeric micelles range from 10 to 100 nm [93]. In addition to
spherical structures, a variety of more complicated shapes such as nanorods, worm-
like micelles or polymersomes with structures similar to lipid bilayers have been
reported [13]. Ultimately the shape of the micelle can be controlled by fine-tuning
the ratio of hydrophilic and hydrophobic block-length [92].
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Particles Nanoparticles are typically generated from block copolymers with
predominant hydrophobic segments. The equilibrium dynamics is greatly reduced
as compared to polymeric micelles and the manufacturing process can be described
by a precipitation rather than a self-assembly process. Hydrophobic cores are largely
matrix-like, which was reported to be superior regarding loading capacity and col-
loidal stability [92]. Typical sizes are larger than those of polymeric micelles, range
from 50 to 200 nm and in contrast to polymeric micelle sizes further vary depend-
ing on the kinetic control variables during the manufacturing process [92]. Hence,
monitoring diameters at different manufacturing conditions provides a technique
to distinguish between micelle- and particle-like assemblies. However, the terms
“particle” and “micelle” are often used imprecisely in literature. Nevertheless, a clear
distinction is not always possible or desirable and in literature hybrid structures are
described.
5.4 Multifunctional carriers
Apparently, a successful gene delivery vehicle ought to be multifunctional, and mod-
ular designed ABCs represent a versatile platform for these approaches. Recently,
first representatives of this new class of smart carriers have emerged: Firstly hydro-
phobic reservoir moieties have been used for co-loading with additional cytostatic
drugs or dyes. Secondly by decoration with receptor ligands, targeting functionality
for specific cell types was achieved. Furthermore, in situ forming sensing formats
were employed for elucidating intracellular trafficking and last but not least stimuli
responsive carriers enable target specific unpacking.
5.4.1 “Theranostics”
It is the aim of “theranostics” to combine drug therapy with diagnostic imaging,
nucleic acid delivery and/or biosensing applications all in one single engineered nano-
carrier [94]. Therefore, polymers have been tagged with imaging labels such as
iron oxide or gold nanoparticles for magnetic resonance imaging or photothermal
treatment [95]. Furthermore, fluorescence based methods have widely been used
to study intracellular trafficking mechanisms [96]. Semiconductor nano-crystals, or
quantum dots (QDs), have recently begun to replace conventional fluorophores. QDs
consist of a semiconductor metal core (e.g. CdSe) surrounded by a coating of wider
bandgap semiconductor metals (e.g. ZnS). As compared to conventional fluorescent
molecules, QDs offer unique optical properties such as wideband excitation and
narrow emission spectra, increased photostability and high quantum yield [97]. By
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varying semiconductor materials and sizes, QDs provide a full range of emission
wavelength from the UV to the near IR, which renders them amongst the ideal
candidates for visualisation in biological environment of cells and tissues [94].
5.4.2 Fluorescence resonance energy transfer (FRET)
To complement “theranostic” imaging, in situ forming nano-sensors based on fluor-
escence (or Förster) resonance energy transfer (FRET) have recently received great
attention. FRET is a physical process and involves the non-radiative transfer of ex-
citation energy from a donor fluorophore to a proximal acceptor molecule by dipole-
dipole interaction [98]. Prerequisites for this phenomenon to occur are an overlap
in donor emission and acceptor excitation spectra and a short distance (<10 nm)
between the two fluorophores (plus a suitable three-dimensional alignment). There-
fore, FRET has been utilised as an optical ruler to probe the dissociation process
between two fluorescently labelled biomolecules [99]. The above mentioned out-
standing optical properties of QDs allow them to function as excellent FRET donors
and QD-FRET sensing formats have recently been incorporated into several carrier
systems. Energy transfer between fluorescently labelled carrier and siRNA allows
these systems to function as on/off-switch (Figure I.8) to monitor the timely dissoci-
ation of the complex [96]. Subsequently, dual labelling allows independent tracking
of carrier and nucleic acid to study the intracellular fate in vitro or the biodistri-
bution in vivo. Surely, these smart imaging formats have the potential to provide
a deeper understanding of fundamental delivery processes and accelerate a more
rational design of prospective gene carriers.
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Figure I.8: Exemplary illustration of FRET switching functionality; upon donor excita-
tion, intact QD-FRET complexes emit light via energy transfer at acceptor
emission wavelength; In contrast to that, dissociated complexes simply emit
light at donor emission frequency.
5.4.3 Stimuli responsive systems
Stimuli responsive systems promise release of the cargo just in time and at the right
place. Lee et al. for instance have reversibly grafted anionic charges onto the poly-
mer backbone to result in gene carriers with increased colloidal stability in physiolo-
gical environments; then, upon acidification in the endosome, anionic functionalities
are cleaved, leading to charge conversion and release into the cytosol [100]. A similar
strategy was reported by Shim et al. for acid degradable PEI-based carrier systems,
leading to efficient siRNA unpacking upon endosomal release [2]. Similarly, conjuga-
tion of siRNA-carrier-complexes with poly(styrene-co-maleic anhydride) polyanions
leads to pH-responsive functionality and subsequently enhanced endosomal release
[70]. Thermoresponsive polymeric micelles were assembled from block copolymers
comprising poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide) and PLA. Mi-
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celles were reported to be stable below 40 °C, whereas higher temperatures led to
aggregation and release of the loaded material. This approach may be useful for
local cancer therapy in combination with cancer heating [71]. Additionally, mag-
netic iron-oxide particles may be employed as a heat source or as a contrast agent
for “theranostic” magnetic resonance imaging. Those are just a few examples for
smart stimuli responsive vector systems. After all, recent progress in nucleic acid
therapy is largely due to advances in vector technology [1] and the evolution of
delivery systems is a currently on-going process.
6 Aims and objectives
The overall goal of this thesis was to contribute to the development of non-viral
delivery systems by establishing a versatile, potent, biodegradable and biocompat-
ible PEG-PCL-PEI-based vector platform. However, a trial and error approach via
screening various types of cationic polymers or polymer blends was not the aim of
this study. In fact, a systematic bottom up study considering all crucial aspects of
non-viral gene delivery was pursued. This included:
(1) systematic chemical manufacturing and characterisation of a library of PEG-
PCL-PEI compounds
(2) testing the feasibility of assembling gene-delivery vehicles from those polymers
plus the physicochemical and toxicological characterisation of the assemblies
(3) optimising the process of carrier formation and nucleic acid loading
(4) reproducible storage of carriers for later in vitro and in vivo use
(5) in vitro and in vivo testing of selected polymer vectors
(6) the manufacture of multifunctional delivery vehicles by co-loading the hydro-
phobic PCL cargo with drugs or dyes
Part I reviews general aspects of gene therapy with focus on the specific require-
ments for the manufacture of multifunctional non-viral vehicles for delivery of siRNA.
Part II covers the issues (1) and (2). It was the aim to establish a poly-
mer library comprising vectors with systematically altered hydrophilic/hydrophobic
ratio. In that way a relationship between chemical composition and carrier prop-
erties was to be derived. This necessitated the assembly of polymer molecules to
gene carriers via the solvent displacement process and a thorough physicochemical
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characterisation of the assemblies. Those investigations included hydrodynamic dia-
meter, morphology, surface charge, PEG shell thickness, colloidal stability and in
vitro toxicity as well as the correlation of those features to the chemical structure.
The balance of hydrophilic and hydrophobic segments is well-known to be a crucial
parameter for all of those properties. Results of part II represent the basis for all
subsequent work and promising polymers were selected for further investigations.
Part III deals with the assembly and loading process (3) of previously se-
lected polymers with the aim of manufacturing compactly condensed, stable and
uniform siRNA complexes. Low N/P ratios (for a decreased toxicity) and highly
concentrated carrier suspensions (due to a limited injection volume) were required
for subsequent in vivo studies. Therefore, assembly process and the siRNA loading
were optimised by investigating various techniques of the solvent displacement and
the siRNA-loading procedure (including siRNA loading while and after carrier as-
sembly). It was hypothesised that a more uniform condensation process leads to a
more homogeneous distribution of charges during the complexation of siRNA. This
improved process in turn may result in smaller complex sizes, more uniform size
distributions, superior complex stability and protection of nucleic acids as well as
increased reproducibility. The combination of these factors may also lead to a boost
in transfection performance. Therefore, complexes formed via a consistent micro-
fluidic mixing process are believed to be superior to those prepared by rapid batch
mixing.
Part IV concerns the transfer of preassembled carriers to the dry state (4) for
an increased shelf-life, which is a prerequisite for effective in vitro and in vivo usage.
This was to be achieved by lyophilisation in presence of a lyoprotectant. By compar-
ing size, morphology and transfection efficiency of dry-stored and freshly-prepared
samples, the feasibility of freeze-drying was to be proven. Lyoprotectant concen-
tration and N/P ratio were regarded as critical parameters upon the lyophilisation
process.
Part V deals with in vitro investigation of transfection efficiency and cell uptake
of previously selected carriers and the correlation of the results to those obtained
under in vivo conditions (5). One goal was to relate vector performance to chem-
ical composition. Furthermore, it was the aim to utilise the hydrophobic cargo for
encapsulation of hydrophobic fluorescent QDs (6). The resulting multifunctional
carrier system represents a promising hybrid system for “theranostic” purposes or
co-delivery of drugs and dyes. Furthermore, af FRET capable system was to be
established by complexation of these fluorescent carriers with fluorescently labelled
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siRNA. As an in situ forming on/off-switch this system may contribute to elucidat-
ing the nucleic acid unpacking process and the intracellular fate.
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Abstract
Amphiphilic PEG-PCL-PEI triblock copolymers self-assemble into nano-scaled, pos-
itively charged, multifunctional carriers, suitable for drug and gene delivery. A
set of block copolymers with varying hydrophilic/hydrophobic ratio (systematically
altered at the borderline of micelle and particle forming polymers) was synthesised,
characterised and assembled into carriers. A detailed structural characterisation in
the liquid state of these assemblies was carried out: carrier size was determined
using dynamic light scattering, cryogenic scanning electron microscopy and atomic
force microscopy. Nuclear magnetic resonance analyses elucidated carrier’s core-shell
structure. ⇣-potential and thickness of the hydrophilic outer polymer shell were de-
termined by laser Doppler anemometry. Subsequently the impact of carrier’s struc-
ture on its features (stability and toxicity) was investigated. Polymers hydrophilic
in nature formed small (<40 nm) micelle-like carriers, whilst hydrophobic polymers
aggregated to larger particle-like assemblies (>100 nm). Monitoring carrier size as
a function of initial polymer concentration clarified different assembly mechanisms.
Shell thickness, colloidal stability and toxicity were found to depend on the length
of the hydrophilic polymer block. Due to controllable size, charge, stability and tox-
icity, this class of novel carriers is a promising candidate for prospective co-delivery
of drugs and nucleic acids.
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1 Introduction
Non viral delivery of nucleic acids for treatment of genetic diseases, including cancer
[101] possesses tremendous potential, yet successful clinical applications of these new
therapeutic agents are still scarce. The lack of efficient and safe delivery systems
remains a critical factor for translational efforts. In the field of drug delivery poor
aqueous solubility represents a severe drawback for many hydrophobic drugs, such
as Sagopilone [53] or Paclitaxel [69]. Essential requirements for delivery vehicles
in both fields are quite similar: Stability and protection from degradation or rapid
excretion, low toxicity, biocompatibility and biodegradability, targeting of specific
cells or tissues.
Recently, amphiphilic block copolymers have attracted increasing attention, ow-
ing to their ability to form various types of nano-carriers that can be optimally
engineered [73]. In aqueous media self organisation leads to formation of aggreg-
ates, particles, micelles, vesicles [92] and even more complex structures [102]. In case
of polyethylene glycol(PEG)-polyester diblock copolymers mainly micelle like struc-
tures and nanoparticles (NPs) have been reported. Sizes and structures generally
depend on the molecular weight (MW) ratio of hydrophilic and hydrophobic seg-
ments [20, 103]. Tuning this delicate balance might help to alter physical properties,
and optimise delivery performance and cytotoxicity.
Cationic amphiphiles make simultaneous delivery of nucleic acids and drugs pos-
sible. Among different vectors multifunctional ABC type block copolymers con-
sisting of PEG, a polyester block like poly-✏-caprolactone (PCL) and a polycation
segment such as linear poly(ethyleneimine) (lPEI) have emerged as promising car-
riers [73, 75]. In aqueous media PEG acts as the shell forming, hydrophilic block,
counteracting protein absorption while maintaining suspension stability. Due to
its hydrophilicity, chain flexibility, electrical neutrality and absence of functional
groups, serum proteins cannot be bound to the PEG modified surfaces [58]. Gener-
ally, high surface density, complete surface coverage and long PEG chains (typically
at least 2k Da) are necessary for effective shielding [15]. PCL segments arranged as
a hydrophobic core could be suitable reservoirs for water insoluble drugs. Biocom-
patibility of both, PEG and PCL, have been demonstrated previously and aliphatic
polyesters like PCL have proven to be biodegradable in aqueous media [76]. Cationic
segments located at the interface between core and shell forming blocks, are in par-
ticular useful for condensation of nucleic acids or negatively charged drugs. Upon
delivery, those can be easily unpacked despite being protected by surrounding PEG
chains. Furthermore positive charges increase colloidal stability and enable cell in-
teraction. In terms of gene delivery PEI is a well known polymer and has shown
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superior transfection efficiency due to high amine density and effective buffering ca-
pacity [3]. As to toxicity, PEI’s positive charges are known to disrupt lipid bilayer
membranes and adhere to outer cell membranes [104]. High MW PEI compounds
generally showed increased cytotoxicity [30], but also the three dimensional structure
and conformational flexibility were demonstrated to have an effect [33]. Compared
to generally utilised branched PEI25k Da, lower MW (2500 Da) linear PEIs (along
with PEG shielding [30]), applied in this work, promise reduced toxicity. Presence of
hydrophobic and cationic moistures makes the carrier multifunctional for co deliv-
ery of nucleic acids and drugs or for theragnostic purposes [69, 83, 75]. To design a
biocompatible and stable vector, the ideal block lengths for hydrophilic, hydrophobic
and charged segments are to be found.
The finding of a structure activity relationship was the main goal of this study.
Therefore a set of PEG-PCL-lPEI triblock copolymers with varying PEG and PCL
molecular weights was synthesised and characterised. In contrast to established wa-
ter soluble copolymers, the hydrophilic/hydrophobic balance was fine tuned at the
borderline between nanoparticle and micelle forming polymers. Completely water
soluble polymeric vectors are known to assemble with DNA to charged polyelec-
trolyte complexes, so-called “polyplexes”, which are commonly used for gene deliv-
ery [3]. Hydrophobic triblock copolymers, presented in this work, self assemble to
nano-carriers of different size and structure, even without addition of surfactants or
oppositely charged compounds. With decreasing hydrophilic/hydrophobic ratio a
transition from partly water soluble micelle like assemblies to mainly water insol-
uble particle like precipitates is observed, even though a clear distinction between
micelle and particle is not always possible or desirable. A detailed structural charac-
terisation of carriers using methods that allow direct analysis of the structure in the
liquid state was carried out. Structural features were correlated to physical charac-
teristics and physiochemical properties. Controlling carrier structure is believed to
be the key for tailoring subsequent carrier features.
2 Materials and methods
2.1 Reagents and chemicals
Tin(II)-ethylhexanoate (Sn(Oct)2, approx. 95%), acryloyl chloride (96%, stabil-
ised), ✏-Caprolactone (✏CL, purum), monomethyl PEG (mPEG, MW=5k/2k/550
Da), Triethylamine (puriss.), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide (MTT) as well as further chemicals and solvents not mentioned in detail
were supplied from Sigma Aldrich GmbH (Steinheim, Germany). Chloroform and
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methyl alcohol (extra dry) plus HPLC grade eluents were purchased from Acros Or-
ganics (Geel, Belgium). Deuterated solvents for nuclear magnetic resonance (NMR)
analyses were obtained from Merck (Darmstadt, Germany). Poly(ethyleneimine)
linear (MW=2500 Da) was provided by Polysciences Inc. (Warrington, PA, USA).
Albumin (BSA, Fraction V, >99%, pulv. Bovine) was acquired from Roth GmbH
(Karlsruhe, Germany).
2.2 Synthesis
Synthesis was carried out by a modified synthesis route that has been described
in detail elsewhere [79]. Briefly, mPEG and ✏CL (amount calculated to result the
designated PCL block length) were put into a reaction flask and dried at reduced
pressure at a temperature of 45 °C (for PEG500) respectively 65 °C (for PEG2k/5k).
Subsequently the flask was purged with dry argon and Sn(Oct)2 (0.1 mol% corres-
ponding to ✏CL), dissolved in dry tetrahydrofuran (THF, c=0.25 m), was injected.
Then, THF was removed in vacuo over 3 h and bulk polymerisation was carried out
at a temperature of 135 °C for 12 h. After cooling to room temperature (RT), the
yellow solid was dissolved in chloroform, purified by precipitation in cold methanol
and dried in vacuo (yield: 80.0%). In a second reaction step 1.00 eq of PEG-PCL
diblock copolymer, dissolved in benzene (c=0.2 g/mL), was put into a reaction
flask, equipped with a condenser. Following, 1.00 eq of triethylamine and 2.00 eq
acryloyl chloride were injected. During 12 h refluxation time at 80 °C, the trans-
parent solution misted due to crystallisation of NHEt3Cl. After removing the salt
by filtration, the polymer was purified by precipitation in cold hexane and dried in
vacuo (yield: 94.7%). For comparison reasons monomethyl PCL (mPCL) with a
molecular weight of 10k Da was synthesised by methanol initiated polymerisation
of ✏CL monomer. Reaction was carried out analogous to PEG-PCL compounds
(yield: 91.6%). Conclusively, in a third reaction step, lPEI2500 was coupled onto
the PEG-PCL linker copolymer by Michael type microaddition reaction. 1.00 eq
of lPEI and 1.00 eq PEG-PCL-linker were added into separate reaction flasks and
dried in vacuo for 3 h. After purging with dry argon, the copolymer was dissolved in
chloroform (c=0.35 g/mL), lPEI in methanol (c=0.15 g/mL). The PEI containing
flask was heated to 60 °C and subsequently the block copolymer solution was added
drop wise. The reaction mixture was provided with a condenser and stirred at 60 °C
for 24 h. After cooling to RT, the crude product was purified by precipitation in
cold diethyl ether and dried in vacuo (yield: 70.1%). The yields of all three steps
are reported exemplarily by means of PEG500-PCL2400-lPEI2500.
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2.3 Basic polymer characterisation
2.3.1 NMR
NMR data was typically collected at 30 °C in ppm relatively to solvent signal using
Jeol ECA-400 and ECA-500 spectrometers (Eiching, Germany) operating at 400
respectively 500 MHz.
2.3.2 FT-IR
FT-IR specta were recorded using a Nicolet FT-IR 510 P spectrometer (Thermo
Fischer Scientific Inc., Waltham, MA, USA) in a range between 4000 and 400 cm 1.
The powder sample was mixed with KBr and pressed into tablets for measurement.
2.3.3 Gel permeation chromatography (GPC)
GPC was used to determine the number- and weight-average molecular weights
(M¯n, M¯w) and the polydispersity (D). Equipment consisted of two PSS SDV linear
M columns (Mainz, Germany) plus precolumn of the same type, a Merck T6300
column oven (Darmstadt, Germany) operating at 35 °C, a 6200A pump by Merck-
Hitachi (Darmstadt, Germany) and a Wyatt Optilap DSP RI-detector (Dernbach,
Germany). A 2.5% (m/m) solution of LiBr in N,N-dimethylacetamide (DMAc)
(HPLC grade) was used as eluent at a flow rate of 0.5 mL/min. Samples were dis-
solved in DMAc/LiBr at concentrations of 2 mg/mL. For each measurement 200 µL
polymer solution was injected. The molecular weights of samples were calculated
based on a calibration curve generated by Poly(methyl methacrylate) standards,
which have a known narrow molecular weight distribution.
2.3.4 Differential scanning calorimetry (DSC)
DSC measurements were carried out on a DSC822e (Mettler Toledo, Schwerzen-
bach, Switzerland) at a heating rate of 20 °C/min using dry nitrogen purge gas.
The samples were first heated to 100 °C, subsequently cooled to -100 °C with li-
quid nitrogen and heated again to 180 °C. Thermograms were normalised to sample
weight. The DIN midpoint of the slope change of the heat flow plot of the second
heating scan was considered as the glass transition temperature (Tg) and the heat
flow capacity change ( cp) was determined. The melting temperatures (Tm) were
taken as the maximum of endothermic peaks. PEG and PCL homopolymers of
identical molecular weights than blocks incorporated in copolymers were measured
in comparison to PEG-PCL diblock copolymers.
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2.3.5 Cu2+-assay
Cu2+-assay [105] was utilised to determine the amine fraction per overall poly-
mer mass. Polymers were dissolved in a mixture (1:1) of double distilled and fil-
trated water and N-Methyl-2-pyrrolidone in concentrations of 0.4 mg/mL. 50 µL
of this solution were mixed vigorously with 50 µL of a auqueous CuSO4 solution
(c=0.145 mg/mL dissolved in 0.1 N KAc, pH=5.5). Subsequently absorption was
measured at 280 nm employing a Pharmacia Biotech Ultrospec 3000 (GE Health-
care, Little Chalfont, Buckinghamshire, UK). Using a bPEI25k Da calibration curve
together with the molecular weight determined by 1H NMR analysis, the amount of
PEI per overall polymer mass was calculated. All date reported represent the mean
values of at least three replicates ± standard deviations.
2.3.6 Critical micelle concentration (CMC)
Polymers were dissolved in double distilled and filtrated water (PEG500-PCL2500-
lPEI2500: c=0.05 mg/mL, PEG2k-PCL2500-lPEI2500: c=0.20 mg/mL, PEG5k-
PCL2500-lPEI2500: c=1.00 mg/mL) and pipetted successively to 80 mL of double
distilled and filtrated water at constant temperature of 25 °C. Surface tension was
measured after each addition step using a Krüss K11 MK2 tensiometer (Hamburg,
Germany) equipped with a PL01 Wilhelmy Plate. Solution was tempered stirring
magnetically for 10 min between measurements. The intersection of two linear
regressions was considered as the CMC value. Volume increase was regarded math-
ematically.
2.4 Assembly of nano-carriers from triblock copolymers
Nano-carriers were prepared by a solvent displacement technique, described in de-
tail elsewhere [106]. Carriers were typically prepared by dissolving 5-30 mg block
copolymer in 1 mL of acetone. The resulting solution was subsequently injected
into a magnetically stirred (500 rpm) phase of 5 mL double distilled and filtrated
water using an Heidolph Pumpdrive 5001 (Nürnberg, Germany) at constant flow
rate (8 ml/min). The ratio of water and organic phase (w:o=5) was kept constant.
After injection of the organic phase, the resulting colloidal suspension was stirred
for 3 h under reduced pressure to remove organic solvent. Nanosuspensions (NSs)
were characterised and used directly after preparation.
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2.5 Characterisation of nano-carriers
2.5.1 Size and ⇣-potential
The average particle size and size distribution of the obtained nano-carriers were
determined by dynamic light scattering (DLS) using a Zetasizer NanoZS/ZEN3600
(Malvern Instruments, Herrenberg, Germany). ⇣-potential was measured by LDA
using the same device. Analyses were typically performed at a temperature of 25 °C
using samples appropriately diluted with filtrated and double distilled water. The
particle mean diameter (z-ave.), the width of the fitted Gaussian distribution, which
is displayed as the polydispersity index (PDI), as well as the average ⇣-potential
values was calculated from data of at least 10 runs. Data are displayed as the mean
value of at least three measurements ± standard deviation.
2.5.2 Fixed aqueous layer thickness (FALT)
FALT was determined examining the influence of ionic strength on particle surface
charge as described in detail elsewhere [107]. Carriers were prepared as described
above (c(NS)=-10 mg/mL) and diluted using NaCl stock solution and double dis-
tilled and filtrated water to reach the desired electrolyte concentration at a polymer
concentration of 0.5 mg/mL. Subsequently size and ⇣-potentials of different dilu-
tions were measured as described above. Date displayed as the mean value of at
least three measurements ± standard deviation.
2.5.3 Atomic force microscope (AFM)
10 µL of the respective NSs (c=1 mg/mL) were pipetted onto a 1·1 cm substrate
piece of freshly cleaved mica and incubated for 5 min. The samples were then rinsed
several times with double distilled and filtrated water in order to remove any excess
material. Once mounted onto the sample stage of the AFM, the sample was allowed
to reach thermal equilibrium (30 min) before analysis. AFM imaging was performed
in liquid phase (double distilled and filtrated water) on a Nanoscope IV system
(Veeco, Santa Barbara, CA, USA). Pyramidal, oxide sharpened Si3N4 tips attached
to a V-shaped substrate (Olympus, Tokyo, Japan) were used for imaging. All images
were measured using tapping mode AFM with constant amplitude attenuation. The
cantilever approach was performed with a drive amplitude of 250 mV. To achieve
high-resolution images the drive amplitude was lowered to ⇠75 mV, while the set
point was adjusted to minimal forces.
42
Part II 2 Materials and methods
2.5.4 Cryogenic scanning electron microscope (cryoSEM)
CryoSEM images were obtained using a JSM-7500F (Jeol, Tokyo, Japan) equipped
with a ALTO-2500 liquid nitrogen (LN2) cryo-transfer system (Gatan Inc., Pleas-
anton, CA, USA) enabling SEM observation at a specimen temperature of -140 °C.
Samples were sputtered with a thin platinum layer directly using the ALTO system.
Carriers were observed at an accelerating voltage of 4 kV.
2.5.5 Structure elucidation via 1H NMR spectroscopy
To elucidate structural features of nano-carriers, a series of 1H NMR experiments
was carried out. Nano-carriers were prepared as described above using deuterated
solvents (D2O, acetone-D6) (c(NS)=8 mg/mL). For temperature-dependent NMR
analyses 500 µL NS were filled into the outer chamber of a cylindrical coaxial NMR-
tube (Wilmad-LabGlass, NY, USA). The inner compartment was filled with an ex-
ternal standard, a solution of pyridine in D2O (c=0.01 Vol%). 1H NMR spectra were
recorded at different temperatures (30-75 °C,  T=5 °C, equilibration time=30 min)
at 500 MHz. Position and intensity of pyridine signals were kept constant in all tem-
perature dependent measurements. For measurements in D2O/acetone-D6 mixtures
NSs were diluted using acetone-D6 and D2O to reach the desired acetone concen-
tration at a polymer concentration of 4 mg/mL. 1H NMR spectra of mixtures were
compared to a polymer-solution in acetone-D6 (c=4 mg/mL).
Additionally mPEG5k-PCL10k-lPEI2500 samples, prepared for variable temper-
ature NMR analyses, were further measured in size and charge via DLS and LDA
(as described in section 2.5.1). Data was collected at temperatures between 25-90 °C
( T=5 °C, equilibration time=15 min). ⇣-potential was measured at RT before and
after temperature treatment. mPCL10k particles were examined for comparison
reasons.
2.5.6 Analysis of colloidal stability
The colloidal stability of nano-carriers was evaluated from their resistance to NaCl-
and albumin-induced aggregation. Nano-carriers were prepared as described above
(c(NS)= 4 mg/mL, respectively 2 mg/mL in case of mPCL). NSs were freed from
loose aggregates by centrifugation (1 min, 1000·g), mixed with water and sub-
sequently with an albumin/NaCl, stock solution to reach the desired albumin/NaCl
concentration at a polymer concentration of 2 mg/mL (respectively 1 mg/mL in case
of mPCL10k). After 10 min turbidity was measured employing Pharmacia Biotech
Ultrospec 3000 (GE Healthcare, Little Chalfont, Buckinghamshire, UK) at 500 nm.
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Measured absorptions were normalised to 100% turbidity. The onset of a dramatic
increase in turbidity was considered as concentration of aggregation. Following, size
and ⇣-potential were measured as described above. Date displayed as the mean
value of at least three measurements ± standard deviation.
2.5.7 Cytotoxicity in HeLa-Luc cells (MTT assay)
MTT assay was performed as described elsewhere [108] to determine the cytotox-
icity of PEG-PCL10k-lPEI2500 carriers. HeLa-Luc cells were seeded into 96-well
plates (Nunc, Langenselbold, Germany) at a density of 8,000 cells/well 24 h prior
to experiment, then the cell culture medium was replaced with increasing polymer
concentration (assembled to carriers) in 100 µL cell culture medium. After 24 h of in-
cubation, medium was replaced by Dulbecco’s Modified Eagle’s Medium (DMEM)
without serum, containing 0.2 mg/mL MTT. After 4 h of incubation at 37 °C,
medium was carefully removed and formazane crystals were dissolved in 200 µL
dimethyl sulfoxide per well. Measurement was performed using an ELISA reader
(Titertek Plus Ms 212, ICN, Eschwege, Germany) at wavelength of 570 and 690 nm.
Relative viability was calculated in % related to cells with untreated cells. Data is
persented as means of four measurements ± standard deviation. The inflexion point
of a sigmoidal regression was considered as IC50 concentration.
3 Results
3.1 Synthesis and characterisation
Triblock copolymers were synthesised in three reaction steps according to Figure II.1.
In the synthesis of the PEG-PCL diblock copolymers, PCL block length was con-
trolled by the initial amount of ✏CL and determined by comparing the intensity of
relevant 1H NMR signals of PEG and PCL. Additionally, GPC was employed to
analyse the uniformity of molecular weight distributions, which were found to be
unimodal with polydispersities between 1.2-1.5 (compare basic polymer character-
isation).
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Figure II.1: Synthesis in three steps: (1) PEG-PCL was produced by ring-opening poly-
merisation initialised by the PEG hydroxyl-endgroup using Sn(Oct)2 as a
catalyst. (2) A double bond was attached onto the PEG-PCL chain-end by
esterification of the PEG-PCL hydroxyl group with acryloyl chloride. (3)
lPEI2500 was coupled onto the PEG-PCL-linker copolymer by Michael-type
microaddition reaction.
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Basic polymer characterisation exemplarily for mPEG500-PCL2400-lPEI2500 (all
other compounds were characterised in the same manner):
mPEG-PCL diblock copolymer: 1H NMR (400 MHz, CDCl3):  =1.34-1.41 (m,
65.43 H, *-[CO-(CH2)2-CH2-(CH2)2-O]m-*), 1.62-1.66 (m, 132.25 H, *-[CO-CH2-
CH2-CH2-CH2-CH2-O]m-*), 2.29-2.32 (t, 3J=7.40 Hz, 65.24 H, *-[CO-CH2-(CH2)4-
O]-*), 3.34 (s, 3.00 H, CH3-O-*), 3.55-3.56 (m, 2.07 H, Me-O-CH2-CH2-*), 3.60-3.65
(m, 39.29 H, *-[(CH2)2-O]-*), 3.69-3.70 (t, 3J=4.85 Hz, 3.57 H, *-O-CH2-CH2-O-
[CO-(CH2)5-O]-H), 4.04-4.08 (t, 3J=6.75 Hz, 63.71 H, *-[CO-(CH2)4-CH2-O]m-*),
4.21-4.24 (t, 3J=4.85 Hz, 2.43 H, *-O-CH2-CH2-O-[CO-(CH2)5-O]-H) ppm.
mPEG-PCL-linker: 1H NMR (400 MHz, CDCl3):  =1.36-1.40 (m, 75.40 H,
*-[CO-(CH2)2-CH2-(CH2)2-O]m-*), 1.62-1.65 (m, 158.55 H, *-[CO-CH2-CH2-CH2-
CH2-CH2-O]m-*), 2.28-2.32 (t, 3J=7.45 Hz, 74.72 H, *-[CO-CH2-(CH2)4-O]-*), 3.38
(s, 3.00 H, CH3-O-*), 3.53-3.56 (m, 2.36 H, Me-O-CH2-CH2-*), 3.59-3.68 (m,
38.26 H, *-[(CH2)2-O]n-*), 3.68-3.70 (t, 3J=4.80 Hz, 2.58 H, *-O-CH2-CH2-O-[CO-
(CH2)5-O]m-H), 4.04-4.07 (t, 3J=6.80 Hz, 68.02 H, *-[CO-(CH2)4-CH2-O]m-*), 4.13-
4.16 (t, 3J=6.70 Hz, 2.45 H, (*-CH2-O-CO-C2H3), 4.21-4.23 (t, 3J=4.80 Hz, 2.70 H,
*-O-CH2-CH2-O-[CO-(CH2)5-O]m-H), 5.81-5.83 (dd, 2J=1.30 Hz, 3Jcis=10.30 Hz,
0.78 H, *-CO-CH=CHH), 6.08-6.15 (dd, 3Jcis=10.30 Hz, 3Jtrans=17.40 Hz, 0.82 H,
*-CO-CH=CHH), 6.37-6.42 (dd, 2J=1.30 Hz, 3Jtrans=17.40 Hz, 0.80 H, *-CO-
CH=CHH) ppm. 13C NMR (500 MHz, CDCl3):  =24.93 (*-[CO-CH2-CH2-(CH2)3-
O]m-*), 25.88 (*-[CO-(CH2)2-CH2-(CH2)2-O]m-*), 28.70 (*-CO-(CH2)3-CH2-CH2-
]m-*), 34.47 (*-[CO-CH2-(CH2)4-O]m-*), 59.38 (CH3-O-*), 63.80 (*-O-CH2-CH2-O-
[CO-(CH2)5-O]m-*), 64.49 (*-[CO-(CH2)4-CH2-O]m-), 69.53 (*-O-CH2-CH2-O-[CO-
(CH2)5-O]m-*), 70.93 (*-[(CH2)2-O-]n-), 72.30 (MeO-CH2-*), 128.90 (*-CO-CH-
=CH2), 130.90 (*-CO-CH=CH2), 173.88 (*-[CO-(CH2)5-O]-*) ppm.
mPEG-PCL-lPEI: 1H NMR (400 MHz, CDCl3):  =1.10-1.15 (t, 3J=7.06 Hz,
12.17 H, CH3-CH2-CO-*), 1.35-1.66 (m, 69.88 H, *-[CO-(CH2)2-CH2-(CH2)2-O-]m-
*), 1.60-1.66 (m, 137.29 H, *-[CO-CH2-CH2-CH2-CH2-CH2-O]m-*), 2.28-2.33 (t,
3J=7.50 Hz, 69.37 H, *-[CO-CH2-(CH2)4-O]m-*), 2.60-2.85 (m, 212.47 H, *-[(CH2)2-
NR]k-*), 3.38 (s, 3.41 H, CH3-O-*), 3.40-3.45 (m, 14.34 H,*-(CH2)2-NC3H5O-*),
3.53-3.56 (m, 2.42 H, Me-O-CH2-CH2-*), 3.60-3.70 (m, 30.01 H, *-[(CH2)2-O]-
*), 4.03-4.08 (t, 3J=6.67 Hz, 66.15 H, *-[CO-(CH2)4-CH2-O]m-*), 4.21-4.24 (m,
1.60 H, *-O-CH2-CH2-O-[CO-(CH2)5-O]-H, *-CH2-O-CO-(CH2)2-NR2) ppm. GPC:
M¯n=7240 Da, M¯w=9230 Da, D=1.27. FT IR (KBr, cm 1) ⌫ 3250 (s, ⌫NH), 2947
(s, ⌫asCH2), 2866 (s, ⌫sCH2), 1725 (s, ⌫crC=O), 1187/1245 (s, ⌫C-O-C).
Polyester block lengths, as determined by 1H NMR, are reported in Table II.1 and
values were found to be in the range of desired molecular weights.
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Table II.1: Composition of block copolymers with different hydrophilicity along with hy-
drodynamic diameters and PDIs (determined by DLS) of carriers assembled
from these polymers
Polymer m(PCL)a/Da m(PEG)/ z-ave./nm PDI
m(PCL)b
PEG500-PCL2400-lPEI2500 3780 0.132 115.6±2.8 0.172±0.020
PEG500-PCL5k-lPEI2500 6470 0.077 123.6±3.6 0.116±0.011
PEG500-PCL10k-lPEI2500 11465 0.044 124.0±6.9 0.089±0.020
PEG2k-PCL2400-lPEI2500 2325 0.608 24.1±0.2 0.212±0.001
PEG2k-PCL5k-lPEI2500 5435 0.333 25.8±0.2 0.216±0.008
PEG2k-PCL10k-lPEI2500 10580 0.165 95.7±2.0 0.165±0.004
PEG5k-PCL2400-lPEI2500 2700 1.850 35.1±1.6 0.229±0.032
PEG5k-PCL5k-lPEI2500 6720 0.744 46.7±3.4 0.288±0.047
PEG5k-PCL10k-lPEI2500 13120 0.381 42.0±2.5 0.173±0.031
aPCL MWs determined by 1H NMR spectroscopy; bPEG/PCL ratio indicating polymer’s
hydrophilicity; DLS results presented as mean from at least three repetitions ± standard
deviation
Additionally Tm and Tg of diblock copolymers in comparison to homopolymers of
the same molecular weight were determined via DSC (Figure II.2). All DSC curves
display only one Tg close to the Tg of PCL homopolymer (-50---60 °C), suggesting
predominant immiscibility of PEG and PCL moieties [44].
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Figure II.2: DSC thermogramms of mPEG5k and mPCL10k homopolymers in compar-
ison to mPEG5k-PCL10k diblock copolymer (Tg=-52.6 °C, Tm=62 °C)
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In a second reaction step the endgroups of diblock copolymers were modified by
esterification; double bond signals in the 1H NMR spectrum between 5.7 and 6.5 ppm
(13C spectrum: 128⇠131 ppm) proved successful conversion. Finally, vanishing
double bond signal upon conjugation with PEI confirmed effective coupling in the
third reaction step (Figure II.3).
Figure II.3: 1H NMR spectra of mPEG500-PCL10000 (A), mPEG500-PCL10000-linker
(B) and mPEG500-PCL10k-lPEI2500 (C); double bond signals (5.7⇠6.5
ppm) indicate successful endgroup modification and subsequent PEI con-
jugation
Furthermore in FT-IR spectra a C=O stretch at⇠1725, C-O-C stretches at⇠1187/1245
and an amine stretch at⇠3250 cm 1, prove presence of PCL, PEG and PEI segments
(Figure II.4).
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Figure II.4: IR spectra of mPEG500-PCL2400 (A) and mPEG500-PCL2400-lPEI2500
(B); amine stretch at ⇠3265 cm 1 confirms presence of PEI
By dropwise addition of PEG-PCL-linker to PEI the conjugation ratio is supposed
to be close to 1. However, a multi addition of PEG-PCL-linkers on more than one
amine of the same PEI molecule is feasible and integration of the PEI signal in 1H
NMR spectra of all synthesised compounds revealed a coupling ratio close to 1 (data
not shown). The Cu2+-assay was utilised to quantify amine mass fraction per over-
all molecular weight. As expected, amine weight fraction decreases with increasing
PEG/PCL molecular mass as displayed in Figure II.5A, also illustrating polymers’
hydrophilicity. Molecular weight composition, as determined by 1H NMR spectro-
scopy and Cu2+-assay, is presented in Figure II.5B. Yields for the three reaction
steps were ⇠75, ⇠90 and ⇠70%, respectively, depending on PEG-PCL composition.
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Figure II.5: Block copolymer composition by % (A) and MW (B) (PEG MW as specified
by manufacturer, PCL MW as determined by 1H NMR analysis, PEI weight
fraction ± standard deviation as determined by Cu2+ assay from at least
three replicates)
3.2 Carrier size and assembly mechanism
The PEG/PCL ratio, as reported in Table II.1, is a characteristic indicator for
carrier structure. With increasing ratio the size of carriers (constant initial polymer
concentration in acetone: 25 mg/mL) decreases. CryoSEM and AFM images in the
liquid state are consistent with DLS measurements and demonstrate spherical shape
(Figure II.6). PDI values were found to be unimodal.
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Figure II.6: CryoSEM images of PEG500-PCL10k-lPEI2500 carriers (A); AFM im-
ages in the liquid state of PEG500-PCL10k-lPEI2500 (B), PEG2k-PCL10k-
lPEI2500 (C) and PEG5k-PCL10k-lPEI2500 (D) carriers
Trends in size and structure as a function of polymer hydrophilicity can be explained
by diverse carrier forming mechanisms: hydrophobic polymers precipitate quickly
upon injection into the water phase, whereas longer PEG segments control carrier
formation leading to smaller micelle-like structures. To monitor the transition from
particles to micelles, carriers were formed as a function of initial polymer concen-
tration in the acetone phase during solvent displacement process (Figure II.7). Hy-
drophobic carriers develop in size (70-140 nm) upon rise of polymer concentration,
whereas hydrophilic carriers remain fairly constant (⇠35 nm).
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Figure II.7: Carrier size as a function of initial polymer concentration in the organic
phase during solvent displacement process; data acquired from at least three
repetitions ± standard deviation
3.3 PEG shell thickness measurements
FALT of the outer PEG shell was determined by measuring the ⇣-potential as a
function of electrolyte concentration (c). In pure water, decreasing ⇣-potential with
increasing PEG MW reflects increased shielding of PEI charges on the PCL surface
by presence of the outer PEG shell. The hydrophilic PEGmoisture shifts the slipping
plane away from the surface of the PCL core and this subsequently results in a
reduced ⇣-potential. With an increase in ionic strength, ⇣ was found to decrease
according to the Gouy-Chapmann theory. A plot of ln(⇣) against  (=3.3·pc,
where  1 is the Debye length) gives the thickness of the PEG polymer layer in
nm (dshell) as the slope of a linear regression (Figure II.8A). The determined shell
thickness was found to increase with increasing PEG MW. Observed dshell values
for PEG500, 2k and 5k are in a good agreement with theoretical calculations for
a random coil, where the radius of gyration (Rg) is calculated by Equation II.1 or
II.2, depending on solvency power [109] (Table II.2); where a is the segment length
(which is 0.36 in case of PEG [109]) and N is the degree of polymerisation (which is
calculated from the PEG molecular weight specified by the manufacturer). Together
with DLS data the core diameter of the respective carrier can be easily calculated.
Figure II.8B shows a dimensional sketch of the three different core-shell carriers
bearing different PEG chain length linked to PCL and PEI segments of constant
size. Although the FALT is increasing from 1.7 to 3.3 nm with increasing PEG
MW, the decreasing core diameter is the size-dominating factor.
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Rg = a ·N1/2 (⇥ solvent) (II.1)
Rg = a ·N3/5 (good solvent) (II.2)
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Figure II.8: FALT-measurements: PEG shell thickness (which can be read of the slope)
increases with increasing PEG MW; values presented as means from at least
three measurements ± standard deviation (A); dimensional sketch of carriers
assembled from polymers bearing different PEG MWs (B)
To estimate the surface potential ( 0) the Eversole and Boardman equation was
utilised by plotting  ln ⇥tanh   e⇣4kT  ⇤ versus  as described elsewhere [110]; where e is
the electron charge (1.60·10 19 C), k is the Boltzmann constant (1.38·10 23 J/K) and
T is the absolute temperature (298.15 K). Furthermore the surface charge density  0
was derived from  0, employing Equation II.3, where n is the ion number per volume
unity (6.02·1023 m 3), ✏0 is the dielectric permittivity (8.85·10 12 C·V 1·m 1), ✏r is
the dielectric constant of water at RT (78.28) and z is the valency of the ion [111].
The number of charges was calculated from  0 together with the surface area of
the PCL core and e.  0 and  0, together with the number of positive charges on
the surface of each PCL sphere, are displayed in Table II.2. The number of pos-
itive charges was found to decrease with increasing hydrophilicity. Since lPEI2500
contains approximately 60 aminogroups (being only partly protonated plus some
amines are possibly trapped inside the PCL core due to phase mixing), calculated
charges are in the expected range.
 0 =
p
8kTn✏0✏r · sh
✓
ze 0
2kT
◆
(II.3)
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Table II.2: Shell thickness values of carriers with different PEG block length determined
by FALT measurement (dshell) in comparison to calculated values (Rg) and
electrochemical characteristics
compound dshella Rgb/nm  0/mV  0/mC·cm 1 # of
/nm chargesc
PEG500-PCL10k-lPEI2500 1.7±0.1 1.2⇠1.6 39.6±0.6 0.322±0.006 789±14
PEG2k-PCL10k-lPEI2500 2.2±0.1 2.4⇠3.5 36.3±0.9 0.290±0.009 158±5
PEG5k-PCL10k-lPEI2500 3.3±0.1 3.8⇠6.2 26.1±0.7 0.200±0.006 41±1
avalues determined by FALT measurements; bradii of gyration, calculated from Equation
II.1 and II.2; cnumber of charges located on the surface of the PCL core surface; values
are presented as means from at least three measurements ± standard deviation
3.4 Structure elucidation using 1H NMR techniques
The change in NMR line width can be utilised to examine the hypothetical core
shell structure. 1H NMR spectra of PEG5k-PCL10k-lPEI2500 dissolved in acetone-
D6 were compared to carriers of the same polymer suspended in D2O/acetone-D6
mixtures (Figure II.9). As acetone-D6 is a good solvent for PEG and PCL, the
copolymer is dissolved as a homogenous solution: Both, PEG ethylene protons at
⇠3.6 ppm and PCL signals (e. g. triplet at ⇠4.1 ppm), are sharp and completely
resolved (Figure II.9A). However, spectra in D2O (Figure II.9B-F) change: With
increasing D2O concentration PCL signals get weaker in intensity and poorer in
resolution, while the PEG signal keeps fairly constant in size and shape (apart from
minor changes).
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Figure II.9: 1H NMR spectra of PEG5k-PCL10k-lPEI2500 dissolved in acetone-D6 (A)
in comparison to carriers of the same polymer suspended in D2O/acetone-D6
mixtures (B-F)
A set of variable temperature 1H NMR analyses in D2O with pyridine (signals
between 7.2⇠8.5 ppm not shown) as an external standard was carried out (Fig-
ure II.10). Evidently at higher temperatures there is an increase in signal intensity
and resolution of PCL signals, while the PEG signal intensity decreases (along with
an upfield-shift).
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Figure II.10: Temperature dependent 1H NMR spectra of PEG5k-PCL10k-lPEI2500 car-
riers suspended in D2O
Samples prepared for temperature dependent NMR analyses were further char-
acterised in size and ⇣-potential via DLS and LDA (Figure II.11). PCL particles
increase in size starting at ⇠60 °C, probably indicating swelling and beginning
disassembly due to melting. mPEG5k-PCL10k-lPEI2500 carriers, however, first
gradually decrease in size between 40⇠80 °C, followed by rapid enlargement start-
ing at ⇠80 °C. ⇣-potentials measured at RT before and after temperature treatment
revealed a decreased charge (-14.3±3.4 mV), indicating an irreversible structure
change.
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Figure II.11: Size difference of mPEG5k-PCL10k-lPEI2500 carriers in comparison to
mPCL10k particles as a function of T
3.5 Analysis of stability
Colloidal stability was first analysed by determining the resistance to aggregation
in presence of NaCl. PCL10k particles were compared to PEG-PCL10k-lPEI2500
carriers. An increase in turbidity (Figure II.12A), hydrodynamic diameter and PDI
(Figure II.13) signed beginning PCL precipitation above concentrations of ⇠12 mm
solutions of NaCl. By contrast all three tested triblock copolymers showed greatly
improved stability up to the highest tested concentration of 500 mm. Next, albumin
was used as a less polarising polyanion to probe the shielding effect of the PEG
corona. Under these conditions stability of the three tested triblock copolymers
was found to increase in a PEG MW dependent manner (Figure II.12B). PEG5k-
PCL10k-lPEI2500 carriers completely resisted to aggregation up to the highest
tested concentration (10 mg/mL).
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Figure II.12: Stability against NaCl (A) and albumin (B); values presented as means
from at least three measurements ± standard deviation
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Figure II.13: Hydrodynamic diameter (A) and PDI (B) of nano-carriers with different
PEG shell thickness as a function of NaCl concentration monitored by DLS;
increase in size and PDI sign PCL aggregation
At concentrations above ⇠5 mg/mL aggregated PEG500 and 2k containing carriers
were found to resuspend, most likely due to an albumin coating layer leading to
peptisation. This is in agreement with ⇣-potential measurements at different elec-
trolyte concentrations, showing a reversal of the charge sign between 2⇠4 mg/mL
for all the three compounds (Figure II.14). Thus improved stability of the PEG5k
compound is truly due to PEG repulsion, as it has proven to be stable despite charge
neutrality.
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Figure II.14: Hydrodynamic diameter (A), PDI (B) and ⇣-potential of nano-carriers with
different PEG shell thickness as a function of albumin concentration mon-
itored by DLS; increase in size and PDI sign aggregation mPEG500 and
mPEG2k bearing carriers in a PEG length dependent manner; reversal of
the ⇣-potential charge sign 2⇠4 mg/mL
Further, thermodynamic stability of more hydrophilic, micelle-like carriers (PEG-
PCL2400-lPEI2500) was probed utilising CMC measurements. For the three differ-
ent PEG500, 2k and 5k compounds CMC values were found to be 0.408, 0.374
and 0.268 µg/mL. Together with the molecular weight, determined by NMR meas-
urements, molar concentrations (6.0·10-7, 5.5·10-7, 2.6·10-7 m) as well as the free
energies ( G°, -41.2, -41.4, -43.3 kJ/mol) were calculated according to Equation II.4,
with the gas constant R (8.31 J·mol 1·K 1) and the CMC in mol/L (Figure II.15,
Table II.3).
 G° = RT ·ln(CMC) (II.4)
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Figure II.15: CMC determination of hydrophilic copolymers mPEG500-PCL2400-
lPEI2500 (A), mPEG2k-PCL2400-lPEI2500 (B) and mPEG5k-PCL10k-
lPEI2500 (C) via tensiometer (Willhelmy Plate) measurement; CMC de-
termined as the intercept of two linear regressions
Table II.3: CMC and  G° values calculated using MWs derived from 1H NMR analyses
compound CMC/mg·mL 1 CMC/10 8 mol·L 1  G°/kJ·mol 1
PEG500-PCL2400-lPEI2500 0.408 6.0 -41.2
PEG2k-PCL2400-lPEI2500 0.374 5.5 -41,.4
PEG5k-PCL2400-lPEI2500 0.268 2.6 -43.3
3.6 Cytotoxicity assay
MTT assay was utilised to determine in vitro cytotoxicity of carriers assembled
from more hydrophobic PEG-PCL10k-lPEI2500 polymers, lPEI2500 was included
for comparison reasons. By contrast to water-soluble compounds, MTT assay was
utilised to determine carrier’s cytotoxicity considering its three-dimensional struc-
ture. Cytotoxicity was found to decrease with increasing PEG molecular weight.
Furthermore, all block copolymer compounds were less toxic compared to lPEI2500
(Figure II.16). bPEI25k Da, tested under the same conditions, was found to be
more toxic (IC50: 7.5±0.5 µg/mL).
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Figure II.16: Cytotoxicity of polymers bearing different PEG MWs in comparison to
lPEI2500 determined by MTT assay; values presented as means from four
measurements ± standard deviation
4 Discussion
A flexible carrier system, forming structures well positioned between particles and
micelles, was successfully synthesised and characterised to elucidate the structure
activity relationship of carriers intended for drug and gene delivery. Compared
to coupling methods using Dicyclohexylcarbodiimide/N-Hydroxysuccinimide chem-
istry [77], the synthesis route offers fewer steps, milder reaction conditions and a
more effective purification [79]. Apart from ammonium salt in the second reac-
tion step, the absence of by-products allows straightforward purification by simple
precipitation. By contrast to physically adsorbed PEG or surfactants coated on the
particle surface, covalently bound PEGs were proven to be more effective in shielding
[20].
Sizes of carriers, assembled from those polymers, were demonstrated to decrease
with increasing polymer hydrophilicity. Similar trends in size have previously been
reported on the basis of PEG-polylactide (PEG-PLA) [103], PEG-polylactide-co-
glycolide (PEG-PLGA) [20] and PEG-PCL [53] diblock as well as PCL-PEG-PCL
[46] triblock copolymers. Even microparticles from PEG-PCL diblock copolymers
prepared via double emulsion technique follow the same rules [44]. Amphiphilic trib-
lock copolymers consisting of PEG (⇠2 kDa), PCL (⇠10 kDa) and cationic poly(2-
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aminoethyl ethylene phosphate) (PPEEA), synthesised by Wang et al., formed carri-
ers of 100⇠120 nm in diameter [75]; more hydrophilic carriers with similar structure
bearing a shorter PCL segment (⇠3.5 kDa) lead to considerable smaller assemblies
(⇠60 nm) [73]. Unimodal PDI values indicate the absence of subpopulations with
different degrees of association [56]. Gradually increasing PDI values with increas-
ing hydrophilicity are somehow unexpected, as PDI is supposed to decrease with
the formation of higher ordered structures [93]. As observed in this experiment an
increasing PDI for micelle-like carriers, however, might reflect the dynamic nature of
these associates. Systematic studies focusing on size and structure of carriers made
from amphiphilic cationic triblock copolymers have, to our knowledge, not yet been
reported.
Trends in size can be explained by different assembly mechanisms, leading to
distinct carrier structures. In case of hydrophobic polymers, formation is mainly
governed by polymer agglomeration, leading to larger (> 100 nm) particle like pre-
cipitates. In FALT measurements, those aggregates were demonstrated to bear less
charge density, sourrounded by a smaller, less dense PEG shell. Assembly mechan-
ism was clarified by formation at varying initial polymer concentration: As size is
controlled by the local polymer concentration at the particle formation site, higher
polymer concentrations subsequently lead to larger particles. As to more hydrophilic
polymers, rather small (<40 nm) core corona polymeric micelles are formed. The
PEG block exerts a strong effect on micelle formation, by moderating association of
polymer molecules and preventing agglomeration of PCL segments. Those micelle-
like structures were shown to have a higher charge density plus a thicker PEG shell
(FALT measurements). Formation mechanism of micelle-like carriers is unaffected
by initial polymer concentration, as geometry of polymer unimers rather than their
concentration controls the size of a micellar system. These structural differences
between hydrophobic and more hydrophilic carriers have a considerable impact on
carrier properties and are supposed to affect vector efficiency as well.
FALT was employed for measuring the thickness of the covalently bound PEG
shell. FALT is a reliable technique, e. g. for measuring the amount of hydro-
philic polymer coated onto negatively charged liposomes [112], polystyrene (PS)
[113] or PLGA [109] nanoparticles. Thicker hydrophilic layers have proven to en-
hance protein-repelling properties and affect biodistribution profiles [18]. By giving
the distance from the outer PEG sphere to the positively charged core surface, meas-
urements in particular contribute to structure elucidation, indirectly constituting the
PCL-PEG core shell structure with PEI accessible located at the interface. Result-
ing sizes depend on PEG chain length and are in the same order of magnitude than
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those determined on PEG2k modified liposomes [112] and micelles [18]. Further, val-
ues are in good agreement with theoretical calculations assuming a randomly coiled
chain. Slightly lower experimental values, especially in case of increasing PEG MW,
may be explained by the formation of loops and tails that are anchored to the PCL
surface.
Electrochemical characteristics ( 0,  0 and the number of positive charges on the
particle surface) were derived from FALT measurements.  0 values obtained were
close to ⇣ values as generally observed for moderately charged colloidal systems.
As shown in case of liposomes [111],  0 is a characteristic indicator for colloidal
stability. The number of positive charges on the PCL core surface was found to
decrease with increasing polymer hydrophilicity. This in particular points to an
effect on the aggregation number of each polymer sphere; assumed that PEI charges
are exclusively located on the PCL surface, a carrier bearing less charge subsequently
contains fewer polymer molecules. Hence decreasing carrier sizes with increasing
hydrophilicity seem to result in decreasing aggregation numbers, which has been
clarified above in carrier formation experiments as a function of initial polymer
concentration. This phenomenon could be explained by the occupied area per corona
chain, which is decreasing with decreasing PEG chain length. To minimise interfacial
energy attributed to the corona chain, the aggregation number and the core size
increase. From a more visual point of view one could argue with molecular geometry
[51]: with increasing PEG chain length the hydrophilic head becomes more bulky,
which leads to a more cone shaped molecule; forming a micelle from these molecules
leads automatically to a smaller sphere than in case of more cylindrical shaped
molecules [103].
1H NMR measurements in solvent mixtures and as a function of temperature
were utilised to further elucidate carrier’s core-shell structure. When internal in-
termolecular motion is restricted, nuclear spin-spin relaxation (T2 relaxation) is
decreased, which leads consequently to a broadening of line widths [81]. In D2O/
acetone-D6 solvent mixtures, PCL signals successively broaden with increasing D2O
concentration, whereas PEG signal keeps fairly constant. These findings correspond
to carrier-structure in aqueous media: Due to H-bonding between ether ogygens and
water molecules, PEG segments create an exterior hydrophilic corona, preserving
most of their mobility characteristics. PCL groups are in a different environment,
forming a central hydrophobic core by minimising solvent interaction. Line broad-
ening of PCL signals occurs due to restricted motion inside the hydrophobic core,
while PEG is an extended solvated state in all different solvent mixtures. The slight
broadening at the base of PEG signals is expected for a flexible PEG chain at the
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end of a rigid PCL core and originates from PEG protons in more than one chem-
ical environment. Those are preferably located at the core facial region, suggesting
partial miscibility of PEG and PCL domains. Notably, in comparison PLA-PEG
or PLGA-PEG NPs [60], signals of hydrophobic protons in D2O are supressed, but
could still be observed. This is also the case for surfactant micelles with a liquid-like
core [114], which conforms to the hypothesis of micellar dynamics and demonstrates
that prepared polymeric carriers are truly in an intermediate state between micelles
and particles. Increased core mobility of PCL in comparison to PLA or PLGA might
occur due to glass transition temperatures: Whilst for mPCL10k Tg was observed
at ⇠-60 °C via DSC, glass transition temperatures of PLA or PLGA typically ex-
ceed RT (depending on tactility, crystallinity and in case of PLGA composition)
leading to “frozen” micelles in the latter case [115]. In 1H NMR spectra at higher
temperatures, line broadening for PEG signals increases whilst there is a decrease
of PCL signals. Similar trends have previously been reported on PEG-PLA struc-
tures [60] and suggest that changes in structure and conformation have taken place:
With a temperature increase above the lower critical solution temperature (LCST)
of PEG (⇠70 °C [60]) the polymer chains turn from hydrophilic to hydrophobic
due to a breakage of hydrogen bonding and subsequently collapse onto the hydro-
phobic carrier core, losing most of their mobility. This leads to a gradual decrease
in PEG signal intensity at higher temperatures. Additionally the shift upfield of
the PEG signal suggests movement to a less polar environment [114]. However, the
higher temperature had an impact on core mobility as well, which leads to a higher
amount of PCL protons detectable and increased resolution. Especially above the
Tg of PCL (⇠-60 °C by DSC), it should be even easier to observe PCL protons,
since chain mobility would be greater.
Measuring z-ave and ⇣-potential of samples prepared for temperature dependent
NMR analyses as a function of T revealed revealed differences between mPEG500-
PCL10k-lPEI2500 carriers and mPCL10k particles: The latter increase in size start-
ing at ⇠60 °C, probably indicating swelling and beginning disassembly due to melt-
ing. mPEG5k-PCL10k-lPEI2500 carriers, however, first gradually decrease in size
between 40⇠80 °C, followed by rapid enlargement starting at ⇠80 °C. This is in
agreement with temperature dependent NMR experiments, suggesting PEG dehyd-
ration overlaid by an increase in size due to melting of the PCL core. Maximum
detected decrease in size (⇠5 nm), determined at 80 °C, is consistent with FALT
measurements. A decreased charge of nano-carriers after temperature treatment
indicates an irreversible structure change, suggestive for irreversible phase mixing
of PCL and PEI moieties in the molten state.
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For finding a structure activity relationship, the impact of different structures on
subsequent carrier features like colloidal stability was demonstrated. While increas-
ing ionic strength, PEG steric shielding is supposed to decrease due to a breakdown
of hydrogen bonding between PEG ether oxygens and water molecules and a sub-
sequent dehydration of the outer shell. Additionally the electrolyte neutralises core
surface charge and Van der Waals interaction between PCL cores will lead to ag-
gregation. Against NaCl, all triblock carriers showed increased stability compared
to naked PCL particles. On the one hand this could be due to the sterically shielding
PEG layer, but on the other hand positive PEI charges could also further stabilise
colloidal suspensions due to repulsive Coulomb forces. In the latter case, according
to the principle of hard and soft acids and bases, a rather “soft” polyanion would
be more suitable for PEI charge neutralisation than chloride. In experiments with
albumin, enhanced colloidial stability for carriers bearing longer PEG chains was
clearly demonstrated. Hence, smaller core corona micelle-like carriers were more
stable against albumin-induced aggregation than bigger particles surrounded by a
thinner less dense PEG shell. This is probably owed to incomplete PEG coating
leading to naked PCL patches on the particle surface [62]. Increasing colloidal sta-
bility against electrolytes with increasing PEG MW has previously been reported
based on PEG-PLA carriers [56]. In case of triblock copolymers presented in this
work steric PEG shielding is of prime importance, as stabilising positive charge is
reduced upon complexation with negatively charged drugs or nucleic acids.
CMC values, reflecting thermodynamic stability, were found to be in the range
of concentrations determined for PEG-PCL [52], PEG-PCL-PEG [46] or PEG-PCL-
PPEEA [74] amphiphiles. As carriers are rapidly diluted upon intravenous injection,
low CMC values are important prerequisites for in vivo experiments. But even at
concentrations below CMC values, carriers are not necessarily supposed to fall apart.
Micelles formed from block copolymers are commonly also more kinetically stable
than those formed from low molecular weight surfactants [42]. Physical interac-
tion of core chains and semi-crystalline moieties [47] decrease the dynamic nature
of formed micelles, making carriers less prone to disassembly. Negative  G° values
prove advantageous thermodynamic stability compared to low MW amphiphiles, as
generally observed for polymeric micelles; values in the same order of magnitude,
hardly depending on PEG molecular weight, are suggestive for a self-assembly pro-
cess, hypothesised for all of the hydrophilic carriers bearing short PCL2400 blocks.
Finally the impact of carrier structure on cytotoxicity was investigated utilising a
MTT assay. As expected longer PEG chains resulted in reduced toxicity. Generally,
charge neutralisation (e.g. by loading with negatively charged compounds [17]) and
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sterical shielding (commonly by PEG) are strategies to reduce cytotoxicity. Hence,
experiments with placebo carriers in this work reflect the worst-case scenario. Tox-
icity analysis comparing PEG-PEI block copolymers with different PEG MW and
grafting degree revealed, that the number of PEG chains, rather than their MW
affects cytotoxicity [116]. However, in those experiments water-soluble PEG-PEI
compounds were investigated and charge shielding was mainly dependent on the
grafting degree. This work focused on self-assembled carriers of different size and
structure. Consequently effective charge shielding depends on the density and thick-
ness of the outer PEG shell, which was found via FALT measurements to increase
in size with larger PEG MW. In summary, toxicity tests complete structure activ-
ity investigations carried out in this work: Polymers with increased hydrophilicity
were found to assemble to smaller, micelle-like carriers with a thicker PEG shells.
Those compounds showed decreased ⇣-potential and charge density. Fewer charges,
surrounded by a larger PEG shell therefore resulted in increased colloidal stability
and reduced cytotoxicity.
5 Conclusions
A set of PEG-PCL-PEI triblock copolymers was successfully synthesised and charac-
terised. Block lengths were systematically altered to elucidate the structure activity
relationship. As a function of hydrophilicity different assembly mechanisms lead
to diverse structures: whereas more hydrophilic carriers assembled to micelle-like
structures with core-corona architecture and diameters of several tens of nanomet-
ers, more hydrophobic polymers precipitated to larger (>100 nm) particulate carri-
ers. Changes in size were found to result from varying aggregation numbers. Car-
rier architecture was elucidated (cryoSEM, AFM, 1H NMR, FALT) and correlated
to stability and cytotoxicity: Increasing hydrophilicity results in stability increase,
combined with a decrease of cytotoxicity due to effective PEG charge shielding.
Those trends in size, structure and properties are fundamental and may be applic-
able for numerous amphiphile based vector systems in the field of drug and gene
delivery. Rather than identifying suitable vectors by trial and error, a more sys-
tematic approach was investigated in this work. This strategy could be the key to
tailoring the properties of multifunctional carriers.
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Abstract
Amphiphilic cationic block copolymers consisting of poly(ethylene glycol), poly(✏-
caprolactone) and poly(ethyleneimine) spontaneously assemble to nano-sized par-
ticulate carriers, which can be utilised for complexation of nucleic acids (small-
interfering RNA), representing a multifunctional vector system, designed for drug
and gene delivery. Apart from polymer design and charge ratio, a more homogeneous
complexation could lead to a more uniform charge distribution, subsequently in-
creasing colloidal stability, RNA protection and consequently transfection efficiency.
Microfluidic mixing techniques, bringing cationic polymer and nucleic acid together
at a constant ratio during the entire mixing process, have the potential for a gentler
complexation. In the present study carriers were prepared by a solvent displace-
ment technique. In a first step complex size for addition of RNA during (addition
to the aqueous or the organic phase) or after (classical pipetting or microfluidic
mixing) carrier assembly was determined by dynamic light scattering. Suitable N/P
ratios have previously been selected by measuring size and ⇣-potential as a function
of N/P. Subsequently, for the most promising techniques (loading after assembly),
colloidal stability, the ability to protect RNA as well as transfection efficiency in
vitro were compared. Finally, parameters for the superior microfluidic mixing pro-
cess were optimised with the help of a central composite design. Generally, gentler
loading leads to more homogeneous complexes. Hence, possibly due to a more con-
sistent surface coating, loading after carrier assembly resulted in less aggregation.
In comparison to bulk mixing, microfluidic assembly exhibited smaller diameters
(179±11 vs. 230±97 nm), less heterogeneity (PDI=0.205±0.028 vs. 0.353±0.161),
enhanced RNA protection (RNA recovery=30.6±1.0 vs. 15.4±1.4%) as well as in-
creased transfection performance (34.8±1.5 vs. 24.5±2.2% knockdown). Therefore,
microfluidic complexation represents a reproducible alternative for formulating gene
delivery carriers with superior colloidal stability, RNA protection and transfection
efficiency.
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1 Introduction
Administration of small-interfering RNA (siRNA) represents a promising strategy
to address various diseases currently considered untreatable. However, transition to
clinical trials has been slow due to a lack of suitable carrier systems [101]. Basic
requirements for those vectors are: stability, biocompatibility and biodegradability,
low toxicity, targeting of specific cells or tissues, the ability to protect nucleic acids
from rapid degradation or excretion. The latter is critical in case of siRNA, as it
is even more susceptible to degradation than DNA [6]. A class of carriers, having
the potential to comply with most carrier requirements, is based on cationic am-
phiphiles [73, 117]. In aqueous media block copolymers, consisting of poly(ethylene
glycol) (PEG), poly(✏-caprolactone) (PCL) and linear poly(ethyleneimine) (lPEI),
self-assemble spontaneously to core-shell structured nano-carriers [77, 118]. The
hydrophilic PEG shell is thought to reduce protein adsorption while maintaining
suspension stability, possibly leading to increased blood circulation times in vivo
[119]. Biodegradable PCL segments, aggregated to a hydrophobic core, could serve
as reservoirs for water-insoluble drugs or dyes rendering this carrier system multi-
functional for co-delivery of drugs and nucleic acids or for “theranostic” purposes
[69]. Cationic PEI segments can be utilised for complexation with nucleic acids
(e.g. siRNA). Structure and self-assembly properties of these polymers were previ-
ously investigated [118]. While most studies focused on designing adequate carrier
molecules, scant attention has been paid to the complexation process itself, even
though it has a crucial effect on essential complex characteristics [120, 121], the
ability to protect nucleic acids from degradation and subsequently on gene delivery
efficiency. One of the most important parameters for complexation is the ratio of
positively charged carrier and negatively charged nucleic acid molecules, which is
generally calculated on the basis of PEI nitrogen per nucleic acid phosphate (N/P).
With decreasing N/P, overall surface charge decreases progressively to the point of
aggregation at nearly neutral conditions. Net charge has a direct influence on cell in-
ternalisation [122] and toxicity [104, 33]. High positive surface charge might, up to a
certain degree, lead to enhanced cell internalisation in vitro [6], but it will definitely
be detrimental under in vivo conditions, where cationic carriers are in contact with
negatively charged blood components and tissue membranes. Furthermore, due to
toxicity concerns, in most scenarios N/P is rather fixed and it would be advant-
ageous to control complex characteristics without altering the ratio of polymer and
nucleic acid. Different complexation conditions and techniques offer the opportun-
ity for optimising carrier loading at fixed N/P. Typical complexation procedure for
water-soluble cationic polymers comprises mixing of aqueous polymer and nucleic
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acid solutions by pipetting [120], whereas the order of addition is unclear: Some
experimenters prefer addition of cationic polymer solution to a solution of nucleic
acid [74, 123, 124], while others favour vice versa [82]. Moreover, a dependency on
the N/P has been claimed [125]. In addition, predominantly hydrophobic assemblies
with a rather rigid structure are capable of loading after carrier formation, which is
believed to be advantageous for controlling complex size and charge [74, 123]. More
recently, fluidic mixing techniques have emerged [126]; these automated devices,
bringing cationic polymer and nucleic acid together at a constant ratio during the
entire mixing process, have the potential to increase complex homogeneity and avoid
order of addition problems. Fluidic setups have been employed for creation of micro
droplets by mixing two immiscible solvents [127] or (as used in the present study)
for mixing aqueous phases. In the latter case fabrication of poly- or lipoplexes using
mm- [120, 128] or µm-scaled [129, 130] channels has been reported, whereas smaller
volumes (as utilised in the present study) promise even greater control, due to a
more confined diffusion [127]. In case of all preparation conditions and techniques,
a more homogeneous complexation process is supposed to give rise to a tighter com-
plexation. This is believed to increase colloidal stability and siRNA protection.
More uniform complexes with enhanced stability and a size suitable for endocytosis
(150-200 nm [131, 6]) are easier to characterise and are thought to boost transfec-
tion efficiency. To prove this hypothesis, it was the aim of the present study to
correlate different complex preparation techniques to subsequent carrier properties.
Therefore, two complexation techniques after carrier assembly (classical pipetting
and microfluidic mixing) were compared to two methods during assembly (addition
of siRNA to the aqueous or the organic phase) and the effect on complex size was
monitored by dynamic light scattering (DLS). Furthermore, for the two most prom-
ising techniques, complex stability as a function of incubation time (10-240 min),
resistance of condensed siRNA against degradation (RNase digestion) as well as
transfection efficiency in vitro were evaluated. Among all employed techniques, mi-
crofluidic mixing facilitates gentler preparation conditions and therefore represents
a promising alternative for complexation of nucleic acids.
2 Materials and methods
2.1 Reagents and chemicals
Non-coding control DsiRNA and hGAPDH-DsiRNA for RT-PCR experiments as
well as 2’-O-methylated 25/27mer DsiRNA targeting Firefly Luciferase for all other
complexation experiments were purchased from Integrated DNA Technologies (IDT,
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Leuven, Belgium). Fetal Calf Serum used in stability and transfection experiments
was obtained from Cytogen (Sinn, Germany). Heparin sodium (150000 IE/g) for
displacement of siRNA was applied from SERVA Electrophoresis (Heidelberg, Ger-
many). First Strand cDNA Synthesis Kit and RNase I (#EN0531) were obtained
from FERMENTAS (St. Leon-Rot, Germany). QuantiFastTM SYBRTM Green PCR
Kit, Hs_GAPDH_primer, Hs_ -actin-primer and DNase I (18U) were provided by
Qiagen (Hilden, Germany). SYBRTM Gold reagent, LipofectamineTM 2000 (LF)
and PureLinkTM RNAMini Kit were applied from Invitrogen (Karlsruhe, Germany).
Other chemicals and solvents were supplied by Sigma Aldrich GmbH (Steinheim,
Germany) at the highest grade commercially available.
2.2 Polymer synthesis and characterisation
PEG-PCL-lPEI triblock copolymer was synthesised and characterised as described
in detail elsewhere [118]. Block length for PEG, PCL and PEI are 500, 10000 and
2500 Da, respectively.
2.3 Cu2+-assay
Cu2+ assay was utilised to determine the amine fraction per overall polymer mass
[105]. Polymers were dissolved in a mixture (1:1) of double-distilled and filtrated wa-
ter and N-Methyl-2-pyrrolidone in concentrations of 0.4 mg/mL. 50 µL of this solu-
tion were mixed vigorously with 50 µL of an aqueous CuSO4 solution (c=0.145 mg/mL
dissolved in 0.1 N potassium acetate buffer, pH=5.5). Subsequently absorption was
measured at 280 nm employing a Pharmacia Biotech Ultrospec 3000 (GE Healthcare,
Little Chalfont, Buckinghamshire, UK). Using a lPEI2500 Da calibration curve, the
amount of PEI per overall polymer mass was calculated.
2.4 Assembly of unloaded nano-carriers
Nano-carriers were prepared by a solvent displacement technique described in detail
elsewhere [132]. Briefly, 1 mg of block copolymer was dissolved in 200 µL of acetone.
This solution was subsequently injected into a magnetically stirred (500 rpm) phase
of 1 mL double-distilled and filtrated water. The resulting colloidal suspension was
stirred for 3 h under reduced pressure to remove organic solvent. Nano-suspensions
(NSs) were characterised and used directly after preparation.
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2.5 Carrier loading by different techniques
Two different post-assembly loading techniques were applied: conventional mixing
by pipetting aqueous siRNA solution to previously prepared unloaded NSs (T1) and
microfluidic-assisted mixing (T2). In case of conventional carrier loading for each
measurement a fresh sample was prepared. The appropriate amount of siRNA was
added to an aliquot of NS in one single step followed by vigorous mixing. Size and
⇣-potential were measured after 10 min of incubation at room temperature (RT).
For microfluidic-assisted loading, the Fluence Microfluidic Tool Kit (Epigem Ltd.,
Redcar, UK) was used. Setup consisted of a three-way mixing chip (50-100R3),
plugged onto the baseboard (Fig. 2). Chip inlets were independently fed with NS
and aqueous siRNA solution employing syringe-pump drives (Aladdin-1000, World
Precision Instruments, Sarasota, USA) equipped with 500 µL syringes (Hamilton,
Bonaduz, Switzerland). Flow rate (FR) ratio and/or concentration of fluids were
modified to adjust final carrier loading ratio. Up to reaching dynamic equilibrium
the first 200 µL of each run were discarded. Subsequently loaded carriers were
collected and characterised directly after preparation. For loading during solvent
displacement process, carriers were assembled with additional siRNA in the water
(T3) or acetone phase (T4) and mixed vigorously before organic phase injection.
Size and ⇣-potential were measured directly after carrier assembly.
2.6 Cryogenic transmission electron microscopy (cryoTEM)
CryoTEM was carried out as described in detail elsewhere [133]. Briefly, 6 µL NS
were placed on a perforated copper grid (R 3.5/1, Quantifoil Micro Tools GmbH,
Jena, Germany) and the sample was frozen in liquid ethane (⇠-180°C) in a cryo box
(Carl Zeiss NTS GmbH, Germany). The sample was then transferred with a liquid
nitrogen cooled holder (626, Gatan Inc., USA) into the pre-cooled cryo-electron
microscope (CM 120, Philips, Netherlands) operated at 120 kV and viewed under
low dose conditions. The images were recorded with a 1k CCD Camera (FastScan
F114, TVIPS, Gauting, Germany).
2.7 Size and ⇣-potential
The average size and size distribution as well as the ⇣-potential of nano-carriers
were determined by DLS and laser Doppler anemometry (LDA) using a Zetasizer
NanoZS/ZEN3600 (Malvern Instruments, Herrenberg, Germany) equipped with low
volume sizing- (ZEN2112) or ⇣-cell (ZEN1010). Analyses were performed at a tem-
perature of 25 °C using samples appropriately diluted with filtrated and double-
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distilled water. The particle mean diameter (z-ave.), the width of the fitted Gaus-
sian distribution, which is displayed as the polydispersity index (PDI), as well as
the average ⇣-potential values were calculated from data of at least 10 runs.
2.8 Stability
Stability of complexes, assembled (c(RNA)=100 µm, c(NS)=0.5 mg/mL) by classical
pipetting (T1) and microfluidic mixing (T2), was investigated via DLS at respective
N/P ratios (9, 13, 20) in filtrated and double-distilled water as well as in serum (10%
of bovine serum was added 10 min after carrier assembly). Values were determined
after t=30, 60, 120, 240 min in comparison to t0=10 min. Changes in z-ave. and
PDI are displayed as variations in the ratio of final and initial values (t/t0).
2.9 RNase assay in presence of heparin
Firstly, stability of carriers was tested by measuring siRNA displacement from com-
plexes in presence of the competing polyanion heparin. 30 µL aliquots of com-
plexes, freshly-prepared by classical pipetting or microfluidic mixing at N/P=9
(c(RNA)=100 µm, c(NS)=0.5 mg/mL), were incubated with heparin at various
concentrations (6.25, 12.50, 31.25, 43.75, 62.50, 312.50, 625.00 mg/L) in PBS buf-
fer (pH=7.4) for 20 min at RT. Subsequently, SYBRTM Gold intercalation assay
was carried out as previously reported [134]. Fluorescence intensity ( ex=495 nm,
 em=537 nm) was analysed in opaque FluoroNunc 96 well plates (Nunc, Thermo
Fisher Scientific, Langenselbold, Germany) using a Safire II (Tecan Group Ltd.,
Männedorf, Switzerland). Uncomplexed siRNA served as a positive control and
relative amounts of displaced siRNA at respective heparin concentrations were cal-
culated. Subsequently, to prove stability and integrity of siRNA complexes, RNase
digestion in presence of heparin was investigated. Above-mentioned complex-heparin
mixtures were repeatedly prepared with additional RNase (9 µg/aliquot). The
samples were then incubated for 1 h at 37 °C and additional 30 min at 70 °C
to inactivate RNase. Intact siRNA was then displaced from the polymer by adding
excess heparin (50 µg/aliquot) and detected via SYBRTM Gold intercalation assay.
Relative values of recovered siRNA were calculated and the total amount of dis-
placed siRNA in presence of heparin plus recovered siRNA in presence of heparin
and RNase was normalised to 100%.
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2.10 RT-PCR
SKOV3 cells were seeded in 6-well-plates (Nunc, Thermo Fisher Scientific, Lan-
genselbold, Germany) at a density of 5000 cells/well, 24 h before transfection. Sub-
sequently, fresh medium (containing 10% bovine serum) and 100 µL of NS, loaded
via T1 and T2 at N/P=9 (c(RNA)=100 µm, c(NS)=0.5 mg/mL), were added to
each well at a final siRNA concentration of 100 pmol/well. LF (0.5 µL/10 pmol of
siRNA) served as a positive control. After 4 h of incubation at 37 °C, medium was
exchanged and cells were incubated for another 24 h before they were washed with
cold PBS and lysed with lysis buffer. Afterwards, mRNA was isolated from culture
cells using the PureLinkTM RNA Mini Kit (with additional DNase I digestion) and
reverse transcribed to cDNA employing the First Strand cDNA Synthesis Kit on a
TGradient thermocycler (Biometra GmbH, Goettingen, Germany). RT-PCR was
performed employing the SYBRTM Green PCR Kit and a Rotor-Gene 3000 RT-PCR
thermal cycler (Corbett Research, Sydney, Australia). Hs_GAPDH-primers were
used to quantify hGAPDH_gene expression and Hs_ -actin-primers were utilised
as internal standard to determine relative expression levels for each gene. Calib-
ration curves for GAPDH and  -actin mRNA were prepared by serial dilutions of
cDNA of the blank sample (untreated cells).
2.11 Response surface design
Parameters for microfluidic carrier loading were optimised employing a response sur-
face design. An orthogonal circumscribed central composite design, which includes
additional centre and star points, (24 + 2·4 star points + 4 centre points, ↵=1.607)
was chosen to study the effect of four factors on z-ave. (Table III.1) in 28 runs. The
order of experiments has been fully randomised to avoid bias. Factors of interest
and their limits were determined in preliminary experiments. Intervals were chosen
to maintain the orthogonalised values of the design. NS was prepared under con-
stant conditions as described above to minimise variability. For statistical analysis
the Statgraphics Plus software (V2.1, Statpoint Technologies, Warrenton, Virginia,
USA) was utilised.
2.12 Statistics
Unless otherwise noted, all measurements were carried out in quadruplicates and
values are presented as mean values ± standard deviation. To identify statistic-
ally significant differences, ANOVA with t-test analysis was performed. Probability
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values of p<0.05 were considered as statistically significant (*p<0.05, **p<0.01,
***p<0.001).
3 Results and discussion
3.1 Aggregation behaviour as a function of N/P
Z-ave. and ⇣-potential of unloaded carriers were determined via DLS and LDA
(85±5 nm, 39±2 mV). Diameters measured by cryoTEM are in a good agreement
and demonstrate spherical shape (Figure III.1A). Analogous to typical “polyplex”
preparation, carriers were firstly loaded by pipetting nucleic acid solution to a small
batch of NS (T1). To determine an N/P range suitable for further investigations,
the evolution of z-ave. and ⇣-potential of complexes as a function of carrier/siRNA
ratio was measured (Figure III.1B). With decreasing N/P carrier size increases from
unloaded (N/P=1) up to a maximum at N/Pt7, which is attained close to the
neutralisation point, as evidenced by the inversion of the ⇣-potential. At lower N/P,
particle diameter as well as ⇣-potential decrease down to the size of ⇠130 nm and
⇠-17 mV.
Figure III.1: CryoTEM images of blank carriers (A). Z-ave. and ⇣-potential (includ-
ing a sigmoidal regression) of loaded carriers (T1, c(RNA)=100 µm,
c(NS)=0.5 mg/mL) as a function of N/P obtained by DLS and LDA.
N/Peff was calculated by recalibrating N/P in reference to the isoelec-
tric point. Measurements were carried out in quadruplicates and values are
presented as mean values ± standard deviation (B).
The observed aggregation behaviour, often referred to as reentrant condensa-
tion, was previously reported in a variety of polyelectrolyte-colloid systems such as
micelles [135], liposomes [136] or solid particles [137]. It is defined by a balance
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of short-range attractive and long-range repulsive forces [138]. The former origin-
ate from inhomogeneous surface covering, caused by electrostatic interaction. Upon
surface coating, polyelectrolyte chains avoid each other, maximising their distance
on the carrier surface which leads to a patchwork-like coating, comprising domains
with excess positive or negative charge. The resulting dipolar structure gives rise
to a short-range attractive potential. Repulsive forces stem from the net charge of
like-charged carriers. With decreasing N/P, this charge decays progressively from
the positive value of bare carriers, inverting its sign at the isoelectric point, down
to negatively charged carriers with anionic surface coating. The addition of more
counterions than necessary for neutralisation is commonly referred to as overchar-
ging effect [138]. Close to isoelectric conditions, due to prevailing attractive forces,
large clusters are observed; whilst at low N/P the size of carriers equals again their
original unloaded size plus a layer of adsorbed siRNA. From here on further de-
creasing the N/P in equilibrium leads to an excess of siRNA, which does not adsorb
to the carrier but remains freely dissolved. Due to charge sign and insufficient
protection of nucleic acid, those negatively charged complexes (N/P<7) are not
suitable for cell internalisation despite their relatively small diameter. Regarding
charge, size and cytotoxicity the N/P range between 9⇠20 appears to be attract-
ive for further investigation. Furthermore one might argue that the N/P ratio at
the isoelectric point where charges counterbalance is supposed to be 1 rather than
⇠7. In case of a block copolymer, calculation of the N/P requires knowledge of the
protonable PEI fraction, which can be either calculated from the molecular weight
(MW) of distinct blocks or by Cu2+-assay. The latter method, which was applied
for these experiments, quantitatively determines the amount of PEI per molecular
mass. However, both methods consider every single nitrogen, lacking information
on the 3D structure of the complex. Hence, the observed discrepancy between cal-
culated and expected N/P supposedly occurs due to amine groups, inaccessible for
complexation with nucleic acid phosphates. This could either be due to encapsu-
lation into the hydrophobic PCL core, or due to steric shielding of PEG moieties.
Both, shielding by hydrophilic PEG [118] as well as hydrophobic PCL [139, 82]
or poly(methyl methacrylate) [123] was previously demonstrated to affect toxicity
and cell internalisation. Additionally, (especially at neutral or basic pH) incomplete
amine protonation could further increase the gap between stoichiometric composi-
tion and experimental ⇣-potential. Wang et al. assembled particle-like carriers from
cationic PEG-PCL-poly(2-aminoethyl ethylene phosphate) amphiphiles for siRNA
loading after assembly [74]. Similarly, those systems exhibited a mismatch between
stoichiometric N/P (calculated from MW) and charge. Isoelectric conditions were
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reached between N/P 1⇠5. Consequently, the effective N/P ratio (N/Peff ), rep-
resenting the ratio of accessible nitrogen charges and siRNA phosphates for compl-
exation, is believed to be the decisive parameter. As shown in Figure III.1B, the
isoelectric point could be utilised for N/P-scale recalibration: conventional values
are converted to effective ones.
3.2 Different loading techniques
Due to toxicity concerns, in most scenarios the applicable N/P range is rather lim-
ited. To reach the goal of small and uniform complexes with a slightly positive net
charge, different loading techniques were compared at three different N/P ratios (9,
13, 20). Loading after assembly was carried out by classical pipetting (T1) or by
employing a microfluidic device (T2) (Figure III.2).
syringe-pump connections
mixing chip
outlet
100 +m
A
B
Figure III.2: Setup of the microfluidic mixing device (A). Microscope image of the mixing
chip operated with aqueous Nile Blue and Fluorescein solutions (B).
For loading during assembly siRNA was added to the aqueous (T3) or the organic
(T4) phase. The trend of larger diameters in the proximity of the isoelectric point
was found for all tested techniques. However, especially at low N/P ratios, post-
assembly loading appears to be superior for formulating compactly condensed com-
plexes. Loading during assembly generally produced larger diameters together with
greater aggregation (Figure III.3). In addition, for all tested N/P ratios microfluidic
loading further reduced the carrier diameter.
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Figure III.3: Z-ave. (A) and PDI (B) of unloaded carriers (z-ave.=85±5 nm,
PDI=0.132±0.023) in comparison to those loaded with siRNA by differ-
ent techniques at defined N/P ratios (N/P ratio was determined by Cu2+
assay). Measurements were carried out in quadruplicates and values are
presented as mean values ± standard deviation.
Homogeneous charge distribution upon complexation is important for minim-
ising short-range attractive forces, which will consequently lead to less pronounced
aggregation peaks in the proximity of the isoelectric point. This is believed to be
the reason for increased complex size in case of loading during assembly: rapid
aggregation processes upon injection into the water phase could lead to inhomogen-
eous distribution of charges, while loading after assembly enables successive surface
coating. Microfluidic loading, enabling consistent fusion, exhibited the smallest com-
plexes with very low standard deviation for all investigated N/P ratios. Optimising
process parameters might help to further reduce aggregation.
3.3 Comparison of classical pipetting and microfluidic mixing
Due to a significantly reduced complex diameter, we focused on loading after carrier
assembly. Thus, classical pipetting was directly compared to microfluidic mixing.
Z-ave. of carriers loaded after assembly by both techniques, using different siRNA
concentrations (1.5, 15, 100 µm) at previously selected N/P ratios (9, 13, 20) was
detected via DLS (Figure III.4). In case of high N/P and diluted concentrations
results are comparable. Vice versa microfluidic mixing leads to smaller complexes:
Forming carriers via classical pipetting at N/P=9 with a 100 µm siRNA solution
results in complexes 230±97 nm (PDI=0.353±0.161) in diameter, whereas merging
the same volumes and concentrations by a microfluidic device results in 179±11 nm
(PDI=0.205±0.028) sized complexes. Size distribution of the latter complexes is
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unimodal, whilst classical pipetting leads to a mixture of at least two different size
distributions (Figure III.4).
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Figure III.4: Z-ave. determined by DLS of carriers loaded via T1 (classical pipetting)
andT2 (microfluidic mixing) at previously evaluated N/P ratios using three
different siRNA concentrations (1.5, 15, 100 µm) (c(NS)=0.5 mg/mL).
Measurements were carried out in quadruplicates and values are presen-
ted as mean values ± standard deviation (A). Detailed size distribution at
N/P=9 using c(RNA)=100 µm (B).
Stability as a function of incubation time of complexes, assembled (c(RNA)=100 µm,
c(NS)=0.5 mg/mL) via T1 and T2 at respective N/P ratios, was investigated by
DLS in water as well as in serum (10%). As to samples in pure water, negligible
changes in size an PDI were detected for both assembly techniques up to the longest
tested time span of 240 min (Figure III.5). By contrast, in presence of serum, an
increase in z-ave. and PDI was observed, especially for carriers assembled by clas-
sic pipetting (T1) at high N/P ratios (Figure III.6). The latter finding appears to
be unexpected, as in pure water aggregation was previously found to decrease at
higher N/P (Figure III.1B). However, this can be explained by charge interaction:
Carriers bearing high positive surface charge are known to be unstable in presence of
polyanionic (blood) components such as serum albumin [118], whereas nearly isoelec-
tronic assemblies are more likely to resist ion induced aggregation. Hence, carriers
assembled in the vicinity of the neutralisation point (e.g N/P=7, Figure III.1B)
show an increased stability in presence of polyanions and the importance of assem-
bling slightly positive carriers is pointed out once again. Complexes prepared via
microfluidic device (T2) generally showed increased stability in presence of serum
(Figure III.6C/D), supposedly due to a more homogeneous distribution of surface
charges and avoidance of naked cationic patches [62].
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Figure III.5: z-ave and PDI after incubation in water for t=30, 60, 120, 240 min de-
termined by DLS. Ratio of values determined at t and t=10 min (t0) of
complexes loaded via T1 (classical pipetting, A/B) and T2 (microfluidic
mixing, C/D). Unloaded carriers (N/P=1) were measured for comparison
reasons. Measurements were carried out in quadruplicates and values are
presented as mean values ± standard deviation. The experimental points
are connected by lines to guide the eye only.
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Figure III.6: z-ave and PDI after incubation in bovine serum (10%) for t=30, 60, 120,
240 min determined by DLS. Ratio of values determined at t and t=10 min
(t0) of complexes loaded via T1 (classical pipetting, A/B) and T2 (mi-
crofluidic mixing, C/D). Unloaded carriers (N/P=1) were measured for
comparison reasons. Measurements were carried out in quadruplicates and
values are presented as mean values ± standard deviation. The experi-
mental points are connected by lines to guide the eye only.
The amount of free siRNA was detected by SYBRTM Gold assay and due to more
stable complexes decreased values were detected for microfluidic-assisted fusion in
comparison to classical pipetting (Figure III.7). The carrier’s ability to resist en-
zymatic degradation by RNase was demonstrated in digestion studies. In a prelimin-
ary experiment complexes prepared by both techniques (N/P=9, c(RNA)=100 µm)
were incubated with different amounts of RNase. Free siRNA served as a control.
Whilst uncomplexed siRNA was degraded rapidly, it was protected almost com-
pletely by both complex types even at high RNase concentrations (Figure III.8).
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Figure III.7: Accessible siRNA concentration of carriers loaded via T1 (classical pipet-
ting) and T2 (microfluidic mixing) at previously evaluated N/P ratios us-
ing three different siRNA concentrations (1.5, 15, 100 µm) determined by
SYBRTM Gold assay. Measurements were carried out in quadruplicates
and values are presented as mean values ± standard deviation.
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Figure III.8: Recovery of siRNA after RNase digestion. Carriers were assembled by clas-
sical pipetting (T1) and microfluidic mixing (T2). Uncomplexed siRNA
was used as a control. Measurements were carried out in quadruplicates
and values are presented as mean values ± standard deviation.
To prove the ability of complexes to protect siRNA from digestion in presence of
competing anions (heparin), different concentrations of free heparin plus a constant
amount of RNase were incubated together with complexes prepared by both tech-
niques. Displaced siRNA before digestion as well as recovered siRNA after digestion
were quantified. The amount of recovered siRNA decreases rapidly as a function of
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heparin concentration (Figure III.9A). Moreover, in case of microfluidic formed com-
plexes, a higher amount of siRNA was recovered, especially for intermediate heparin
concentrations (c(heparin)=31.25 mg/L: RNA recovery=30.6±1.0 vs. 15.4±1.4%).
High heparin concentrations led to almost complete siRNA digestion in case of both
complexation techniques. In addition, the two different complex types were tested
for transfection efficiency in cell culture experiments (SKOV3 cells). Folate receptor-
positive cells may be useful in further active targeting studies [7]. Microfluidic loaded
carriers were shown to significantly down-regulate siRNA expression more effectively
(34.8±1.5 vs. 24.5±2.2% knockdown, Figure III.9B).
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Figure III.9: Carriers were assembled via T1 (classical pipetting) and T2 (microfluidic
mixing) (N/P=9, c(RNA)=100 µm, c(NS)=0.5 mg/mL). Amount of re-
covered siRNA after incubation with RNase and different concentrations of
heparin (A). Transfection efficiency in vitro (SKOV3 cells) was determined
by RT-PCR. Hs_GAPDH-primers were used to quantify hGAPDH_gene
expression, Hs_ -actin-primers were utilised as internal standard to de-
termine relative expression levels for each gene (B). Measurements were
carried out in quadruplicates and values are presented as mean values ±
standard deviation.
Decreasing complex size could be achieved by different means: (1) increasing the
N/P ratio, (2) working with diluted RNA solutions, (3) employing different loading
techniques. Increasing N/P is typically accompanied by higher cytotoxicity. Increas-
ing size of PEI-DNA-polyplexes at up-scaled concentrations was previously reported
[131]; by contrast, working in a highly diluted regime of concentrations to reach small
carriers gives rise to further problems such as decreasing transfection efficiency in
vitro [6] or limited injection volume in vivo. Consequently an assembly mechanism
as homogeneous as possible is believed to be the key for formulating adequately
sized and stable carriers bearing slightly positive net charge. This hypothesis is in
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agreement with the observation of smaller, more uniform and increasingly stable
(as proved for elaborated N/P under serum conditions) complexes for microfluidic-
assisted fusion and has previously been reported for microfluidic-assembled poly-
[120, 129] or lipoplexes [130, 125]. In addition, for those complexes a smaller amount
of free siRNA, increased stability against heparin displacement and RNase digestion
in presence of heparin were detected. This is in agreement with the assumption
of a tighter compaction of nucleic acids due to a more homogeneous distribution
of charges on the carrier’s surface, caused by an increasingly uniform loading pro-
cess. Stability against enzymatic degradation is a precondition for successful in vivo
application. Complexes prepared by both techniques have proven to be extraordin-
ary effective in siRNA protection. Under harsh conditions in presence of additional
polyanions (heparin), microfluidic-assembled complexes were shown to be even more
effective. Higher knockdown efficiency of microfluidic-assembled carriers may be ex-
plained by size differences: in case of conventional-assembled carriers only the frac-
tion with smaller diameter should be suitable for endocytosis, whilst aggregates may
be excluded. Further, enhanced siRNA protection could have been a factor. Since
the results are shown as values normalised to  -actin, a slight difference in  -actin
expression towards lower expression levels may cause a normalised value of more
than 100%. The lower "NegCon-siRNA" bar for Lipofectamine indicated indirectly
that Lipofectamine is more toxic than the other samples [134, 140]. For PEI/DNA-
polyplexes [129] as well as for lipoplexes [130] fabricated in a microfluidic device,
superior transfection efficiencies in vitro have previously been reported. However,
possibly due to a less defined fusion process, preparing poly- [120] or lipoplexes
[128] in a device with mm-scaled tubes did not significantly enhance transfection
efficiency. Under in vivo conditions greater differences in knockdown performance
are expected, as sedimentation of large particles cannot contribute to transfection
efficiency [141] and siRNA protection is even more crucial.
3.4 Statistical analysis of the microfluidic mixing technique
As microfluidic mixing emerged as the most promising technique, parameters were
studied in detail. Four factors were evaluated as potential for influencing complex
size (Table III.1): (A) concentration of the RNA solution (c(RNA)), (B) the FR
ratio of RNA solution and NS (FRRNA/FRNS), (C) the concentration of the NS
(c(NS)), (D) the summation of both FRs (FRtot).
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Table III.1: Investigated factors and levels of the central composite design
Level
Factor -↵ -1 0 1 ↵ Unit
(A) c(RNA) 3.48 5.00 7.50 10.00 11.52 mm
(B) FRRNA/FRNS 0.35 0.50 0.75 1.00 1.15 -
(C) c(NS) 0.35 0.50 0.75 1.00 1.15 mg/mL
(D) FRtot 19.64 50.00 100.00 150.00 180.36 mL/min
(A) concentration of the RNA solution; (B) FR ratio of RNA solution and NS; (C) con-
centration of the NS; (D) summation of both FRs.
Concentrations of the respective fluids (A, C) control the N/P as well as the final
concentration. Changing the ratio of FRs (B) represents a straightforward way to
precisely control the N/P. The total FR (D) has an effect on shear stress and dif-
fusion behaviour [142], thus influencing complex diameter without altering N/P or
concentrations. On the one hand low N/P ratios at high carrier concentrations are
prerequisites for prospect in vivo experiments, on the other hand, as demonstrated
above, those conditions favour aggregation, especially if inappropriate parameters
and techniques are chosen for complex formation. A central composite design was
chosen to estimate the effects of all variables and their interactions. The experi-
mental plan was carried out on three factor levels, circumscribing the orthogonal
design space. Additional star points allow estimation beyond experimental limits.
Centre points were measured repeatedly to include scattering data. Analysis of
the experimental variation, by calculating average and standard deviation from all
experiments carried out with centre point settings (108.5±2.0 nm), proves the ro-
bustness of the method. The standardised Pareto chart summarises the result of the
statistical analyses (Figure III.10A). The length of each bar is proportional to the
standardised effect (estimated effect divided by its standard error). Effects passing
the vertical line (↵=0.05) are considered as statistically significant at the confid-
ence level of 95%. Open bars represent increasing, black bars decreasing complex
diameters. Measured sizes range from 77 to 184 nm and were mainly influenced
by factors, affecting the ratio of charges (A, B, C). However, an increase of the
ratio independent total FR (D) caused a further decrease in carrier size. Response
surface analysis of the data resulted in the following second order polynomial re-
gression equation (Equation III.1, R2 = 0.970), quantifying the relationship between
significant factors and z-ave.:
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z   ave. = 104.898–0.468·A+ 44.096·C + 0.269·D–167.546·B (III.1)
+17.142·AB–0.002·D2 + 96.054·B2
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Figure III.10: Standardised Pareto chart (A). Main effect plots (calculated by Eq. III.1
showing z-ave. as a function of each factor (B).
Main effect plots (Figure III.10B) were calculated from this regression equation
by modifying the respective factor while residual factors are kept constant at the
0-level. Surface plots (Figure III.11,III.12,III.13) containing two variables, illustrate
the interacting influences. As above-mentioned, combinations increasing the N/P
lead to a decrease in complex diameter, down to the size of almost unloaded carriers.
Raising the total FR to values higher than ⇠100 µL/min leads to a further decrease
in complex size (Figure III.11B). Utilising the data from this design, diameters from
any factor combination can easily be predicted. For instance, factorial analysis gives
optimised parameters (A=0.73 µm, B=1.15, C=0.74 mg/mL, D=99.21 µL/min) for
a desired particle diameter of 150 nm, which in turn corresponds to an N/P of
10.54. DLS measurements of carriers loaded with this parameters yield complexes
154±6 nm (PDI=0.188±0.007) in diameter.
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Figure III.11: Surface plots (calculated by Eq. III.1) showing the interacting influences
between two factors.
Figure III.12: Surface plots (calculated by Eq. III.1) showing the interacting influences
between two factors.
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Figure III.13: Surface plots (calculated by Eq. III.1) showing the interacting influences
between two factors.
In this approach statistical tools were utilised for optimising process parameters.
Decreasing sizes with increasing mixing speeds due to increasing shear stress and
a shorter time for the particle to grow have previously been reported [143, 120].
Model predictions are in accordance with what one would expect and prove the
reproducibility of microfluidic loading as well as the usability of factorial analysis
for evaluating formulation variables in an efficient and comprehensive manner.
4 Conclusions
Apart from polymer design and N/P there are several formulation parameters (con-
centration of used solutions, addition of nucleic acids while or after carrier assembly,
style and speed of mixing carrier with nucleic acid), which need to be considered
when assembling complexes for gene delivery purposes. This was demonstrated
on the basis of complexes, assembled from predominantly hydrophobic PEG-PCL-
lPEI amphiphiles and siRNA. To evaluate suitable N/P ratios for further invest-
igations, size and charge of carrier-siRNA complexes as a function of N/P were
monitored. A discrepancy between the observed N/P at isoelectric conditions and
the expected N/P for a stoichiometric mixture of charges was found. This mis-
match can be explained by the 3D structure, partly blocking cationic charges from
complexation. The straightforward approach of recalibrating the N/P scale with
the help of the isoelectric point may be applicable for other particulate cationic
carrier systems. Subsequently, the diameters of complexes, prepared by four dif-
ferent techniques were compared. Loading after carrier assembly generally led to
less pronounced aggregation in the vicinity of the isoelectric point, possibly due to
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a more gentle complexation procedure. Therefore, complexes prepared after car-
rier assembly by bulk pipetting and microfluidic mixing were thoroughly investig-
ated: At low N/P ratios and high siRNA concentrations the latter were smaller in
size (179±11 vs. 230±97 nm) and PDI (0.205±0.028 vs. 0.353±0.161). Whereas
complexes prepared by bulk mixing comprised a mixture of different sizes, micro-
fluidic assembly led to unimodal size distributions. Further, for those assemblies, a
smaller amount of free siRNA, increased stability against heparin displacement and
increased resistance against RNase digestion in presence of heparin were detected
(c(heparin)=31.25 mg/L: RNA recovery=30.6±1.0 vs. 15.4±1.4%). Furthermore
at elevated N/P under serum conditions, microfluidic assembled complexes exhib-
ited superior colloidal stability. In vitro microfluidic-assembled carriers exhibited
significantly increased transfection efficiency (34.8±1.5 vs. 24.5±2.2% knockdown).
Hence, microfluidic complexation offers an easy to use, scalable and reproducible
alternative to classical pipetting. Those findings on assembly mechanism and tech-
niques are fundamental and may be applied to further particulate cationic carrier
systems in the field of drug and gene delivery, giving rise to more uniform, stable
and less toxic formulations.
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Abstract
The purpose of the present study was to transfer aqueous PEG-PCL-PEI nano-
suspensions into dry ready-to-use formulations, suitable for delivery of siRNA. There-
fore, freshly-prepared nano-suspensions were lyophilised with glucose as lyoprotect-
ant. Firstly, the required glucose concentration for sufficient stabilisation of un-
loaded carriers was determined via dynamic light scattering. Morphology of fresh
and rehydrated carriers was visualised by cryoSEM. Subsequently, the feasibility of
siRNA loading before and after lyophilisation was investigated. For both strategies
complex diameter and in vitro transfection efficiency were determined and correlated
to freshly-prepared samples. Hydrodynamic diameter (95.2±1.4 nm) and size distri-
bution (0.132±0.019) of unloaded nano-suspension were restored after rehydration
by addition of  1.5% of glucose before lyophilisation. Moreover, after loading of re-
hydrated carriers with siRNA, no significant difference in complex size was observed
as compared to freshly-prepared ones. Stabilisation of pre-formed carrier/siRNA
complexes during lyophilisation is feasible at elevated N/P (e.g. 20) and glucose con-
centrations above 5%. As determined via real-time-PCR, lyophilised samples were
as active as freshly-prepared ones regarding transfection efficiency. In conclusion,
lyophilisation is an effective technique to produce physically stable PEG-PCL-PEI
formulations. These general findings may be applicable to further particulate gene
delivery systems to shelf ready-to-use formulations.
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1 Introduction
In recent years many nonviral gene delivery vehicles, such as liposomes, micelles,
“polyplexes”, solid particles or intermediate structures were widely investigated [119].
Most of these formulations basically consist of aqueous colloidal systems, suffer-
ing from inherent thermodynamic instability, subsequently leading to aggregation
over time [144]. This unstable nature of colloidal systems necessitates prepara-
tion immediately before administration and hampers reproducibility as well as their
clinical application. Lyophilisation, offering the opportunity of dry storage and in
situ sample rehydration, has been employed for particles [145], liposomes [146] or
“polyplexes” [144] with encouraging results: In a vast majority of colloidal systems,
carrier diameters could be completely restored, if proper lyoprotectants in adequate
lyoprotectant/nano-carrier ratios were used. Applicable additives were typically
sugars (e.g. glucose, sucrose and trehalose) [147], whereas the sugar type seems
to be of lesser importance [148]. Protectants in general limit mechanical damage
upon freezing and carriers are incorporated in a glassy matrix, which inhibits nano-
carrier aggregation [149]. However, full maintenance of physicochemical properties
does not ensure complete recovery of transfection efficiency [150]. It is well known,
that structural changes during lyophilisation of DNA [151] and PEI/DNA complexes
[150] may possibly decrease transfection efficiency and siRNA is even more suscept-
ible to degradation than DNA [6]. By contrast, there are examples of successfully
regaining transfection efficiency after freeze-drying [152, 144].
A promising class of multifunctional gene delivery carriers is based on cationic
amphiphiles [73]. In aqueous media block copolymers, consisting of poly(ethylene
glycol) (PEG), poly(✏-caprolactone) (PCL) and poly(ethyleneimine) (PEI), self-
assemble spontaneously to core-shell structured nano-carriers. Core-forming bio-
degradable PCL segments, which could serve as reservoirs for water-insoluble drugs
or dyes, are surrounded by hydrophilic PEG moistures, maintaining suspension sta-
bility. Cationic PEI segments are amenable for complexation with nucleic acids (e.g.
siRNA) [118].
It was the aim of the present study to transfer aqueous PEG-PCL-PEI nano-
suspensions into dry ready-to-use formulations, suitable for delivery of siRNA. There-
fore, freshly-prepared suspensions were lyophilised together with glucose (glc) as lyo-
protectant. Firstly, freeze-drying of unloaded carriers was investigated as a function
of glc concentration (cglc) before and after lyophilisation and rehydration by means
93
Part IV 2 Materials and methods
of dynamic light scattering (DLS). Morphology was visualised by cryogenic scanning
electron microscopy (cryoSEM). In addition to lyophilisation of unloaded carriers,
the feasibility of siRNA loading before and after lyophilisation and rehydration was
investigated at different polymer/siRNA ratios (the ratio is generally referred to as
PEI nitrogen per nucleic acid phosphate: N/P). Diameters and in vitro transfec-
tion efficiency of complexes assembled with siRNA before or after lyophilisation and
rehydration were determined and compared to freshly-prepared samples.
2 Materials and methods
PEG-PCL-lPEI triblock copolymer was synthesised and characterised as described
in detail elsewhere [118]. Block length for PEG, PCL and PEI are 500, 10000 and
2500 Da, respectively. 2’-O-methylated 25/27mer DsiRNA targeting Firefly Luci-
ferase was purchased from Integrated DNA Technologies (IDT, Leuven, Belgium).
QuantiFastTM SYBRTM Green PCR Kit, Hs_GAPDH_primer and Hs_ -actin-
primer were provided by Qiagen (Hilden, Germany). LipofectamineTM 2000 (LF)
was obtained from Invitrogen (Karlsruhe, Germany).
Nano-carriers were prepared by solvent displacement [132]. For complexation,
the appropriate amount of siRNA was added to an aliquot of nano-suspension (NS)
in one single step followed by vigorous mixing. Lyophilisation was conducted on an
Alpha 1-4 LSC freeze-dryer (Martin Christ, Osterode, Germany).
The mean particle diameter (z-ave) and polydispersity index (PDI) were de-
termined by DLS (Zetasizer NanoZS/ZEN3600, Malvern Instruments, Herrenberg,
Germany). CryoSEM images were obtained on a JSM-7500F (Jeol, Tokyo, Japan)
equipped with an ALTO-2500 liquid nitrogen (LN2) cryo-transfer system (Gatan
Inc., Pleasanton, CA, USA). Samples were sputtered with platinum using the ALTO
system. Optical microscope images were captured on a light microscope (Stemi 2000-
C, Carl Zeiss, Jena, Germany) on samples prepared in transparent 96 well plates
(Nunc, Thermo Fisher Scientific, Langenselbold, Germany).
Transfection efficiency in vitro was investigated via real-time-PCR (RT-PCR).
SKOV3 cells were lysed 24 h after transfection. mRNA was isolated from culture
cells and reverse transcribed to cDNA. Subsequently, RT-PCR was performed using
a SYBRTM Green PCR Kit and a Rotor-Gene 3000 RT-PCR thermal cycler (Corbett
Research, Sydney, Australia). Calibration curves for GAPDH and  -actin mRNA
were prepared by serial dilutions of cDNA of the blank sample (untreated cells).
All measurements were carried out in triplicates and values are presented as
mean values ± standard deviation.
94
Part IV 3 Results and discussion
3 Results and discussion
Z-ave and PDI of freshly-prepared unloaded carriers were determined via DLS
(95.2±1.4 nm, PDI=0.132±0.019). Freeze-drying without lyoprotectant resulted in
a fibrous polymer residue, forming large, visible aggregates upon rehydration. How-
ever, employing a cglc of  1.5% led to incorporation of cariers into an amorphous,
honey-like matrix and ensured virtually unchanged carrier size and size distribution
after rehydration (Fig. 1A). CryoSEM images of freshly-prepared nano-suspensions
were in agreement with the results from light scattering experiments and revealed
a uniform distribution with marginal aggregation. Images after rehydration proved
that spherical carriers were still intact. However, despite unchanged carrier sizes as
determined by DLS, onset aggregation to worm like assemblies was observed (Fig.
IV.1C). Stabilisation of unloaded carriers has previously been reported for other
core-shell type particulate carrier systems [145], required concentrations of sugar
protectant are consistent with literature [149].
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Figure IV.1: Ratio of final and initial (f/i) z-ave and PDI of nano-carriers, lyophilised as
a function of cglc. Insets: Optical microscope images of dry nano-carriers,
lyophilised with 0 and 1.5% of glc (A). Cryo-SEM images of freshly-prepared
(B) and rehydrated (C) nano-carriers (cglc=1.5%).
In addition to lyophilisation of unloaded carriers, the feasibility of complexation
with siRNA was investigated. Generally, complexation could be carried out after
(L1) or before (L2) lyophilisation (Fig. IV.2A). On the one hand, lyophilisation
of pre-formed complexes, for formulation of easy-to-use transfection agents sounds
appealing. On the other hand, there is the risk of nucleic acid degradation [146]
or alteration in complex structure [150] during lyophilisation and long-term stor-
age. For both strategies, direct lyophilisation in well plates (Fig. IV.2A) enables
straightforward rehydration by addition of cell culture medium [153]. Stability of
unloaded suspensions is mainly owed to electrostatic repulsion of PEI charges. Suc-
cessive neutralisation upon addition of siRNA leads to poor stability at low N/P
96
Part IV 3 Results and discussion
ratios. Therefore, at these conditions, there is also an increased risk of aggregation
during freeze-drying and the applicable route of lyophilisation and formulation is
ultimately a question of N/P and the amount of lyoprotectant. Z-ave and PDI of
complexes, formed via strategy L1 or L2 at two different N/P ratios (10 and 20)
were compared to their freshly-prepared counterparts (Fig. IV.2B). No significant
changes between freshly-prepared complexes and those assembled after lyophilisa-
tion (L1) were observed. By contrast, formulation route L2 resulted in pronounced
aggregation, especially at low N/P. An increased need of lyoprotectant with larger
amounts of nucleic acid was expected [154] and therefore lyophilisation of complexes
(L2) was further investigated at elevated glc concentrations (1.5-15%, Tab. IV.1). In
case of N/P=20 recovery of complex diameter was virtually attained above ⇠5% of
glc. At N/P=10 complete recovery of complex characteristics could not be achieved
even at cglc as high as 15%. Albeit there was a decrease in aggregation as a func-
tion of cglc and carriers are likely to be regained by a further increase in protectant
concentration, this would not be reasonable in order to attain highly concentrated,
nearly isotonic nano-suspensions after rehydration.
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Figure IV.2: Organisation chart of different formulation strategies (L1: complexation
after lyophilisation, L2: lyophilisation of complexes). Nano-suspensions
and residues after lyophilisation were captured with a light microscope in
96 well plates (A). Ratio of final and initial (f/i) z-ave and PDI of carri-
ers loaded at various N/P ratios (10 and 20) and lyophilised by different
strategies (L1, L2, cglc=1.5%) (B).
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Table IV.1: Ratio of final and initial (f/i) z-ave and PDI of complexes lyophilised (L2)
at two different N/P ratios (10 and 20) as a function of cglc.
cglc/% N/P=10 N/P=20
z-ave (f/i) PDI (f/i) z-ave (f/i) PDI (f/i)
1.5 34.49±5.29 3.93±1.89 1.54±0.13 2.06±0.30
3.0 33.49±4.74 1.80±0.34 1.21±0.04 1.24±0.12
5.0 30.44±3.47 1.82±0.91 1.22±0.13 1.13±0.14
10.0 16.92±8.75 3.59±1.55 1.06±0.01 1.26±0.11
15.0 4.47±1.01 2.61±0.38 1.00±0.01 1.21±0.14
Transfection activity of formulations, lyophilised via both strategies, was determ-
ined via RT-PCR and compared to freshly-prepared complex suspensions (Fig. IV.3).
Effective knock-down was detected at N/P=20 and all stored formulations were as
efficient as freshly-prepared. This is in agreement with reports on lyophilised non-
viral delivery systems [146, 155], even though there is some controversy in literature
[37]. Therefore, minor changes in aggregation tendency of resuspended unloaded
carriers (as previously observed in cryoSEM) are not regarded to be critical.
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Figure IV.3: Transfection efficiency (SKOV3-cells) was determined in vitro by RT-PCR.
Hs_GAPDH-primers were used to quantify hGAPDH_gene expression,
Hs_ -actin-primers were utilised as internal standard to determine relative
expression levels for each gene. Lipofectamine (LF) was used as a posit-
ive control. Freshly-prepared complexes were compared to ones assembled
after (L1) and before (L2) lyophilisation (cglc=5%, N/P=10 and 20).
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4 Conclusions
In conclusion, the results of this study demonstrate that lyophilisation is a very ef-
fective technique to produce physically stable PEG-PCL-PEI formulations. Size and
PDI of unloaded nano-suspensions (95.2±1.4 nm, PDI=0.132±0.019) were preserved
during lyophilisation upon addition of lyoprotectant (⇠1.5% of glc). No significant
difference between freshly-prepared complexes and those assembled from lyophilised
carriers was observed. Furthermore, higher glc concentration (⇠5%) facilitates the
stabilisation of pre-formed carrier/siRNA complexes at elevated N/P ratio of 20. In
case of lower N/P (10), stabilisation could not be achieved in the range of applic-
able cglc. RT-PCR experiments in vitro proved, that all lyophilised formulations
were as active as freshly-prepared ones. These findings are fundamental and may
be applicable to further charged particulate gene delivery systems to reproducibly
shelf ready-to-use formulations for prospect in vitro and in vivo studies.
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Abstract
Amphiphilic cationic triblock-copolymers based on polyethylene glycol, poly-✏-capro-
lacton and polyethylene imine represent a versatile gene delivery platform, capable
of co-delivery of nucleic acids, drugs and/or dyes. It was the aim of the current
study to provide basic knowledge for a more rational vector design by deriving a
structure-activity relationship in vitro and in vivo toghether with the establishment
of an imaging technique which is sensitive for nucleic acid unpacking. The latter
is based on quantum dot mediated fluorescence resonance energy transfer method
(QD-FRET). Cell uptake in vitro was measured by flow cytometry. Transfection
efficiencies of nano-carriers with different PEG shell thicknesses were determined
in vitro and in vivo by quantitative real time PCR. For in vivo experiments a
nanosuspension was intracheally instilled to balb/c mice. Furthermore, a prototype
FRET pair was established by co-loading with QDs and fluorescently labelled siRNA
and switching functionality was demonstrated by fluorescence spectroscopy as well
as fluorescence microscopy in vitro. While nano-carriers prepared from the rather
hydrophobic PEG500-block-copoylmer showed good transfection efficiency (61±5%
knockdown in vitro, 55±18% knockdown in vivo), poor performance was found in
case of the predominantly hydrophilic PEG5000-counterpart (13±6% knockdown in
vitro, 30±17% knockdown in vivo). This is in agreement with flow cytometry stud-
ies, revealing 5-fold higher cellular uptake of carriers with thinner PEG shell after
240 min of incubation. QD-FRET complexes emitted light at the acceptor’s emis-
sion wavelength upon donor excitation, proving successful FRET-effect and hence,
complex integrity. Upon complex dissociation, which was simulated by addition
heparin, a dose-dependent decrease in FRET-efficiency was observed. In summary,
we successfully established a FRET-capable multifunctional gene delivery system,
applicable for pulmonary delivery of siRNA. We believe that in vitro/in vivo correl-
ation of structure and function as well as sensitive imaging functionality for mechan-
istic investigations are prerequisites for a more rational design of amphiphilic gene
carriers.
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1 Introduction
Development of safe and effective non-viral gene or siRNA delivery systems rep-
resents a strong scientific barrier [119]. The rational development of new delivery
platforms, however, requires knowledge of the delivery process on a systemic and cel-
lular level. To gain those mechanistic insights, efficient tracking and sensing formats
are required and experiments not only need to be carried out in vitro, but also in
vivo.
Since the early attempts of using cationic homopolymers such as polyethylene
imine (PEI) for complexation of nucleic acids a constant evolution of vector tech-
nology led us to increasingly smarter multifunctional delivery vehicles [1]. Notably,
tailored multifunctional polymeric vectors for simultaneous transport of different
therapeutic agents gained increasing interest [69, 117, 156], especially for pulmon-
ary co-delivery of drugs and nucleic acids [157]. Due to their modular design and
their possibility to be optimally engineered amphiphilic block-copolymers, which are
capable to self-assemble to various types of colloids (e.g. micelles, nanoparticles)
[69, 74, 73], are especially suitable for multifunctional delivery of hydrophobic drugs
(e.g. paclitaxel [69]), nucleic acids [117] and/or dyes [13]. Recently, amphiphilic
block-copolymers comprising polyethylene glycol (PEG), poly-✏-caprolacton (PCL)
and PEI segments were shown to be effective, stable, biodegradable and biocompat-
ible delivery vectors, particularly for small interfering RNA (siRNA) [118, 76, 158].
Self-assembly in aqueous milieu leads to nano-carriers with a “core-corona-structure”,
whereas the stabilising and protecting hydrophilic PEG shell surrounds the hydro-
phobic PCL core. The PCL domain serves as a reservoir for hydrophobic drugs
or dyes. The ratio of hydrophilic and hydrophobic segments was shown to have a
strong impact on the physicochemical and biological characteristics [118]. Whereas
increasing PEG shell-thickness is known to reduce toxicity and increase colloidal
stability [118], this generally leads to a diminished transfection activity [80]. How-
ever, pronounced stealth properties may prove advantageous for prospective receptor
mediated targeting approaches [159]. PEI, located at the interface between hydro-
philic and hydrophobic moieties, is capable of electrostatic interaction with nucleic
acids [158]. Polyplexes which are assembled from PEI or PEG-PEI and nucleic
acids exclusively by electrostatic interaction are oftentimes prone to disassembly
especially in a medium of high ionic strength (e.g. under serum conditions) [80].
As compared to those systems, amphiphilic PEG-PCL-PEI carriers are formed by a
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self-assembly process even in absence of opposite charges and in addition to its cargo
functionality the hydrophobic core region is furthermore capable to increase carrier
stability [80, 139]. Moreover, to increase flexibility and reproducibility, carriers may
be shelved in absence of nucleic acids under dry conditions. Afterwards, rehydration
and nucleic acid loading can take place directly before usage [160, 158].
As dyes for “theranostic” approaches luminescent semiconductor quantum dots
(QDs) have begun to replace conventional flourophores due to their unique proper-
ties such as wideband excitation and narrow emission spectra, high quantum yields
and photo/chemical stability [94]. Furthermore, the emission wavelength can be
tuned in the full range from UV to near infrared (NIR), allowing excitation and
visualisation in biological environments of cells and tissues as in vitro and in vivo
imaging probes [99, 161]. The presence of a core-shell structure (e.g. CdSe/ZnS)
can reduce heavy metal cytotoxicity and prevent leaching [94]. Moreover, QDs were
shown to replace conventional fluorophores as more powerful donors for fluorescence
resonance energy transfer (FRET) [94]. FRET involves the non-radiative transfer of
excitation energy from a fluorescent donor to a proximal acceptor owing a suitable
excitation spectrum. With two fluorophores, independently attached onto a pair of
distinct biomolecules, FRET has proven to be a versatile tool for probing a variety of
biological processes [98, 96]. The incorporation of QD-FRET based sensing formats
into gene delivery carriers may be useful to provide a deeper understanding in fun-
damental aspects of gene therapy by functioning as a highly sensitive on/off-switch
to probe the dissociation in the course of the unpacking procedure [94, 162], which
is a crucial step in the gene delivery process; ultimately, in order to be effective, the
complex has to be designed in a way to protect nucleic acids from degradation in
the bloodstream or the endosomal compartment plus to enable the release of genetic
material on target [3]. FRET based monitoring capabilities may facilitate the design
of a carrier exhibiting a in this vein tailored complextion strength. Subsequent to
carrier-nucleic acid dissociation, both flourophores may be individually tracked e.g.
via fluorescence microscopy.
In the literature QDs most often serve as a central nanoscaffold, around which
diverse functionalities are chemically tethered [94, 163, 95, 99, 164] or for labelling
via covalent linkage [165, 99]. Herein, we report a straightforward and versatile
approach of tagging gene carriers via physical entrapment. The encapsulation of
hydrophobic QDs into the PCL core of amphiphilic siRNA delivery vehicles com-
bines nucleic acid delivery and imaging capabilities in one single carrier platform.
In order to fabricate a FRET-capable delivery vehicle, which is designed for the
elucidation of the gene-delivery process, QD-loaded carriers were subsequently com-
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plexed with Alexa Fluor(AF)-labelled siRNA. However, depending on the intended
purpose, the QDs employed in this prototype “theranostic” delivery system, may
easily be exchanged by arbitrary nanoscaled hydrophobic substances.
The aim of the current study was the evaluation of a multifunctional and QD-
FRET-capable delivery platform in vitro and in vivo. We believe that those ther-
anostic imaging and delivery formats have the potential to provide deeper insights
into the siRNA-delivery process, leading to the design of more rational, tailored
colloidal gene carriers.
2 Material and methods
2.1 Reagents and chemicals
Non-coding control Dicer substrate interfering RNA (DsiRNA), hGAPDH-DsiRNA,
mGAPDH-DsiRNA and AlexaFluor647-labelled DsiRNA (AF-siRNA) were pur-
chased from Integrated DNA Technologies (IDT, Leuven, Belgium). Fetal Calf
Serum (FCS) was obtained from Cytogen (Sinn, Germany). Heparin sodium (150,000
IE/g) was procured from SERVA Electrophoresis (Heidelberg, Germany). First
Strand cDNA Synthesis Kit and RNase I (#EN0531) were obtained from FER-
MENTAS (St. Leon-Rot, Germany). QuantiFastTM SYBRTM Green PCR Kit,
Hs_GAPDH_primer, Mm_GAPDH-primer, Hs_ -actin-primer, Mm_ -actin-pri-
mer, and DNase I were provided by Qiagen (Hilden, Germany). Hydrophobic cad-
mium selenide, zinc sulphide core-shell QDs with an emission wavelength of 605 nm
(organic QDot 605 ITK), SYBRTM Gold reagent, LipofectamineTM 2000 (LF) and
PureLinkTM RNA Mini Kit were purchased from Invitrogen (Karlsruhe, Germany).
Balb/c mice were purchased from Harlan Laboratories (Horst, The Netherlands).
SKOV3 cells were obtained from ATCC, LG Promochem (Wesel, Germany). Fur-
ther chemicals and solvents, which are not mentioned in detail, were supplied by
Sigma Aldrich (Steinheim, Germany) at the highest grade commercially available.
2.2 Polymer synthesis and characterisation
PEG-PCL-PEI triblock-copolymers were manufactured by a three-step synthesis-
route and characterised as described in detail elsewhere [118]. Briefly, in a first re-
action step, hydroxy-terminated monomethyl-PEG (in different molecular weights)
was employed as a macroinitiator for the Sn(Oct)2-catalysed ring opening poly-
merisation of ✏-caprolacton (amount calculated to result the designated PCL block
length). Subsequently, the endgroup of the resulting PEG-PCL diblock copolymer
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was modified by reaction with acryloyl chloride in a second reaction step. Con-
clusively, in a third reaction step, lPEI2500 was coupled onto the modified PEG-
PCL copolymer by Michael-type microaddition reaction. Block length for PCL
and PEI are 10,000 and 2500 Da, respectively. To monitor the impact of PEG chain
length on transfection efficiency, carriers with two different PEG segment length (500
and 5000 Da) were chosen. Accordingly, the blockcopolymers PEG500-PCL10,000-
PEI2500 and PEG5000-PCL10,000-PEI2500 were used in the course of the following
investigations.
2.3 Assembly of nano-carriers
Nano-carriers were prepared by a solvent displacement technique, as described in
detail elsewhere [118]. Briefly, carriers were prepared by dissolving 1 mg of polymer
in 200 µL of acetone. The resulting solution was subsequently injected into 1 mL of
magnetically stirred (300 rpm) double distilled and filtrated water. After injection of
the organic phase, the resulting colloidal suspension was stirred for 3 h under reduced
pressure to remove organic solvent. Nanosuspensions (NSs) were characterised and
used directly after preparation.
2.4 QD loading of nano-carriers
Hydrophobic QDs were stored as a 1 µm stock dispersion in decane. Prior to usage,
QDs were transferred from decane to acetone by injection of 125 µL of QD dispersion
into a magnetically stirred (300 rpm) 2.5 mL phase of acetone. Subsequently, the
liquid was evaporated for 3 h while stirring under reduced pressure, whereas acetone
was refilled in 10 min intervals. The resulting reddish dispersion was used directly
after preparation. Transferred QDs were then added to a solution of the respective
polymer in acetone to reach the final polymer/QD ratio and a polymer concentration
of 5 mg/mL. The solvent displacement procedure was carried out as described above.
2.5 Complexation of nano-carriers with siRNA
Freshly-prepared nano-carriers (blank or QD-loaded) were complexed with siRNA
(or AF-siRNA) at respective N/P-ratios by addition of the appropriate amount of
aqueous siRNA solution (c=100 µm) to an aliquot of NS (c=1 mg/mL) followed by
vigorous mixing. siRNA-loaded nano-carriers were characterised and used directly
after preparation.
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2.6 Size measurements
The average particle size and size distribution were determined by dynamic light
scattering (DLS) using a Zetasizer NanoZS/ZEN3600 (Malvern Instruments, Her-
renberg, Germany). Analyses were performed at a temperature of 25 °C using
samples appropriately diluted with filtrated and double distilled water. The particle
mean diameter (z-ave.) and the width of the fitted Gaussian distribution, which is
displayed as the polydispersity index (PDI), were calculated from data of at least
10 runs and are displayed as the mean value of three independent measurements ±
standard deviation.
2.7 In vitro experiments
2.7.1 Cellular uptake
Celullar uptake of nano-carriers was determined by flow cytometry measurements
[19]. Nano-carriers were assembled in triplicates and complexed with AF-siRNA at
N/P=5 as described above. SKOV3 cells were seeded at a density of 8·104 cells per
well in 24-well plates 24 h prior to the experiment. Subsequently, freshly-prepared
carrier complexes were added to reach a siRNA concentration of 50 pmol per well.
After different incubation times (15-240 min), cells were washed with PBS buffer
and incubated for 5 min with 0.4% trypan blue to quench extracellular fluorescence.
Afterwards, cells were detached using 100 µL of trypsin and treated with 900 µL of
PBS solution containing 10% FCS. Cells were then collected by centrifugation and
resuspended in 300 µL of FACS Cellfix solution (BD Biosciences, San Jose, CA). Cell
suspensions were measured on a FACS CantoTM II (BD Biosciences, San Jose, CA)
with excitation at 633 nm and emission filter set to 660 nm bandpass. 10,000 viable
cells were evaluated in each experiment and the geometric mean fluorescence intens-
ity (MFI) was calculated as the mean value of three independent measurements.
Data acquisition and analysis was performed using FACSDiva software (BD Bios-
ciences, San Jose, CA). Results are presented as mean values ± standard deviation
of three independent experiments.
2.7.2 Transfection efficiency
In vitro transfection efficiency was determined by quantitative real time (qRT-PCR).
SKOV3 cells were seeded in 6-well-plates at a density of 1.5·106 cells/well 24 h before
transfection. Subsequently, fresh medium (containing 10% FCS) and NS complexed
with hGAPDH_DsiRNA or negative control DsiRNA at N/P=5, were added to each
well to reach a final siRNA concentration of 100 pmol/well. LF (0.5 µL/10 pmol of
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siRNA) served as a positive control. After 4 h of incubation at 37 °C, the medium
was exchanged and cells were incubated for another 20 h before they were washed
with cold PBS and lysed with lysis buffer (PureLinkTM RNA Mini Kit). After-
wards, mRNA was isolated from culture cells using the PureLinkTM RNA Mini Kit
(with additional DNase I digestion, 18 U per isolation) and reverse transcribed to
cDNA employing the First Strand cDNA Synthesis Kit on a TGradient thermocycler
(Biometra GmbH, Goettingen, Germany). qRT-PCR was performed employing the
SYBRTM Green PCR Kit and a RotorGene3000RT-PCR thermal cycler (Corbett
Research, Sydney, Australia). Hs_GAPDH-primers were used to quantify hGAPDH
gene expression and Hs_ -actin-primers were utilised as internal standard to de-
termine relative expression levels for each gene. Calibration curves for GAPDH and
 -actin mRNA were prepared by serial dilutions of cDNA of the blank sample (un-
treated cells). Measurements were carried out in triplicates. Values are presented
as mean values ± standard deviation.
2.7.3 Confocal laser scanning microscopy
CLSM was performed on a Zeiss (Jena, Germany) Axiovert 200M to visualise inter-
actions of FRET-complexes with SKOV3 cells. A diode laser (405 nm) was chosen
for excitation; emission was detected in the blue (420-480 nm, DAPI), green (545-
635 nm, QD) and red (> 650 nm, AF) channel. QD fluorescence was pseudo coloured
as green in order to distinguish it from red AF fluorescence. QD-loaded carriers were
prepared and complexed with AF-siRNA at N/P=5 as described above. Cells were
seeded at a density of 1.5·104 cells per well in 8 well chamber slides. 24 h after
seeding, cells were treated with freshly-prepared carrier complexes to reach a con-
centration of 50 pmol siRNA per well and incubated in medium containing 10% FCS
for 4 h at 37 °C. Subsequently, cells were washed with PBS (pH 7.4), quenched with
0.4% trypan blue solution, washed again with PBS and fixed using 4% paraformalde-
hyde in PBS. Fixed cells were then nucleus-stained with DAPI (Molecular Probes,
Eugene, OR, USA), washed with PBS for two more times and finally embedded
utilising FluorSave reagent (Calbiochem, Merck Biosciences, Darmstadt, Germany).
2.8 In vivo experiments
Six-week-old balb/c mice (⇠20 g) were used for in vivo experiments. All animal ex-
periments were carried out according to the German law of protection of animal life
and were approved by an external review committee for laboratory animal care (ref-
erence number 2011/43, Regierungspraesidium Giessen). On the day of the experi-
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ments, mice were anaesthetised with xylazine (13 mg/kg) and ketamine (65 mg/kg).
Mice (n=5 for each group) were intubated through mouth and trachea with the flex-
ible tube of a 24-gauge catheter (BD Insyte, Becton Dickinson GmbH, Heidelberg,
Germany). Freshly-prepared nano-carriers were complexed with mGAPDH_siRNA
or negative control siRNA at N/P=5. After 5 min of incubation, NS containing
35 µg siRNA per mouse was was intratracheally instilled into the lungs. Control
mice were treated with the same volume of 5% glucose. After 5 days, mice were
sacrificed, and lungs were inflated and fixed in situ with 4% paraformaldehyde. For
bronchoalveolar lavage (BAL) tracheae were cannulated and lungs were rinsed 10⇥
with 1 mL of fresh ice-cold PBS. Samples for microscopic analysis were embedded in
paraffin. The deparaffinised slices (3 µm) were embedded with FluorSave to protect
the fluorophores.
For measuring in vivo transfection efficiency tissue samples were placed into a
mortar together with a small amount of liquid nitrogen and grinded into a powder
using the pestle. After addition of 1 mL peqGOLD TriFastTM (PEQLAB Bio-
technologie GmbH, Erlangen, Germany) into the frozen tissue powder, the tissue
suspension was incubated at room temperature for 5 min. Subsequently, the sus-
pensions were added to 200 µL of chloroform each and mixed by shaking for 15 sec.
After incubation of 2-15 min at room temperature, the suspensions were centrifuged
for 5 min at 12,000⇥g to form a pellet and the supernatant was transferred into a
tube for mRNA isolation. After addition of 500 µL of isopropanol followed by vigor-
ous mixing, the mRNA containing solution was stored at -80 °C for 30 min. Then,
the sample was allowed to thaw and centrifuged at 4 °C and 12,000⇥g for 10 min.
The supernatant was discarded and the pellet was vigorously mixed with 1 mL of
aqueous ethanol solution (75%). Then, the sample was centrifuged (4 °C, 12,000⇥g,
5 min) one more time and the resulting pellet was stored in ethanol at -80 °C. The
specimen was allowed to thaw, the supernatant was discarded and the pellet was
dried under reduced pressure for 30 min. Finally, the pellet was dissolved in 60 µL
of RNase free water and incubated for 10-15 min at 55 °C. Samples were stored at
-80 °C and isolated mRNA was further quantified by qRT-PCR as described above.
2.9 Fluorescence spectra
Fluorescence spectra were utilised to prove FRET induced AF emission upon QD
excitation at 430 nm. QD loaded carriers (7.5 pmol QD per mg polymer) were
complexed with siRNA at N/P=10. To evaluate the appropriate amount of AF
for optimal FRET efficiency, AF-siRNA was mixed with unlabelled siRNA prior
to complexation to reach various AF/QD ratios (0, 0.25, 0.5, 1, 2, 4 mmol AF-
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siRNA per mg polymer) at constant N/P. Uncomplexed AF-siRNA was measured
for comparison reasons. Fluorescence was analysed 30 min after complexation in
opaque FluoroNunc 96 well plates (Nunc, Thermo Fisher Scientific, Langenselbold,
Germany) with a TECAN Safire 2 plate reader (Männedorf, Switzerland). Emission
wavelength step size was set to 1 nm. Relative fluorescence values as a function of
emission wavelength were calculated from data of at least 10 reads.
2.10 SYBRTM Gold assay
To mimic FRET switching functionality, fluorescent siRNA was displaced from the
carrier by addition of heparin, whereas in parallel SYBRTM Gold intercalation assays
were applied to quantify the degree of displacement. The QD-bearing nanoparticle
batches, complexed at N/P=10 with AF-siRNA, were standardised to the same
polymer concentration, to equalise the absorption of intercalate-signal by the pres-
ence of water insoluble polymer, and added to opaque FluoroNunc 96 well plates
(Nunc, Thermo Fisher Scientific, Langenselbold, Germany) for analysis. Nano-
carriers without siRNA served as blank control. Samples were incubated 10 min
in the dark after adding SYBRTM Gold reagent and analysed with the TECAN
Safire 2 applying 485 nm excitation and 520 nm emission wavelength. Each data
point was recorded as the mean value of 10 runs. Sapmles were prepared in quadrup-
licates and values are presented as mean values ± standard deviation. Subsequent
to SYBRTM Gold measurements, fluorescence spectra of FRET-complexes with and
without heparin were recorded as described above.
3 Results and discussion
To delineate a relationship between polymer structure and nano-carrier perform-
ance, the influence of the PEG shell thickness was evaluated. Two different PEG
chain lengths (PEG500, PEG2000) with different abilities to shield the cationic PEI
charges were employed in the subsequent experiments to prove the impact on cell
interaction and ultimately transfection efficiency. Intracellular uptake was quanti-
fied via flow cytometry (Figure V.1). Whereas PEG500-PCL10,000-PEI2500 vectors
showed a rapid cell uptake within 2 h, fluorescence of cells incubated with PEG5000-
carriers remained at baseline level.
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Figure V.1: In vitro cell uptake of nano-complexes with different PEG shell-thicknesses
determined by flow cytometry ( ex: 633 nm,  em: 660 nm); measurements
were carried out in triplicates and values are presented as mean values ±
standard deviation.
Flow cytometry results are in a good agreement with transfection efficiencies,
that were not only determined in vitro, but also in vivo (Figure V.2 A). Nano-carriers
constructed from polymers with shorter PEG segments (i.e. PEG500) showed su-
perior transfection efficiency (61±5% knockdown in vitro, 55±18% in vivo). By con-
trast, poor transfection performance was observed for the nano-carriers composed
of PEG5000-PCL10,000-PEI2500 (13±6% knockdown in vitro, 30±17% knockdown
in vivo). Decreased normalised GAPDH expression for negative control samples
of the PEG500 polymer (Figure V.2 A) indirectly suggest elevated toxicity of this
vector system. To determine the spatial distribution of AF-siRNA containing carri-
ers in the lung after intratracheal administration, histology specimens of fixed lung
samples were investigated by fluorescence microscopy (Figure V.2 B) and emission
was predominantly observed in the alveolar region of the lung tissue.
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Figure V.2: A: In vitro and in vivo knockdown efficiency of nano-complexes with differ-
ent PEG moiety. In vitro transfection efficiency (SKOV3 cells) was determ-
ined by qRT-PCR. Hs_GAPDH-primers were used to quantify hGAPDH
gene expression, Hs_ -actin-primers were utilised as internal standard to
determine relative expression levels for each gene. Lipofectamine (LF) was
used as a positive control. Values are presented as mean values ± standard
deviation (n=3). For in vivo measurements nano-complexes were instilled
into the lungs of balb/c mice 5 d prior to sacrifice. Subsequently, mRNA
was isolated from the murine lung tissue and knockdown was determined by
qRT-PCR analogous to in vitro samples with Mm_GAPDH and Mm_ -
actin primers. Values are presented as mean values ± standard deviation
(n=5 for each group). B: Fluorescence microscopy image of lung tissue
instilled with carrier complexes from PEG500-PCL10,000-PEI2500 carriers
and AF-siRNA after lavage. Uptake of siRNA into the alveolar epithelium
is represented by the fluorescently labelled siRNA shown in red.
The results obtained from cell uptake and transfection efficiency studies are in
line with differences in the shielding of positive PEI charges by PEG segments of
different length. Surface charge and cytotoxicity of this type of carrier system were
previously shown to decrease as a function of PEG segment length [118]. As high
surface charge enhances the adhesion of the cationic complexes to the negatively
charged cell membranes, an increased cellular uptake of nano-carriers via passive
endocytosis is obtained, however, at a higher cytotoxic potential. Similar results
were previously reported for branched PEI bearing block-copolymers as a function
of PEG graft density [80, 139, 77] as well as for cationic amphiphiles with increasing
PEG segment length [67]. While an increased positively-charged carrier surface may
result in high transfection efficiency in vitro, it can be detrimental under in vivo con-
ditions, where interaction with negatively-charged tissues may irreversibly lead to
cell death/necrosis [33]. Accordingly, positively charged nanoparticles were shown
to cause increased toxicity on local and systemic level after intratracheal administra-
tion [166]. Further, in case of nanospheres translocating across the alveolar barrier,
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clearance mechanisms are known to lead to rapid excretion of hydrophobic and/or
highly charged substances [16, 15]. Having a closer look on the data presented in
Figure V.2 A, this trend can be recognised for the investigated system with differ-
ent PEG shell thickness: For the hydrophobic carrier, knockdown-efficiency in vivo
slightly decreases as compared to the in vitro experiment, whereas the vice versa ef-
fect was seen for the more hydrophilic vector. Nevertheless, the results from in vitro
and in vivo transfection experiments demonstrated excellent agreement, whereas
nano-carriers prepared from PEG500-PCL10,000-PEI2500 turned out to be more
effective under both experimental conditions. Therefore, this ratio of hydrophilic
and hydrophobic polymer blocks results in a yet active vector with advantageous
toxicity as compared to PEI homopolymers [118]. Fluorescence after instillation
of PEG500-PCL10,000-PEI2500 carriers was primarily observed in the alveolar re-
gion of the lung tissue, whereas no emission was found in the vascular endothelium
(Figure V.2 B). This suggests that carrier complexes remained in the lung and no
translocation through the air-blood barrier took place, at least in the observed time
span of 4 h. This is in a good agreement with studies on nanoparticles of various
sizes (20, 100, 1000 nm) by Sarlo et al., where no extra-pulmonary translocation of
particles  100 nm was detected [167]. Whereas the air-blood barrier was reported
to be permeable to hydrophilic pharmaceuticals such as nucleic acids [168], no such
effects were seen in our studies for AF-siRNA. Moreover, the micrograph of alveolar
tissue after lavage and removal of macrophages, other mobile cells, and surface-
bound particles confirms the internalisation of the siRNA containing nanocarriers
into the epithelium, which is the prerequisite for gene knockdown. This is a great
improvement in comparison to lipid siRNA carriers that were reported to be found
only in macrophages after pulmonary administration [169]. These results are also
in accordance with the efficient in vivo knock-down, which was obtained from the
homogenised lung tissue of PEG500-PCL10,000-lPEI2500 carriers. Therefore, from
a clinical point of view, the amphiphiles presented in this work represent a promising
carrier system for local treatment of airway diseases due to their increased retention
time in the lung which is subsequently leads to high local drug concentrations [170].
To prove the concept of utilising loading of hydrophobic PCL moieties for “ther-
anostic” purposes, QDs were encapsulated during the solvent displacement process.
For obtaining a co-loaded complex with FRET functionality, AF-siRNA was sub-
sequently used for complexation (Figure V.3). This was performed as a prototype
for the well performing PEG500-PCL10,000-lPEI2500 nano-carrier. QD605 ( em:
605 nm) and AF647 ( ex: 647 nm,  em: 679 nm) were chosen as a FRET donor-
acceptor pair. QD-emission and AF-excitation spectra are well overlapping between
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600 and 650 nm, which is one of the prerequisites for successful FRET occurrence.
Furthermore, acceptor and donor are required to be in close proximity (<10 nm,
[99]), which is generally feasible, because cationic PEI charges for nucleic acid compl-
exation and hydrophobic PCL moieties for QD encapsulation are covalently tethered
in the block-copolymer structure and hence in close contact upon following nano-
carrier preparation [118]. Therefore, the distance of the fluorophores was within the
range for the FRET-effect, whereas the energy transfer is supposed to take place
at the interface between PCL core and PEG shell. Since QDs have a broad ex-
citation window, an excitation wavelength of 450 nm was chosen in order to avoid
direct acceptor excitation. Hence, it is strongly expected that intact complexes can
emit FRET-induced red light at 679 nm wavelength upon excitation at 450 nm
wavelength. By contrast, after unpacking and dissociation of the complex, emission
wavelength is supposed to shift to 605 nm wavelength due to direct QD emission.
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Figure V.3: Schematic illustration of the self-assembly process of QD-loaded nano-
carriers by the solvent displacement method, followed by nano-carrier com-
plexation with AF-siRNA. Intact FRET complexes emit at AF emission
wavelength (679 nm) upon QD excitation (450 nm).
In a first step, loading capacity of the PCL core was evaluated. The hydro-
dynamic diameter was measured by DLS for various polymer/QD ratios (Table V.1).
With increasing payload, carrier size and polydispersity increased from 94 nm (PDI
=0.176) for unloaded carriers to a maximum diameter of 179 nm (PDI=0.392) for
10 pmol QD/mgpolymer. To maintain sizes below the limit of endocytotic cell up-
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take [131], 7.5 pmol QD/mg polymer yielding an average hydrodynamic diameter of
145 nm were used for further experiments.
Table V.1: Z-ave. and PDI of nano-carriers, loaded with various amounts of QDs; values
are presented as mean values ± standard deviation (n=3).
n(QD)/m(polymer) z-ave PDI
/pmol·mg 1 /nm
0.0 93.5±9.3 0.176±0.069
1.25 94.8±3.2 0.185±0.006
2.5 96.9±1.7 0.176±0.029
5.0 134.4±3.4 0.298±0.057
7.5 144.8±1.4 0.288±0.080
10.0 178.9±3.5 0.392±0.058
To test the hypothesis of FRET switching, QD-loaded carriers (7.5 pmol QD
per mg polymer) were combined with AF-siRNA, whereas a mixture of labelled and
unlabelled siRNA was employed for complexation to enable a constant N/P ratio
at different QD/AF-ratios. Dose-dependent FRET induced AF signal emission at
679 nm was clearly identified upon QD excitation at 450 nm (Figure V.4). Rather
weak AF intensity in comparison to the QD signal may be due to the self-quenching
among a large number of AF molecules incorporated into a singe complex [171,
172]. For the control samples, that are QD-loaded carriers with unlabelled siRNA
(Figure V.4-(1)) and uncomplexed AF-siRNA (Figure V.4-(7)), no AF emission was
noticed. Along with an increase in AF fluorescence, mitigating QD fluorescence
intensity as a function of AF concentration was observed. This is supposed to be
due to the transfer of energy from the donor to the acceptor, apparently leading to
a decrease of donor fluorescence [99]. Hence, as shown in Figure V.4, detecting the
ratio of donor and acceptor emission intensity can easily be employed for monitoring
the degree of complex integrity in a sensitive manner.
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Figure V.4: Fluorescence emission spectra ( ex: 430 nm) of QD-loaded nano-carriers
(7.5 pmol QD per mg polymer), complexed at N/P=10 with 0 (1), 0.25 (2),
0.5 (3), 1 (4), 2 (5) and 4 (6) mmol of AF-siRNA per mg polymer. The ratio
of FRET induced AF (I679) and QD (I605) fluorescence intensity was used as
a measure for FRET-efficiency. Uncomplexed AF-siRNA (7) was included
for comparison reasons.
The concept of FRET monitoring was not only confirmed by fluorescence spectro-
scopy but also via fluorescence microscopy in vitro (SKOV3 cells). Upon excitation
at 405 nm, QD (green channel) and AF fluorescence (red channel) were observed as
an orange overlay in the cytosol (DAPI stained nuclei in blue channel) (Figure V.5).
Presence of AF fluorescence upon QD excitation proved intact FRET complexes in
vitro.
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Figure V.5: Microscope image of QD-FRET complexes in SKOV3 cells;  ex: 405 nm;
DAPI stained nuclei in blue; QD emission in green; Red FRET-induced AF
emission proves complex integrity; orange colour indicates colocalisation.
Next, to test our design, we examined if AF emission could be quenched together
with recovery of QD signal intensity (Figure V.6). Therefore, to mimic intracellular
unpacking, polyanionic heparin was added to displace the majority of AF-siRNA
from the carrier. As monitored by SYBRTM Gold assay, up to 81±2% of the siRNA
were displaced upon addition of the maximum amount of heparin. As expected,
this resulted in a decrease in AF emission together with an increase in QD fluor-
escence emission intensity. After addition of heparin, the ratio of acceptor/donor
fluorescence intensity decreased from 0.70 to 0.20. In line with SYBRTM Gold meas-
urements this clearly indicates that most of the fluorescent dye was displaced from
the carrier surface.
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Figure V.6: The amount of siRNA displacement from the complex as a function of the
competing polyanion heparin was measurend via SYBRTM Gold assay; val-
ues are presented as mean values ± standard deviation (n=4). B: Repres-
entative fluorescence spectrum ( ex=430 nm) of FRET-complexes (7.5 pmol
QD and 4 mol AF-siRNA per g polymer) before and after displacement with
heparin; decrease of acceptor/donor fluorescence intensity ratio (I679/I605)
proves displacement of AF-siRNA from the carrier surface.
In the course of this work, the hydrophobic cores of amphiphilic nano-carriers
that perform well in vitro and in vivo were successfully charged with fluorescent
QDs and subsequently co-loaded with fluorescently labelled siRNA to provide FRET
functionality. The resulting hybrid PEG-PCL-PEI QD-FRET gene carriers combine
the benefits of cationic amphiphilic gene vectors such as high transfection efficiency,
stability or low toxicity with bright QDs as imaging probes and FRET switching
functionality for mechanistic investigations. QD-FRET studies in the literature
commonly focus on a central QD scaffold with various functionalities grafted onto
the surface [173]. On the basis of this principle, together with receptor binding
functionality, biosensors for enzymes [161], dynamic biophysical processes [174] and
various other organic molecules [175] have been studied. Carriers with central QD
scaffolds have further been utilised in the field of gene delivery as multifunctional
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“theranostic” vehicles [176, 177]. To elucidate the delivery process, those FRET
capable systems have been employed for intracellular tracking of nucleic acid [178],
drug [164] or combined nucleic acid/drug payloads [156]. In a different approach QDs
have further been used to tag well-known carrier systems such as liposomes [95] or
“polyplexes” based on PEI [95], PEG-PEI [165] or chitosan [99] to study their fate
and unpacking behaviour. In these studies, however, carrier and nucleic acid were
independently linked to fluorescent functionalities in a multi step process instead of
physical entrapment. Whereas basic encapsulation of hydrophobic QDs into PLGA
nanospheres [179] or micelles from PEG-PLGA, [180], Pluronic [181], or other types
of block-copolymers [182] for therapeutic imaging and drug delivery [97] purposes
represents a well known procedure, most of those systems are neither FRET capable,
nor designed for gene delivery. Hence, physical entrapment of QDs for probing the
fate of multifunctional amphiphilic gene-carriers has, to our knowledge, not yet been
reported and may be applicable for various colloidal vector systems.
4 Conclusions
In summary, we reported herein the in vitro and in vivo evaluation of a PEG-PCL-
PEI delivery system, which is capable of simultaneous delivery of nucleic acids plus
hydrophobic substances such as drugs or dyes. In a first step, transfection perform-
ances of nano-carriers with different PEG shell thicknesses were not only determined
in vitro but also in vivo. For the latter, siRNA loaded nano-carriers were pulmonary
delivered to the lungs of balb/c mice. While nano-carriers constructed from rather
hydrophobic amphiphiles (PEG500-PCL10,000-PEI2500) revealed good transfection
efficiency (61±5% knockdown in vitro, 55±18% knockdown in vivo), poor perform-
ance was found for their hydrophilic counterparts (PEG5000-PCL10,000-PEI2500)
(13±6% knockdown in vitro, 30±17% knockdown in vivo). This is in a good agree-
ment with flow cytometry results, revealing 5-fold higher uptake of PEG500-carriers,
possibly due to an thinner PEG shell and therefore an increased surface charge.
Fluorescent microscopy images of murine lung tissue after instillation of AF-labeled
carrier complexes revealed emission predominantly in the alveolar region, rendering
this carrier system as promising for local treatment of airway diseases. Second, a well
performing nano-carrier system was tested for its co-loading capability by charging
the PCL reservoir with hydrophobic QDs. Subsequent complexation with fluores-
cently labelled AF-siRNA resulted in FRET capable carriers and energy transfer
efficiency was optimised as a function of the ratio of acceptor/donor fluorophores.
Fluorescence spectroscopy was further employed for in vitro FRET imaging. Fi-
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nally, nucleic acid unpacking was mimicked by addition of heparin and thus the
feasibility of FRET-switching functionality was approved (ratio of acceptor/donor
fluorescence decreased from 0.70 to 0.20). As compared to QD-FRET systems in the
literature based on covalent labelling or ligand strategies, the approach reported in
this work offers the straightforward tagging of amphiphilic gene carriers with fluor-
escent QDs. In this versatile system the employed hydrophobic QDs could easily
be exchanged by their analogues with varying optical characteristics (e.g. for non-
invasive NIR detection in vivo), hydrophobic drugs or a mixture thereof to result
in tailored vehicles for “theranostic” approaches and/or for co-delivery of drugs and
nucleic acids. Subsequent studies deploying “theranostic” and FRET functionality of
this delivery system in vitro and in vivo are believed to enlighten the basic principles
of the delivery process.
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Summary
Part I briefly reviews the most important aspects of non-viral gene delivery: Gene
therapy offers the opportunity of directly introducing genetic material into cells for
a causal therapy of yet incurable diseases. Gene carriers are required for formulation
of nucleic acids, to enable cell internalisation and to prevent enzymatic degradation.
Gradually, non-viral approaches have been considered as superior to viral ones and
the discovery of RNAi enabled a new scope of transient gene therapy. Tailored
polymeric carriers protect and guide the nucleic acid payload on its way into the
target cell to tackle various challenges that arise in vitro and in vivo. Early non-
viral gene delivery carriers such as PEI homopolymers have been constantly evolved
to increasingly smart multifunctional delivery vehicles. In particular amphiphilic
block copolymers, with their potential to self-assemble to various types of nano-
carriers are regarded as suitable platforms for those sophisticated delivery systems.
The modular designed PEG-PCL-PEI block copolymer platform, which has been
established in the course of this thesis, represents a promising candidate of this new
class of multifunctional, amphiphilic, cationic gene delivery vehicles.
It was the aim of part II to establish a set of carriers with varying hydro-
philic/hydrophobic ratio and to derive a relationship between chemical structure
and carrier characteristics. Therefore, a block copolymer library was synthesised,
characterised and assembled into carriers. Subsequently, a non-invasive structural
characterisation of the carrier assemblies in the liquid state was carried out. Carrier
size was determined using DLS, cryoSEM and AFM. The core-corona structure of
assemblies was elucidated via ⇣-potential measurements and the PEG shell thick-
ness was identified for different PEG segment lengths. Following, the impact of
carrier structure on physicochemical and biological features was investigated: Col-
loidal stability and toxicity were found to depend on the length of the hydrophilic
polymer block. Polymers hydrophilic in nature formed small (<40 nm) micelle-like
carriers, whereas hydrophobic polymers aggregated to larger particle-like assemblies
(>100 nm). Monitoring carrier size as a function of initial polymer concentration
clarified different assembly mechanisms. The uncovering of a structure-function re-
lationship allowed the systematic picking of representative compounds from each
carrier class (particle and micelle) for further investigation. Contrary to screening
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different polymers by trial and error, this systematic approach enables the selective
manufacturing of tailor-made gene vectors.
It was the aim of part III to understand and optimise the assembly and loading
process of previously picked polymer compounds. It is well known that polymer
design and N/P ratio have a huge impact on carrier characteristics. The manu-
facturing process, however, had previously only roughly been investigated. Hence,
for manufacturing compactly condensed carrier complexes at low N/P, it was hy-
pothesised that a more homogeneous complexation procedure is supposed to lead
to a more uniform distribution of charges and subsequently to increased colloidal
stability, RNA protection and finally transfection efficiency. Microfluidic mixing
techniques, bringing cationic polymer and nucleic acid together at a constant ratio
during the entire mixing process, have the potential for a gentler complexation. In a
first step, to elucidate complex formation and to narrow down suitable N/P ratios,
size and ⇣-potential were measured as a function of N/P. Then, the optimal timing
for addition of siRNA was investigated. Therefore, complex diameters for addition
of siRNA during (addition to the aqueous or the organic phase) or after (classical
pipetting or microfluidic mixing) carrier assembly were monitored. Subsequently,
for the most promising techniques (loading after assembly), colloidal stability, the
ability to protect RNA as well as transfection efficiency in vitro were compared. Fi-
nally, parameters for the superior microfluidic mixing process were optimised with
the help of a central composite design. It was noticed that the loading procedure is
a predominantly charge controlled process and a discrepancy between stoichiomet-
ric and effective N/P was owed to the 3D-structure of the complex. As expected,
a gentler loading leads to more homogeneous complexes. Hence, possibly due to
a more consistent surface coating, loading after carrier assembly resulted in less
aggregation. In comparison to bulk mixing, microfluidic assembly exhibited smal-
ler diameters (179±11 vs. 230±97 nm), less heterogeneity (PDI=0.205±0.028 vs.
0.353±0.161), enhanced RNA protection (RNA recovery=30.6±1.0 vs. 15.4±1.4%)
as well as increased transfection performance (34.8±1.5 vs. 24.5±2.2% knockdown
in vitro). Hence, it was demonstrated that the Coulomb driven process can be con-
trolled effectively by varying the basic conditions of charge fusion. This enables
the manufacturing of carrier complex suspensions at high concentrations and low
N/P ratios, which are prerequisites for in vivo usage. In particular the microfluidic
complexation procedure represents a reproducible alternative for formulating gene
delivery carriers with superior colloidal stability, RNA protection and transfection
efficiency. The data collected in the central composite design enable the predic-
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tion and fine-tuning of complex-size as a function of various intimately connected
parameters.
It was the overall goal of part IV to transfer preassembled carriers and carrier-
complexes to the dry state as ready-to-use formulations, which is a prerequisite
for effective in vivo usage. Therefore, freshly-prepared nano-suspensions were lyo-
philised with glucose as lyoprotectant. Firstly, the required glucose concentration
for sufficient stabilisation of unloaded carriers was determined via DLS. Morpho-
logy of fresh and rehydrated carriers was visualised by cryogenic scanning electron
microscopy. Subsequently, the feasibility of siRNA loading before and after lyophil-
isation was investigated. For both strategies complex diameter and in vitro transfec-
tion efficiency were determined and correlated to freshly-prepared samples. Hydro-
dynamic diameter (95.2±1.4 nm) and size distribution (0.132±0.019) of unloaded
nano-suspension were restored after rehydration by addition of  1.5% of glucose
before lyophilisation. Moreover, after loading of rehydrated carriers with siRNA, no
significant difference in complex size was observed as compared to freshly-prepared
ones. Stabilisation of pre-formed carrier/siRNA complexes during lyophilisation is
feasible at elevated N/P (e.g. 20) and glucose concentrations above 5%. As de-
termined via RT-PCR, lyophilised samples were as active as freshly-prepared ones
regarding transfection efficiency. Therefore, lyophilisation is an effective technique to
produce physically stable PEG-PCL-PEI formulations. These general findings may
also be applicable to further particulate gene delivery systems to shelf ready-to-use
formulations.
In the course of the previous parts, the polymer library was narrowed down to
two paradigmatic compounds. It was the aim of Part V to investigate these poly-
mers in vitro and in vivo to deduce a relationship between chemical composition and
biological activity. Furthermore, it was the goal to prove the feasibility of dual car-
rier loading by charging the PCL cargo with hydrophobic fluorescent QDs followed
by complexation of the resulting carriers with fluorescently labelled siRNA. Hence,
a FRET pair for monitoring nucleic acid unpacking was to be established. In vitro
transfection efficiencies of carriers with different PEG shell thickness were determ-
ined by RT-PCR and cell uptake was measured by flow cytometry. For in vivo exper-
iments nano-carrier suspension was instilled into the lungs of four-week-old balb/c
mice and transfection efficiency was determined after 5 d by RT-PCR. Well per-
forming vectors were subsequently co-loaded with QDs and fluorescent siRNA and
the resulting double-labelled complexes were analysed via fluorescence spectroscopy
and fluorescence microscopy in vitro. Carriers constructed from rather hydrophobic
block copolymers showed superior transfection efficiency (61±18% knockdown in
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vitro, 58±20% knockdown in vivo), whereas poor performance was found in case of
predominantly hydrophilic ones (13±5% knockdown in vitro, 32±10% knockdown
in vivo) in a good correlation in vitro and in vivo. FACS studies revealed that
this might possibly be due to reduced cell uptake of carriers with thicker PEG shell
preventing cell interaction (5⇥ extenuated uptake after 240 min). Double-labelled
nano-carriers emitted light at the acceptor’s emission wavelength upon donor excit-
ation, proving successful FRET-effect and hence, complex integrity. Upon complex
dissociation, which was simulated by addition of the polyanion heparin, a dose-
dependent decrease in FRET-efficiency was observed, resulting in a shift to the
donor emission wavelength. In the course of this part in vitro and in vivo delivery
efficiency of different polymer compounds was investigated and correlated to chem-
ical composition. The ability of double loading is especially useful for “theranostic”
purposes or co-delivery of nucleic acids and drugs. FRET-switching functionality
may be advantageous for monitoring complex stability and nucleic acid unpacking.
The five parts of this thesis comprehend the establishment of a multifunctional
gene therapy platform. Across the scientific disciplines of chemistry, chemical phys-
ics, pharmacy and biomedicine the underlying work covers all aspects of non-viral
gene delivery: In a first step, block copolymers were synthesised and character-
ised. Subsequently, the polymeric amphiphiles were assembled into carriers and
their physicochemical properties were thoroughly investigated. Then, the nucleic
acid loading process was optimised, carriers were transferred into stable ready-
to-use formulations and finally tested for their in vitro and in vivo transfection
efficiency. Furthermore, the feasibility of multifunctional carrier co-loading and
FRET-monitored nucleic acid unpacking was approved. With the aim of deducing
a structure-activity relationship, a library of block copolymers with systematically
varying hydrophilic/hydrophobic ratio was built and, with advancing knowledge
about the delivery system, confined to the most promising compounds. This refine-
ment process resulted in the selection of two paradigmatic carriers with oppositional
chemical composition, physicochemical characteristics and subsequently distinct in
vitro and in vivo behaviour.
Zusammenfassung
Kapitel I fasst die wichtigsten Aspekte nicht-viraler Gentherapie zusammen: Im Ge-
gensatz zu einer symptomatischen Behandlung schwerwiegender Erkrankungen er-
möglicht die Gentherapie einen kausalen Therapieansatz durch direkte Manipulation
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genetischen Materials. Trägersysteme werden im Rahmen dieser Therapie erforder-
lich, um Nucleinsäuren vor Abbau zu schützen und um eine Wechselwirkung negativ
geladener Nucleinsäuren mit der Zellmembran überhaupt erst zu ermöglichen. Maß-
geschneiderte Vektoren schützen hierbei genetisches Material und transportieren es
spezifisch über die vielen Hindernisse biologischer Systeme hinweg zum Wirkort.
Während anfangs vor allem virale Vektoren im Focus wissenschaftlicher Bemühun-
gen standen, zeichnete sich in den letzten Jahren ein Umdenken hin zu nicht-viralen
Ansätzen ab. Ferner eröffnete die Entdeckung der RNAi-Technologie neue Mög-
lichkeiten zur vorübergehenden Abschaltung bestimmter Gene. Nicht-virale Träger-
systeme der ersten Stunde bestanden hauptsächlich aus Homopolymeren wie PEI
zur Komplexierung von Nucleinsäuren. Seitdem setzte jedoch eine rasante Weiter-
entwicklung dieser Systeme ein, welche bis zum heutigen Zeitpunkt immer wieder
neue, ausgefeilte und multifunktionale Vektoren hervorgebracht hat. So finden selbst-
organisierende Blockcopolymere als Nanoträger Anwendung und deren Eigenschaf-
ten können durch chemische Modifikation optimal angepasst werden. Die modu-
lar aufgebauten PEG-PCL-PEI Blockcopolymere, welche im Rahmen dieser Arbeit
synthetisiert und untersucht wurden, bieten als vielversprechende Vertreter dieser
Vektorklasse eine universale Basis für den Aufbau moderner, multifunktionaler Trä-
gersysteme.
Ziel des Kapitels II war der Aufbau einer Vektorbibliothek aus PEG-PCL-
PEI Blockcopolymeren. Das Verhältnis aus hydrophilen und hydrophoben Ketten-
segmenten wurde hierbei systematisch variiert, um einen Zusammenhang zwischen
chemischer Struktur und den physikochemischen und biologischen Eigenschaften
der Träger herzustellen. Die Blockcopolymere wurden in einer dreistufigen Synthe-
se hergestellt, charakterisiert und zu Trägern verarbeitet. Eine nicht-invasive Cha-
rakterisierung dieser Systeme in ihrer wässrigen Umgebung beinhaltete die Bestim-
mung des hydrodynamischen Durchmessers mittels DLS, cryoSEM und AFM. LDA-
Messungen des ⇣-Potentials bestätigten die postulierte Kern-Hülle-Struktur der Trä-
ger und ermöglichten die Kalkulation der Schichtdicke der PEG-Hülle. Anschließend
wurde der Einfluss der chemischen Trägerzusammensetzung auf die physikochemi-
schen und biologischen Eigenschaften (Kolloidstabilität und Toxizität) untersucht.
Überwiegend hydrophile Polymere bildeten kleine (<40 nm), mizellartige Träger,
während eher hydrophobe Ketten sich zu größeren (>100 nm), partikelartigen Vek-
toren zusammenballten. Durch Messung des hydrodynamischen Durchmessers in
Abhängigkeit der Polymerkonzentration während der Herstellung wurden unter-
schiedliche Mechanismen der Selbstorganisation nachgewiesen. Insbesondere wurde
ein direkter Zusammenhang zwischen der Länge des hydrophilen Segments, PEG-
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Schichtdicke, Kolloidstabilität und Toxizität eindeutig bewiesen. Geeignete Verbin-
dungen aus der Vektorbibliothek wurden selektiert und in die nächste Projektphase
überführt. Die Erforschung eines Zusammenhangs zwischen Polymerzusammenset-
zung und den Eigenschaften der Träger ermöglichte die selektive Auswahl repräsen-
tativer Polymere einer jeden Vektorklasse (Partikel und Mizelle) mit dem Ziel der
Herstellung maßgeschneiderter Therapiesysteme.
Ziel des Kapitels III dieser Arbeit war die Erforschung und Optimierung des
Prozesses der Selbstorganisation von Polymeren zu Trägern und deren Beladung mit
Nucleinsäuren. Es ist bekannt, dass das N/P-Verhältnis und die chemische Struktur
des Polymers einen großen Einfluss auf die Trägereigenschaften haben. Der Herstel-
lungsprozess und die Beladung von Trägern jedoch wurden bisher kaum untersucht.
Dieses Kapitel basiert auf der Hypothese, dass ein gleichmäßigerer Komplexierungs-
vorgang zu einer homogeneren Verteilung von Ladungen und folglich zu verbesserter
Kolloidstabilität, RNA-Einbettung und letztendlich auch Transfektionseffizienz füh-
ren sollte. Eine microfluidale Herstellungstechnik, bei der Träger und RNA während
des gesamten Herstellungsprozesses gleichmäßig zusammengeführt werden, müsste
folglich ideale Bedingungen zu garantieren. Für die Erforschung des Beladungsme-
chanismus und zur Evaluation geeigneter N/P-Verhältnisse wurden die Komplex-
durchmesser und das ⇣-Potential in Abhängigkeit des N/P-Verhältnisses ermittelt.
Anschließend wurden Vektoren auf unterschiedliche Weise mittels einer Nanoprä-
zipitationsmethode hergestellt. Ein Aspekt der Herstellung beinhaltete die Zugabe
von RNA während des Selbstorganisationsprozesses des Trägers (durch Mischen von
Nucleinsäure mit der wässrigen oder der organischen Phase). Andererseits wurde die
nachträgliche Beladung von bereits gebildeten Trägern untersucht. Hier wiederum
wurde die konventionelle Methode der Zugabe von RNA-Lösung mit einer kontinu-
ierlichen, microfluidalen Technik verglichen. Die hydrodynamischen Durchmesser der
auf unterschiedlichstem Wege hergestellten und beladenen Träger wurden anschlie-
ßend mittels DLS erfasst. Für die vielversprechendste Methode der nachträglichen
microfluidalen Beladung wurden die Prozessparameter im Rahmen eines statisti-
schen Designs im Detail untersucht. Die Beladung von Trägern wurde als überwie-
gend ladungskontrollierter Vorgang identifiziert. Die Diskrepanz zwischen stöchiome-
trischem N/P-Verhältnis und Ladungsneutralität resultiert aus dem dreidimensio-
nalen Aufbau der Trägerkomplexe. Eine nachträgliche Beladung führte wie erwartet
zu kleineren und gleichmäßigeren Komplexen und die beiden Methoden der nach-
träglichen Beladung (konventionelle und microfluidale RNA-Zugabe) wurden daher
genauer untersucht. Dies beinhaltete insbesondere einen direkten Vergleich von Kol-
loidstabilität, der Fähigkeit RNA vor Abbau zu schützen und der Transfektionseffi-
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zienz in vitro. In Übereinstimmung mit der Hypothese der Verbesserung der Träger-
qualität durch eine gleichmäßigere Beladung waren die durch nachträgliche Beladung
entstandenen Komplexe wahrscheinlich deshalb weniger aggregiert, da diese Tech-
nik eine homogenere Anlagerung von Nucleinsäure an der Oberfläche des Trägers
ermöglicht. Diese Annahme wurde durch Messergebnisse an microfluidal beladenen
Trägern gestützt, welche sich durch kleinere Komplexdurchmesser (179±11 vs. 230±
97 nm), gleichmäßigere Größenverteilungen (PDI=0.205±0.028 vs. 0.353±0.161),
verbesserten Schutz der RNA vor Abbau (RNA-Wiedergewinnung=30.6±1.0 vs.
15.4±1.4%) sowie eine gesteigerte Transfektionseffizienz (34.8±1.5 vs. 24.5±2.2%
knockdown) auszeichneten. Im Rahmen dieses Kapitels wurden Wege aufgezeigt,
den Coulomb-kontrollierten Beladungsvorgang effektiv durch Variation der Rah-
menbedingungen der Herstellung zu beeinflussen. Dies wiederum ermöglichte die
Produktion von Nanokomplexsuspensionen hoher Konzentration bei niedrigem N/P-
Verhältnis; beides vorteilhafte Bedingungen für einen effektiven Einsatz in vivo.
Die automatisierte, microfluidale Komplexierungstechnik repräsentiert eine neuarti-
ge Variante, um Nanokomplexe gleichmäßiger, reproduzierbarer und mit verbesser-
ten Eigenschaften herzustellen. Der Datensatz des statistischen Designs ermöglicht
eine Vorhersage und Kontrolle der Komplexgröße in Abhängigkeit sich gegenseitig
beeinflussender Herstellungsparameter.
Es war das Ziel von Kapitel IV Vektoren und Vektorkomplexe in eine la-
gerstabile, trockene Form zu überführen. Wasserfreie Träger könnten anschließend
nach Rehydrierung schnell und reproduzierbar für in vitro und in vivo Experimen-
te zur Verfügung stehen. Im Zuge der Untersuchungen wurden frisch hergestellte
Trägersuspensionen unter Zugabe des Lyoprotektors Glucose gefriergetrocknet. In
einem ersten Schritt wurde anhand von unbeladenen Trägern durch Größenmes-
sung frischer und rehydrierter Träger die erforderliche Stabilisatormenge ermittelt.
Im Zuge dessen wurde auch die Morphologie mittels cryoSEM direkt verglichen.
Anschließend wurde evaluiert, ob auch beladene Träger durch Gefriertrocknung sta-
bilisiert werden können. Für beladene und unbeladene Träger wurden daher nach
Rehydrierung die hydrodynamischen Durchmesser und die Transfektionseffizienzen
in vitro bestimmt und mit denen frisch hergestellter Vektoren verglichen. Bereits
durch Zugabe von 1.5% Glucose konnten Durchmesser (95.2±1.4 nm) und Größen-
verteilung (0.132±0.019) unbeladener Träger nach Rehydrierung wiederhergestellt
werden. Bei anschließender Beladung mit siRNA wurde im Vergleich zu frischen
Trägern kein Unterschied bezüglich der Komplexgröße oder der Größenverteilung
detektiert. Die Trocknung bereits beladener Trägerkomplexe gelingt bei erhöhten
N/P-Verhältnissen (z. B. 20) ab einer Glucosekonzentration von 5%. Bezüglich ihrer
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Transfektionseffizienz (durch RT-PCR ermittelt) unterscheiden sich weder getrock-
nete und anschließend beladene noch vor Trocknung beladene Träger von den frisch
hergestellten Proben. Folglich eignet sich Gefriertrocknung hervorragend zur Über-
führung von Nanoträgern in einen lagerstabilen Zustand und diese Technik könnte
auch für die Stabilisierung anderer amphiphiler Trägersysteme Anwendung finden.
Im Zuge der vorherigen Kapitel wurden letztendlich zwei Verbindungen mit spe-
zifischen Eigenschaften aus der Vektorbibliothek ausgewählt. Diese sollten nun in
Kapitel V zunächst auf ihre Transfektionsaktivität und Zellaufnahme in vitro hin
untersucht werden. In einem nächsten Schritt wurde die Transfektionseffizienz in
vivo ermittelt und mit den Ergebnissen der Zellkulturstudien korreliert. Ziel war
hierbei die Ableitung eines spezifischen Zusammenhangs von chemischer Zusam-
mensetzung und biologischer Aktivität. Ferner sollte die Möglichkeit einer doppelten
Fluoreszenzmarkierung des Trägerkomplexes untersucht werden. Diese sollte durch
Beladung des hydrophoben PCL-Kerns mit Quantenpunkten gefolgt von der Kom-
plexierung mit fluoreszenzmarkierter siRNA realisiert werden. Ziel war folglich die
Etablierung eines FRET-Paars, welches sich vor allem zur Detektion der Komple-
xintegrität eignet. Die in vitro Transfektionseffizienz der beiden Träger mit unter-
schiedlicher PEG-Schichtdicke wurde mittels RT-PCR, die Aufnahme in Zellen mit-
tels FACS bestimmt. Im Rahmen der in vivo Experimente wurde eine Suspension
aus Nanokomplexen in die Lungen von balb/c-Mäusen instilliert und die Transfek-
tionseffizienz wurde nach fünf Tagen mittels RT-PCR quantifiziert. Der Vektor mit
höherer biologischer Aktivität wurde im Anschluss wie beschrieben doppelt fluo-
reszenzmarkiert und mittels Fluoreszenzspektroskopie und Fluoreszenzmikroskopie
in vitro untersucht. In guter Übereinstimmung der Ergebnisse in vitro und in vivo
wurde bei hydrophoben Trägern eine hohe Transfektionseffizienz (61±18% knock-
down in vitro, 58± 20% knockdown in vivo) ermittelt, wohingegen bei hydrophilen
Vektoren kaum Aktivität detektiert wurde (13±5% knockdown in vitro, 32±10%
knockdown in vivo). Die Ergebnisse der FACS-Analyse zeigten, dass die geringe
Aktivität hydrophiler Vektoren durch mangelnde zelluläre Wechselwirkung, höchst-
wahrscheinlich bedingt durch eine dickere PEG-Hülle, verursacht wird (5⇥ niedrigere
Aufnahme hydrophiler Komplexe nach 240 min). Die doppelt markierten hydropho-
ben Träger wurden mittels Fluoreszenzspektroskopie untersucht. Emission von Licht
der Wellenlänge des Akzeptors bei Anregung des Donors lieferte den Beweis für den
Energietransfer im intakten FRET-Komplex. Nach Entpacken der markierten siRNA
(was durch Zugabe von Heparin simuliert wurde) veränderte sich erwartungsgemäß
die Frequenz emittierten Lichts hin zu der des Donors. In diesem Kapitel wurde ein
multifunktionales und biologisch aktives Vektorsystem geschaffen, welches sich her-
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vorragend für theragnostische Zwecke oder zu einer simultanen Verabreichung von
Nucleinsäuren und Wirkstoffen eignet. Der FRET-induzierte Schalteffekt ermöglicht
eine Echtzeituntersuchung von Komplexstabilität und Entladevorgang.
Gegenstand der vorliegenden Dissertation ist die Etablierung eines multifunk-
tionalen Trägersystems für die Gentherapie. Hierfür erforderte das an der Schnitt-
stelle unterschiedlichster wissenschaftlicher Disziplinen angesiedelte Thema fächer-
übergreifendes Arbeiten, um den chemischen, physikochemischen, pharmazeutischen
und biomedizinischen Aspekten der Aufgabenstellung in vollem Umfang gerecht zu
werden; notwendige Arbeiten reichten von der chemischen Polymersynthese und
Charakterisierung über die physikochemische Charakterisierung selbst organisieren-
der amphiphiler Strukturen, die optimale Formulierung dieser Verbindungen mit
Nucleinsäuren, das Überführen der Träger in einen lagerfähigen festen Zustand bis
hin zur Durchführung von Zellkultur- und Tierversuchen. Abschließend wurde das
Trägersystem zusätzlich mit einem FRET-basierenden, sensitiven Mechanismus zur
Detektion und Visualisierung intrazellulärer Vorgänge kombiniert. Zur Herleitung ei-
ner Kausalität zwischen chemischer Zusammensetzung mit physikochemischen und
biologischen Eigenschaften entstand in der Synthesephase dieser Arbeit eine Biblio-
thek aus Blockcopolymeren mit variierender Hydrophilie. Im Zuge der Folgearbeiten
wurden in jedem Arbeitsgang geeignete Verbindungen selektiert und genauer unter-
sucht. Dieser Auswahlprozess endete in einer Gegenüberstellung zweier paradigma-
tischer Polymere mit unterschiedlicher chemischer Zusammensetzung, variierenden
physikochemischen Eigenschaften und folglich auch voneinander abweichendem Ver-
halten in vitro und in vivo.
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Perspectives
One of the major hurdles of cationic non-viral delivery systems is the discrepancy
between cell interaction and toxicity. Cationic surface charge from PEI amine func-
tionalities increases the interaction with negatively charged cell membranes and the
same time, however, this will inevitably increase unwanted interactions with blood
components and tissue membranes in an unspecific manner. As a result membrane
damage and cell necrosis lead to increased toxicity both on cellular and systemic
level, making these highly charged polymers inapplicable for in vivo usage. Shield-
ing of PEI charges by PEG can reduce toxicity but generally also leads to diminished
activity. This basic relationship is the major reason for most active vectors just being
also the most toxic ones. Therefore, to circumvent this charge-toxicity-relationship,
carriers have to be taken up by the target tissue in a selective way, which can be
achieved, up to a certain degree, via targeting ligands. A huge benefit of polymeric
gene carriers is their ability to be optimally engineered by chemical modification.
This also applies for the introduction of targeting functionalities such as transferrin,
EGF or folic acid. Tailored PEG end groups may be utilised for coupling with tar-
geting molecules e.g. by gentle click-chemistry reaction. Rather hydrophilic carriers
with thicker PEG shells, increased colloidal stability and reduced toxicity repres-
ent the ideal candidates for this modification. This may possibly lead to increased
affinity towards target tissue for an effective in vivo usage.
Part V includes a proof of concept study of encapsulating fluorescent QDs into
the carrier PCL core. Whereas basic FRET functionality was shown by fluorescence
studies, the potential of this multifunctional carrier system has not yet been fully
exhausted. FRET based unpacking studies unveiling the kinetics of various carrier
systems may contribute to clarify the mechanistic aspects of the delivery process
and the intracellular fate of carrier and payload in a most sensitive manner. Bright
and durable QDs may further be tracked for studying carrier biodistribution in
vivo. Therefore, red-emitting QDs employed in this study may be exchanged by
NIR emitting ones for non-invasive in vivo imaging.
In the long term, required work is evident: the development of more effective
non-viral vectors and conquering the yet severe toxicity effects of current delivery
systems mainly caused by host immune response. By a deeper understanding in the
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mechanistic aspects of the gene delivery process plus a rational vector design we are
on the right track to achieve that goal. Hopefully this work may contribute to the
enormous scientific effort currently ongoing in the era of genomic medicine.
Ausblick
Zentrales Problem einer Vielzahl nicht-viraler Genvektoren ist noch immer die Dis-
krepanz zwischen zellulärer Wechselwirkung und Toxizität. Einerseits erhöhen die
PEI-Kationen eine Aufnahme in die Zelle, andererseits führen genau diese positi-
ven Ladungen auch zu unspezifischer Wechselwirkung. Daraus wiederum resultiert
eine Schädigung von Membranen und Gewebe und somit eine Erhöhung der To-
xizität auf zellulärer und systemischer Ebene, was eine in vivo Anwendung PEI-
basierender Systeme mit hoher Ladungsdichte erschwert. PEGylierung ist zwar in
der Lage, die Toxizität zu reduzieren, verringert aber aus genannten Gründen auch
meist die Transfektionseffizienz. Diese Ambivalenz der positiven Ladung ist eine
der Hauptursachen dafür, dass die Träger mit hoher biologischer Aktivität meist
auch die mit erhöhter Toxizität sind. Die einzige Möglichkeit, diese Abhängigkeit zu
durchbrechen, besteht in der Erhöhung der Selektivität des Trägersystems. Ziel ist
letztendlich eine spezifische Aufnahme z. B. nur in erkrankte Zellen. Bis zu einem
gewissen Grad ist das durch Einführung von geeigneten Rezeptoren in das Trägersys-
tem heute bereits möglich. Eine der Stärken des in dieser Arbeit präsentierten Trä-
gersystems ist dessen Möglichkeit der chemischen Modifikation. Dies schließt auch
die Einführung neuer Funktionalitäten wie Folsäure, EGF oder Transferrin mit ein.
So könnten beispielsweise die PEG-Endgruppen in einer Weise modifiziert werden,
die eine anschließende Kupplung mit neuen Funktionalitäten, z. B. durch schonen-
de „click-chemistry“-Reaktion, ermöglicht. Hydrophile Träger mit dicker PEG-Hülle,
erhöhter Kolloidstabilität und geringer Toxizität wären die idealen Kandidaten für
eine derartige Modifikation. Diese könnten dann effektiv in vivo Anwendung finden.
Kapitel V schließt mit einer Machbarkeitsstudie zur Verkapselung fluoreszieren-
der Quantenpunkte. Hier wurde das FRET-basierte Schaltprinzip zwar grundsätzlich
etabliert, dessen Potential hingegen noch nicht vollständig ausgeschöpft. Prospektive
Kinetikstudien des Vorgangs der Dissoziation verschiedener Trägerkomplexe könn-
ten dazu beitragen, die mechanistischen Zusammenhänge des Gentransfers besser
zu verstehen und einen Einblick in intrazelluläre Prozesse während des Gentrans-
fers zu erlangen. Ferner könnten Quantenpunkte auch dazu genutzt werden, die
Bioverteilung in vivo zu untersuchen. Die in dieser Arbeit verwendeten roten Quan-
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tenpunkte könnten dabei durch NIR-emittierende Quantenpunkte ersetzt werden,
um eine nicht-invasive Detektion in Echtzeit zu ermöglichen.
Das Langzeitziel bei der Erforschung nicht-viraler Vektoren ist klar: Träger müs-
sen einerseits effektiver, andererseits muss die Toxizität (welche maßgeblich durch
eine nichtspezifische Immunantwort hervorgerufen wird) verringert werden. Durch
rationales Vektordesign, welches wiederum systematische und intensive Grundla-
genforschung bedingt, werden wir zukünftig hoffentlich in der Lage sein, sichere und
effektive Trägersysteme zur kausalen Therapie gegenwärtig als unheilbar klassifizier-
ter Krankheiten zu entwickeln.
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In a nutshell
The great promise that gene therapy holds is the opportunity of directly introducing
genetic material into cells for a causal therapy of yet incurable diseases. One prom-
ising way to achieve that goal is the usage of non-viral delivery vehicles, constructed
from amphiphilic block copolymers.
This thesis presents the establishment of a multifunctional PEG-PCL-PEI block
copolymer platform, designed for multifunctional gene delivery. Across the scientific
disciplines of chemistry, chemical physics, pharmacy and biomedicine the underlying
work covers all aspects of non-viral gene delivery:
In a first step, block copolymers were synthesised and characterised. In a system-
atic approach a library of compounds with varying hydrophilic/hydrophobic ratio
was established. Subsequently, polymers were assembled into gene carriers followed
by a non-invasive structural characterisation. Most importantly it was noticed, that
polymers hydrophilic in nature formed smaller micelle-like carriers, whereas hydro-
phobic polymers aggregated to larger particle-like assemblies. In that vein, carrier
features such as colloidal stability and toxicity were found to depend on chemical
composition.
Second, the nucleic acid loading process was optimised. Herein it was the overall
goal to manufacture compactly condensed carrier complexes by understanding the
basic principles of the electrostatic loading procedure. It was hypothesised that a
more homogeneous fusion of charges is supposed to lead to superior carrier com-
plexes. In that line, a microfluidic mixing technique, bringing cationic polymer and
nucleic acid together at a constant ratio during the entire mixing process, was found
to be the most promising technique. Ultimately, gene delivery carriers with superior
colloidal stability, RNA protection and transfection efficiency were manufactured
and process parameters were optimised with the help of a central composite design.
Third, as a prerequisite for effective in vivo usage, carriers were transferred
into stable ready-to-use formulations by lyophilisation with the help of glucose as
a lyoprotectant. Unloaded nano-suspensions could be restored after rehydration by
addition of small amounts of glucose. Upon loading of those rehydrated carriers,
no significant difference in complex size or transfection efficiency was observed as
compared to freshly-prepared ones. Moreover, the stabilisation of pre-formed car-
rier/siRNA complexes is feasible at elevated N/P and higher glucose concentrations.
Fourth, most promising carriers where tested for their in vitro and in vivo trans-
fection efficiency. Vectors constructed from rather hydrophobic block copolymers
showed superior transfection efficiency, whereas poor performance was found in case
of predominantly hydrophilic ones in a good correlation in vitro and in vivo. FACS
studies revealed that this might possibly be due to reduced cell uptake of carriers
with thicker PEG shell preventing cell interaction. In that way a yet active vector
with diminished toxicity as compared to PEI homopolymers was evaluated. Fluor-
escent microscopy images of murine lung tissue revealed emission predominantly in
the alveolar region, rendering this carrier system as promising for local treatment of
airway diseases.
Finally, the feasibility of multifunctional carrier co-loading and FRET-monitored
nucleic acid unpacking was approved. Double-labelled nano-carriers emitted light at
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the acceptor’s emission wavelength upon donor excitation, proving successful FRET-
effect and hence, complex integrity. The ability of dual loading is especially useful
for “theranostic” purposes or co-delivery of nucleic acids and drugs. FRET-switching
functionality may be advantageous for monitoring complex stability and nucleic acid
unpacking.
In view of prospective experiments, to circumvent the observed charge-toxicity-
relationship, carriers are supposed to be taken up by the target tissue in a selective
way. This can be achieved, up to a certain degree, via targeting ligands. Rather
hydrophilic carriers with thicker PEG shells, increased colloidal stability and reduced
toxicity represent the ideal candidates for this modification.
In the long term, required work is evident: the development of more effective
non-viral vectors and conquering the yet severe toxicity effects of current delivery
systems. By a deeper understanding in the mechanistic aspects of the gene delivery
process plus a rational vector design we are on the right track to achieve that goal.
Übersicht
Im Gegensatz zu einer symptomatischen Behandlung schwerwiegender Erkrankun-
gen ermöglicht die Gentherapie einen kausalen Therapieansatz durch direkte Ma-
nipulation genetischen Materials. Eines der vielversprechendsten Trägersysteme zur
Realisierung dieser Zielsetzung setzt sich aus amphiphilen Blockcopolymeren zusam-
men.
Gegenstand der vorliegenden Dissertation ist die Etablierung eines multifunktio-
nalen PEG-PCL-PEI Blockcopolymer-Trägersystems für die Gentherapie. Hierfür
erforderte das an der Schnittstelle unterschiedlichster wissenschaftlicher Disziplinen
angesiedelte Thema fächerübergreifendes Arbeiten, um den chemischen, physikoche-
mischen, pharmazeutischen und biomedizinischen Aspekten der Aufgabenstellung in
vollem Umfang gerecht zu werden:
Der erste Schritt umfasste den Aufbau einer Vektorbibliothek aus PEG-PCL-
PEI Blockcopolymeren. Das Verhältnis aus hydrophilen und hydrophoben Ketten-
segmenten wurde hierbei systematisch variiert. Anschließend wurden die Blockco-
poylmere zu Trägern verarbeitet und deren Aufbau wurde mittels nicht-invasiver
Methoden charakterisiert. Hierbei wurde beobachtet, dass sich überwiegend hydro-
phile Polymere zu kleineren, mizellartigen Trägern formierten, während eher hydro-
phobe Ketten zu größeren, partikelartigen Vektoren aggregierten. Die Erforschung
eines Zusammenhangs zwischen Polymerzusammensetzung und den Eigenschaften
der Träger (Kolloidstabilität und Toxizität) ermöglichte die selektive Auswahl re-
präsentativer Polymere einer jeden Vektorklasse.
Zweitens: Der Prozess der Selbstorganisation von Polymeren zu Trägern und
deren Beladung mit Nucleinsäuren wurde erforscht und optimiert. Im Rahmen die-
ser Arbeiten war das Ziel die Grundzüge des elektrostatischen Ladungsprozesses
besser zu verstehen und mit Hilfe dieser Erkenntnisse kompakte Nanokomplexe zu
generieren. Dieses Kapitel basiert auf der Hypothese, dass ein gleichmäßigerer Kom-
plexierungsvorgang zu einer homogeneren Verteilung von Ladungen und folglich zu
Trägerkomplexen mit verbesserten Eigenschaften führen sollte. Folglich kristallisier-
te sich eine microfluidale Herstellungstechnik, bei der Träger und RNA während des
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gesamten Herstellungsprozesses gleichmäßig zusammengeführt werden, als die am
besten geeignete Beladungsmethode heraus. Durch diese Technik wurden Komplexe
mit verbesserter Kolloidstabilität, RNA-Einbettung und letztendlich auch Transfek-
tionseffizienz erzielt. Die Prozessparameter wurden anschließend im Rahmen eines
statistischen Designs im Detail untersucht.
Drittens: Die Überführung von Nanoträgern in eine lagerstabile, trockene Form,
stellt eine der Grundvoraussetzungen für die effektive Nutzung in vivo dar. Im Zuge
der Untersuchungen wurden frisch hergestellte Trägersuspensionen unter Zugabe des
Lyoprotektors Glucose gefriergetrocknet. Bereits durch geringe Glucosekonzentratio-
nen konnten die Eigenschaften unbeladener Träger nach Rehydrierung wiederherge-
stellt werden. Bei anschließender Beladung mit siRNA wurde im Vergleich zu frischen
Trägern kein Unterschied bezüglich der Komplexgröße, der Größenverteilung oder
der Transfektionseffizienz detektiert. Darüber hinaus gelingt die Trocknung bereits
beladener Trägerkomplexe bei erhöhten N/P-Verhältnissen sowie höheren Glucose-
konzentrationen.
Viertens: Die vielversprechendsten Träger sollten nun auf ihre Transfektionsakti-
vität hin untersucht werden. In guter Übereinstimmung der Ergebnisse in vitro und
in vivo wurde bei hydrophoben Trägern eine hohe Transfektionseffizienz ermittelt,
wohingegen bei hydrophilen Vektoren kaum Aktivität detektiert wurde. Die Ergeb-
nisse der FACS-Analyse zeigten, dass die geringe Aktivität hydrophiler Vektoren
durch mangelnde zelluläre Wechselwirkung, höchstwahrscheinlich bedingt durch ei-
ne dickere PEG-Hülle, verursacht wird. Im Zuge dieser Arbeiten wurde folglich eine
Verbindung ausgewählt, welche sich durch gute Transfektionseffizienz bei gleichzei-
tig geringerer Toxizität (im Vergleich zu PEI-Homopolymeren) auszeichnet. Fluo-
reszenzmikroskopische Aufnahmen des Lungengewebes untersuchter Mäuse zeigten
vorrangig Emission im Alveolargewebe. Dieses Ergebnis prädestiniert das etablierte
Trägersystem für eine zukünftige Anwendung zur lokalen Therapie von Lungener-
krankungen.
Schließlich wurde die Möglichkeit einer doppelten Fluoreszenzmarkierung von
Trägerkomplexen untersucht. Durch Beladung des hydrophoben PCL-Kerns mit
Quantenpunkten gefolgt von der Komplexierung mit fluoreszenzmarkierter siRNA
wurde ein FRET-Paar etabliert, welches sich hervorragend zur Detektion der Kom-
plexintegrität eignet. Die auf diese Weise doppelt markierten Träger zeichneten sich
durch Emission von Licht der Wellenlänge des Akzeptors bei Anregung des Donors
aus. Sie lieferten damit den Beweis für den Energietransfer im intakten FRET-
Komplex. Es wurde folglich ein multifunktionales und biologisch aktives Vektorsys-
tem geschaffen, welches sich hervorragend für theragnostische Zwecke oder für eine
simultane Verabreichung von Nucleinsäuren und Wirkstoffen eignet. Der FRET-
induzierte Schalteffekt ermöglicht eine Echtzeituntersuchung von Komplexstabilität
und Entladevorgang.
Ein Durchbrechen des Zusammenhangs zwischen Ladung, Aktivität und Toxizi-
tät ist die wohl wichtigste Herausforderung zukünftiger Arbeiten. Dies könnte durch
eine Erhöhung der Selektivität des Trägersystems im Zuge der Einführung von ge-
eigneten Rezeptoren gelingen. Hydrophile Träger mit dicker PEG-Hülle, erhöhter
Kolloidstabilität und geringer Toxizität wären die idealen Kandidaten für eine der-
artige Modifikation.
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Das Langzeitziel bei der Erforschung nicht-viraler Vektoren ist klar: Die Effekti-
vität von Vektoren muss gesteigert, die Toxizität verringert werden. Durch rationales
Vektordesign, welches wiederum systematische und intensive Grundlagenforschung
bedingt, ist zu erhoffen, dass zukünftig sichere und effektive Trägersysteme zur kau-
salen Therapie gegenwärtig als unheilbar klassifizierter Krankheiten entwickelt wer-
den können.
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